<!DOCTYPE html> <html lang=en class="pb-page fonts-loaded" data-request-id=95ef1a56-b061-40e0-97e5-a5ec0d36d5eb style><!--
 Page saved with SingleFile 
 url: https://www.valueinhealthjournal.com/article/S1098-3015(17)30316-9/fulltext#relatedArticles 
 saved date: Sat Jun 25 2022 15:35:14 GMT-0400 (Eastern Daylight Time)
--><head data-pb-dropzone=head><meta charset=utf-8><meta name=pbContext content=";website:website:jval-site;ctype:string:Journal Content;requestedJournal:journal:jval;issue:issue:pii\:S1098301518X00059;pageGroup:string:Article View;journal:journal:jval;wgroup:string:Migrated Websites;page:string:Show Full Text;article:article:pii\:S1098301517303169;product:product:elsevier\:product\:ha">
<meta name=robots content=noarchive>
<meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1, user-scalable=1">
<meta property=og:title content="A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses">
<meta property=og:type content=Article>
<meta property=og:url content=https://www.valueinhealthjournal.com/article/S1098-3015(17)30316-9/abstract>
<meta property=og:site_name content="Value in Health">
<meta property=og:image content=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2119365614/2092813964/gr1.jpg>
<meta property=og:description content="Assessment of drug costs for cost-effectiveness analyses (CEAs) in the United States
is not straightforward because the prices paid for drugs are not publicly available
and differ between payers. CEAs have relied on list prices that do not reflect the
rebates and discounts known to be associated with these purchases.">
<meta name=twitter:title content="A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses">
<meta name=twitter:image content=https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2119365614/2092813964/gr1.jpg>
<meta name=twitter:description content="Assessment of drug costs for cost-effectiveness analyses (CEAs) in the United States
is not straightforward because the prices paid for drugs are not publicly available
and differ between payers. CEAs have relied on list prices that do not reflect the
rebates and discounts known to be associated with these purchases.">
<meta name=twitter:card content=summary_large_image>
<meta name=apple-itunes-app content=686051689>
<meta name=google-play-app content=com.elsevier.stmj.jat.newsstand.jval>
<title>A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses - Value in Health</title><meta name=citation_journal_title content="Value in Health"> <meta name=citation_journal_abbrev content="Value in Health"> <meta name=citation_publisher content=Elsevier> <meta name=citation_title content="A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses"> <meta name=citation_date content=2018/06/01> <meta name=citation_online_date content=2017/09/07> <meta name=citation_volume content=21> <meta name=citation_issue content=6> <meta name=citation_firstpage content=677> <meta name=citation_lastpage content=684> <meta name=citation_pmid content=29909872> <meta name=citation_abstract_html_url content=http://www.valueinhealthjournal.com/article/S1098301517303169/abstract> <meta name=citation_fulltext_html_url content=http://www.valueinhealthjournal.com/article/S1098301517303169/fulltext> <meta name=citation_pdf_url content=http://www.valueinhealthjournal.com/article/S1098301517303169/pdf> <meta name=citation_issn content=1098-3015> <meta name=citation_issn content=1524-4733> <meta name=citation_language content=English> <meta name=citation_doi content=10.1016/j.jval.2017.06.013> <meta name=citation_pmid content=29909872> <meta name=citation_author content="Joseph Levy"><meta name=citation_author_email content=jlevy1@rx.umaryland.edu><meta name=citation_author_institution content="Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA"><meta name=citation_author content="Marjorie Rosenberg"><meta name=citation_author_institution content="Wisconsin School of Business, Department of Risk and Insurance, University of Wisconsin-Madison, Madison WI, USA"><meta name=citation_author content="David Vanness"><meta name=citation_author_institution content="Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI, USA"><meta name=citation_keywords content="cost-effectiveness analysis; drug cost; health economic methods; United States"><meta name=citation_reference content="citation_title=Economic Evaluation in Clinical Trials; citation_author=H.A. Glick; citation_author=J.A. Doshi; citation_author=S.S. Sonnad; citation_author=et al.; citation_publication_date=2014; citation_publisher=Oxford University Press, Oxford, UK; "><meta name=citation_reference content="citation_title=Decision Modelling for Health Economic Evaluation; citation_author=A.H. Briggs; citation_author=K. Claxton; citation_author=M.J. Sculpher; citation_publication_date=2006; citation_publisher=Oxford University Press, Oxford, UK; "><meta name=citation_reference content="citation_title=US-based drug cost parameter estimation for economic evaluations; citation_author=J.F. Levy; citation_author=P.D. Meek; citation_author=M.A. Rosenberg; citation_journal_title=Med Decis Making; citation_volume=35; citation_firstpage=622; citation_lastpage=632; citation_publication_date=2015; "><meta name=citation_reference content="citation_title=National health expenditure projections, 2015–25: economy, prices, and aging expected to shape spending and enrollment; citation_author=S.P. Keehan; citation_author=J.A. Poisal; citation_author=G.A. Cuckler; citation_author=et al.; citation_journal_title=Health Aff (Millwood); citation_volume=35; citation_firstpage=1522; citation_lastpage=1531; citation_publication_date=2016; "><meta name=citation_reference content="citation_title=Cost-Effectiveness in Health and Medicine; citation_author=P.J. Neumann; citation_author=G.D. Sanders; citation_author=L.B. Russell; citation_author=et al.; citation_publication_date=2016; citation_publisher=Oxford University Press, Oxford, UK; "><meta name=citation_reference content="citation_title=What’s in a perspective?; citation_author=H.A. Glick; citation_journal_title=Value Health; citation_volume=13; citation_firstpage=2; citation_publication_date=2010; "><meta name=citation_reference content="citation_title=Beyond AWP … way beyond; citation_author=R.J. Willke; citation_journal_title=Value Health; citation_volume=13; citation_firstpage=1; citation_publication_date=2010; "><meta name=citation_reference content="citation_title=Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report–Part I; citation_author=J.W. Hay; citation_author=J. Smeeding; citation_author=N.V. Carroll; citation_author=et al.; citation_journal_title=Value Health; citation_volume=13; citation_firstpage=3; citation_lastpage=7; citation_publication_date=2010; "><meta name=citation_reference content="citation_title=The high cost of prescription drugs in the United States: origins and prospects for reform; citation_author=A.S. Kesselheim; citation_author=J. Avorn; citation_author=A. Sarpatwari; citation_journal_title=JAMA; citation_volume=316; citation_firstpage=858; citation_lastpage=871; citation_publication_date=2016; "><meta name=citation_reference content="citation_title=How Congress can make drug pricing more rational; citation_author=S. Gottlieb; citation_journal_title=Forbes; citation_publication_date=2016; "><meta name=citation_reference content="citation_title=Prescription Drug Pricing in the Private Sector: A CBO Study; citation_author=J. Somers; citation_author=A. Cook; citation_publication_date=2007; citation_publisher=US Congressional Budget Office, Washington, DC; "><meta name=citation_reference content="citation_title=Prescription drug prices: Why do some pay more than others do?; citation_author=R.G. Frank; citation_journal_title=Health Aff (Millwood); citation_volume=20; citation_firstpage=115; citation_lastpage=128; citation_publication_date=2001; "><meta name=citation_reference content="citation_title=Buyer Power and Healthcare Prices; citation_author=J.B. Kirkwood; citation_journal_title=Washington Law Review; citation_volume=91; citation_firstpage=253; citation_lastpage=293; citation_publication_date=2016; "><meta name=citation_reference content="citation_title=Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force Report–Part IV; citation_author=C.D. Mullins; citation_author=B. Seal; citation_author=E. Seoane-Vazquez; citation_author=et al.; citation_journal_title=Value Health; citation_volume=13; citation_firstpage=18; citation_lastpage=24; citation_publication_date=2010; "><meta name=citation_reference content="citation_title=Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force Report–Part III; citation_author=E.C. Mansley; citation_author=N.V. Carroll; citation_author=K.S. Chen; citation_author=et al.; citation_journal_title=Value Health; citation_volume=13; citation_firstpage=14; citation_lastpage=17; citation_publication_date=2010; "><meta name=citation_reference content="citation_title=Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force Report–Part II; citation_author=L.P. Garrison; citation_author=E.C. Mansley; citation_author=T.A. Abbott; citation_author=et al.; citation_journal_title=Value Health; citation_volume=13; citation_firstpage=8; citation_lastpage=13; citation_publication_date=2010; "><meta name=citation_reference content="citation_title=Prices for brand-name drugs under selected federal programs. Regul Aff; citation_author=J. Somers; citation_author=A. Cook; citation_journal_title=Focus; citation_volume=11; citation_firstpage=13; citation_publication_date=2006; "><meta name=citation_reference content="citation_title=High prices for drugs with generic alternatives: the curious case of Duexis; citation_author=A. Hakim; citation_author=J.S. Ross; citation_journal_title=JAMA Intern Med; citation_volume=177; citation_firstpage=305; citation_lastpage=306; citation_publication_date=2017; "><meta name=citation_reference content="citation_author=Centers for Medicare &amp; Medicaid Services; citation_journal_title=Methodology for calculating the National Average Drug Acquisition Cost (NADAC) for Medicaid covered outpatient drugs; citation_publication_date=2013; "><meta name=citation_reference content="citation_title=What is the price benchmark to replace average wholesale price (AWP)?; citation_author=F.R. Curtiss; citation_journal_title=J Manag Care Pharm; citation_volume=16; citation_firstpage=492; citation_lastpage=501; citation_publication_date=2010; "><meta name=citation_reference content="citation_title=AMCP Pharmaceutical Payment Guide 2013; citation_author=Academy of Managed Care Pharmacy; citation_publication_date=2013; citation_publisher=Academy of Managed Care Pharmacy, Alexandria, VA; "><meta name=citation_reference content="citation_title=Medicaid Rebates for Brand-Name Drugs Exceeded Part D Rebates by a Substantial Margin; citation_title=Report OEI-03-13-00650; citation_author=US Department of Health and Human Services; citation_publication_date=2015; citation_publisher=US Department of Health and Human Services, Washington, DC; "><meta name=citation_reference content="citation_title=Pricing in the market for anticancer drugs; citation_author=D.H. Howard; citation_author=P.B. Bach; citation_author=E.R. Berndt; citation_author=et al.; citation_journal_title=J Econ Perspect; citation_volume=29; citation_firstpage=139; citation_lastpage=162; citation_publication_date=2015; "><meta name=citation_reference content="citation_title=Medicaid Payment for Outpatient Prescription Drugs. Issue Brief; citation_author=Medicaid and CHIP Payment and Access Commission; citation_publication_date=2017; citation_publisher=Medicaid and CHIP Payment and Access Commission, Washington, DC; "><meta name=citation_reference content="citation_author=Center for Medicare &amp; Medicaid Services; citation_journal_title=Medicaid covered outpatient prescription drug reimbursement information by state; citation_publication_date=2017; "><meta name=citation_reference content="citation_title=Office of Inspector General. States’ Collection of Offset and Supplemental Medicaid Rebates; citation_title=Report No. OEI-03-12-00520; citation_author=US Department of Health and Human Services; citation_publication_date=2014; citation_publisher=US Department of Health and Human Services, Washington, DC; "><meta name=citation_reference content="citation_author=Centers for Medicare &amp; Medicaid Services; citation_journal_title=Draft methodology for calculating the National Average Drug Acquisition Cost (NADAC); citation_publication_date=2012; "><meta name=citation_reference content="citation_author=Centers for Medicaid &amp; Medicare Services; citation_journal_title=National Average Drug Acquisition Cost (NADAC) questions and responses; citation_publication_date=2011; "><meta name=citation_reference content="US Department of Veterans Affairs. National Acquisition Center. Office of Acquisition and Logistics. Available from: http://www.va.gov/nac/. [Accessed June 22, 2017]."><meta name=citation_reference content="citation_author=US Government Accountability Office; citation_journal_title=Prescription drugs: comparison of DOD and VA direct purchase prices; citation_publication_date=2013; "><meta name=citation_reference content="citation_title=Prices for Brand-Name Drugs under Selected Federal Programs; citation_author=Congressional Budget Office; citation_publication_date=2005; citation_publisher=Congressional Budget Office, Washington, DC; "><meta name=citation_reference content="citation_title=Prescription Drugs: Innovation, Spending, and Patient Access; citation_author=US Department of Health and Human Services; citation_publication_date=2016; citation_publisher=US Department of Health and Human Services, Washington, DC; "><meta name=citation_reference content="citation_title=Should drug prices be negotiated under Part D of Medicare? And if so, how?; citation_author=R.G. Frank; citation_author=J.P. Newhouse; citation_journal_title=Health Aff (Millwood); citation_volume=27; citation_firstpage=33; citation_lastpage=43; citation_publication_date=2008; "><meta name=citation_reference content="citation_title=Exploring uncertainty in cost-effectiveness analysis; citation_author=K. Claxton; citation_journal_title=Pharmacoeconomics; citation_volume=26; citation_firstpage=781; citation_lastpage=798; citation_publication_date=2008; "><meta name=citation_reference content="US Department of Veterans Affairs. Federal Supply Schedule Modification Request Forms. https://www.va.gov/oal/docs/business/nac/fssWebinarContractorGuide-RequestForModification_20130522.pdf. [ Accessed June 22, 2017]."><meta name=citation_reference content="citation_author=IMS Institute for Healthcare Informatics; citation_journal_title=Medicines use and spending in the US; citation_publication_date=2016; "><meta name=citation_reference content="citation_title=Pharmacy benefit management companies: Do they create value in the US healthcare system?; citation_author=A. Lyles; citation_journal_title=Pharmacoeconomics; citation_volume=35; citation_firstpage=493; citation_lastpage=500; citation_publication_date=2017; "><meta name=citation_reference content="citation_title=A review of US drug costs relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016; citation_author=J. McRae; citation_author=F.R. Vogenberg; citation_author=S.W. Beaty; citation_author=et al.; citation_journal_title=Pharmacoeconomics; citation_volume=35; citation_firstpage=215; citation_lastpage=223; citation_publication_date=2017; "><meta name=citation_abstract content="<h2>Abstract</h2><h3>Background</h3><p>Assessment of drug costs for cost-effectiveness analyses (CEAs) in the United States is not straightforward because the prices paid for drugs are not publicly available and differ between payers. CEAs have relied on list prices that do not reflect the rebates and discounts known to be associated with these purchases.</p><h3>Objectives</h3><p>To review available cost measures and propose a novel strategy that is transparent, consistent, and applicable to all CEAs taking a US health care sector perspective or a societal payer's perspective.</p><h3>Methods</h3><p>We propose using the National Average Drug Acquisition Cost (NADAC), the Veterans Affairs Federal Supply Schedule (VAFSS), and their midpoint as the upper bound, lower bound, and base case, respectively, to estimate net drug prices for various payers. We compare this approach with wholesale acquisition cost (WAC), the most common measure observed in our literature review. The minimum WAC is used to provide the most conservative comparison.</p><h3>Results</h3><p>Our sample consists of 1436 brand drugs and 1599 generic drugs. On average, the upper bound (NADAC) is 1% and 9.8% lower than the WAC for brand and generic drugs respectively, whereas the lower bound (VAFSS) is 48.3% and 54.2% lower than the WAC. The NADAC is less than the WAC in 89.6% of drug groups. The distributions of these relationships do not show a clear mode and have wide variation.</p><h3>Conclusions</h3><p>Our study suggests that the WAC may be an overestimate for the base case because the minimum WAC is higher than the NADAC for most drugs. Our approach balances uncertainty and lack of data for the cost of pharmaceuticals with the need for a transparent and consistent approach for valid CEAs.</p>">
<noscript>
    <style>.requiresJS {
        display: none
    }

    .dartAd {
        display: block !important
    }</style>
</noscript>
<style>:root{--sf-img-15:url("data:null;base64,");--sf-img-19:url("data:null;base64,");--sf-img-18:url("data:null;base64,");--sf-img-17:url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAVCAYAAAB/sn/zAAAAbklEQVR4XmNgGAVDB9iiCyADDSB2hbIfQGkQHySOAqSB+C4QOzFAFILoO1BxDKDFAFH0BUqD+ChAAoivAPENIP4AxP+hNIgPEgfJowA3IL4IxO+hNIiPAcyA+BgQizNArAXRID5IHCdYiy4wwAAAOEEVivTgVkMAAAAASUVORK5CYII=")}#crossmark-icon{display:block;margin:0;border:0}#crossmark-tooltip-130{position:absolute;z-index:999;height:auto;width:146px}@font-face{font-family:icomoon;src:url(data:font/woff;base64,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) format("woff");font-weight:400;font-style:normal}[class*=" icon-"],[class^=icon-]{font-family:icomoon!important;font-style:normal;font-weight:400;font-variant:normal;text-transform:none;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.icon-gizmo-pdf-file2:before{content:"\e987"}.icon-copyright:before{content:"\e97f"}.icon-gizmo-folder-in:before{content:"\e965"}.icon-gizmo-hamburger:before{content:"\e966"}.icon-gizmo-image_figure:before{content:"\e96b"}.icon-gizmo-pdf-file:before{content:"\e96d"}.icon-gizmo-person:before{content:"\e96e"}.icon-gizmo-reprints:before{content:"\e970"}.icon-gizmo-share:before{content:"\e976"}.icon-Email:before{content:"\e90e"}.icon-search:before{content:"\e60e"}.icon-section_arrow_u:before{content:"\e61d"}.icon-arrow_l:before{content:"\e624"}.icon-arrow_r:before{content:"\e625"}@font-face{font-family:Nexus Sans Pro;src:url(data:application/font-woff;base64,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) format("woff")}@font-face{font-family:elsevierWordmarkRegular;src:url(data:application/font-woff;base64,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) format("woff");font-weight:400;font-style:normal}html{font-family:sans-serif;line-height:1.25;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}article,header,section{display:block}h1{margin:.67em 0}figcaption,figure,main{display:block}a{background-color:transparent;-webkit-text-decoration-skip:objects}a:active,a:hover{outline-width:0}strong{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sup{top:-.5em}img{border-style:none}svg:not(:root){overflow:hidden}button{margin:0}button{overflow:visible}button{text-transform:none}button{-webkit-appearance:button}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}.container{margin-right:auto;margin-left:auto;padding-left:16px;padding-right:16px}.container:after,.container:before{content:" ";display:table}.container:after{clear:both}@media (min-width:532px){.container{width:100%}}@media (min-width:768px){.container{width:736px}}@media (min-width:1140px){.container{width:1080px}}@media (min-width:1500px){.container{width:1472px}}.row{margin-left:-16px;margin-right:-16px}.row:after,.row:before{content:" ";display:table}.row:after{clear:both}*,:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}.col-md-2,.col-md-3,.col-md-6,.col-md-7,.col-sm-6,.col-xs-6{position:relative;min-height:1px;padding-right:16px;padding-left:16px}.col-xs-6{float:left}.col-xs-6{width:50%}@media (min-width:768px){.col-sm-6{float:left}.col-sm-6{width:50%}}@media (min-width:1140px){.col-md-2,.col-md-3,.col-md-6,.col-md-7{float:left}.col-md-2{width:16.66667%}.col-md-3{width:25%}.col-md-6{width:50%}.col-md-7{width:58.33333%}}@media (min-width:1500px){.col-lg-1,.col-lg-2,.col-lg-6,.col-lg-9{float:left}.col-lg-1{width:8.33333%}.col-lg-2{width:16.66667%}.col-lg-6{width:50%}.col-lg-9{width:75%}}.clearfix:after,.clearfix:before,.section__separator:after,.section__separator:before{content:" ";display:table}.clearfix:after,.section__separator:after{clear:both}.align-center{text-align:center}.pull-right{float:right}@media (max-width:531px){.hidden-xs{display:none!important}}.hidden-sm{display:block}@media (min-width:532px) and (max-width:767px){.hidden-sm{display:none!important}}.gutterless{padding:0}@-webkit-keyframes fadeOut{0%{opacity:1}to{opacity:0}}@keyframes fadeOut{0%{opacity:1}to{opacity:0}}html{font-size:16px}body{background:#fff;line-height:1.4;word-wrap:break-word;min-height:100vh}.fonts-loaded body{font-family:Helvetica,sans-serif}a{cursor:pointer}a,a:focus,a:hover{color:inherit;text-decoration:none}a:focus,a:hover{outline:0}a i[class*=icon-]:before{display:inline-block}img{max-width:100%}i[class*=icon-]{transition:transform .5s}.text-onDark{color:#fff}.rlist{list-style:none;padding:0;margin:0}.rlist--inline{list-style:none;padding:0;margin:0}.rlist--inline>li{display:inline-block}.rlist--inline.separator>li{border:none;margin-top:0;padding-top:0}.rlist--inline.separator>li:not(:last-of-type){border-right:1px solid #005789}.loa{margin:0 0 10px}button{display:inline-block;border:none;color:#fff;text-align:center;padding:12px;font-size:1rem;background:#a1a1a1;font-weight:700;transition:all .25s;line-height:1rem}.fonts-loaded button{font-family:Helvetica,sans-serif}.btn.disabled,.btn:disabled,.btn[disabled],.button.disabled,.button:disabled,.button[disabled],[type=button].disabled,[type=button]:disabled,[type=button][disabled],[type=submit].disabled,[type=submit]:disabled,[type=submit][disabled],button.disabled,button:disabled,button[disabled]{opacity:.4}.btn.disabled:focus,.btn.disabled:hover,.btn:disabled:focus,.btn:disabled:hover,.btn[disabled]:focus,.btn[disabled]:hover,.button.disabled:focus,.button.disabled:hover,.button:disabled:focus,.button:disabled:hover,.button[disabled]:focus,.button[disabled]:hover,[type=button].disabled:focus,[type=button].disabled:hover,[type=button]:disabled:focus,[type=button]:disabled:hover,[type=button][disabled]:focus,[type=button][disabled]:hover,[type=submit].disabled:focus,[type=submit].disabled:hover,[type=submit]:disabled:focus,[type=submit]:disabled:hover,[type=submit][disabled]:focus,[type=submit][disabled]:hover,button.disabled:focus,button.disabled:hover,button:disabled:focus,button:disabled:hover,button[disabled]:focus,button[disabled]:hover{background:#005789;color:#fff}.btn:active,.btn:focus,.btn:hover,.button:active,.button:focus,.button:hover,[type=button]:active,[type=button]:focus,[type=button]:hover,[type=submit]:active,[type=submit]:focus,[type=submit]:hover,button:active,button:focus,button:hover{cursor:pointer;background:#0067a3;color:#fff}::-webkit-input-placeholder{color:#63666a}.label{display:block;float:none;font-weight:700;margin-bottom:13px}body{font-size:1rem;margin:0;padding:0;color:#505050}div:focus,figure:focus,h1:focus,h2:focus,h3:focus,h4:focus,h5:focus,h6:focus,p:focus,section:focus{outline:none}.skip{height:0;overflow:hidden}button:focus{outline:2px dashed silver;border-color:silver!important}a{color:#005789}a:hover{color:#727272}a:focus{outline:2px dashed silver}a.link--underlined{border-bottom:2px solid #ebebeb}a.link--underlined:hover{border-bottom-color:transparent}.section-paragraph,p{margin-top:10px;margin-bottom:18px}section section{margin-bottom:16px}@media (min-width:532px){section{margin-bottom:55px}}.bulleted:after{content:"•";color:#969696;display:inline-block;width:6px;margin-left:5px;font-size:20px;font-size:1.25rem;height:18px;line-height:21px;margin-bottom:6px;vertical-align:middle;margin-right:8px}.bulleted:last-of-type:after{content:"";width:0;margin:0;display:none}.inline-it{display:inline-block;margin-right:10px}@media (max-width:1139px){.static-md{position:static}}::-webkit-scrollbar{-webkit-appearance:none;width:7px;height:5px}::-webkit-scrollbar-thumb{border-radius:2px;background-color:#000;background-color:rgba(0,0,0,.5)}h1,h3{margin-top:0;margin-bottom:8px}@media (max-width:1139px){h1,h2,h3{margin-bottom:8px}}h3{font-weight:400}h1{font-size:2rem;font-weight:300;line-height:3rem}@media (max-width:1139px){h1{font-size:1.5rem;line-height:2rem}}@media (min-width:1140px){h1.smaller{font-size:1.5rem}}h2{font-size:2.25rem}@media (max-width:1139px){h2{font-size:1.5rem}}h2.top{margin-top:48px;margin-bottom:20px;line-height:1.1}@media (min-width:532px){h2.top{margin-top:55px}}h3{font-size:1.375rem;margin-bottom:12px}@media (max-width:1139px){h3{font-size:1.25rem;margin-bottom:13px}}h4{font-size:1.125rem;font-weight:700;margin-bottom:12px;margin-top:10px}@media (max-width:1139px){h4{font-size:.875rem}}ol:not([class^=rlist]):not([class~=rlist]){list-style:none;padding-left:20px;counter-reset:li}ol:not([class^=rlist]):not([class~=rlist])>li{counter-increment:li;margin-bottom:15px;line-height:28px;line-height:1.75rem}@media (max-width:1139px){ol:not([class^=rlist]):not([class~=rlist])>li{line-height:1.63rem;margin-bottom:10px}}.download-links a{font-size:.875rem;padding-bottom:3px;border-bottom:2px solid #ebebeb}@media (min-width:768px){.download-links a{font-size:1rem}}.download-links.rlist--inline.separator>li:not(:last-of-type){border-right:0}.download-links>li:not(:first-child):before{content:"|";margin-right:6px;margin-left:6px;font-size:14.4px;font-size:.9rem;font-weight:100;display:inline-block;vertical-align:top}.inline-bullet-list{display:flex;flex-wrap:wrap}.inline-bullet-list>li{display:flex}.inline-bullet-list>li:not(:last-child):after{content:"•";color:#969696;display:inline-block;width:6px;margin-left:5px;margin-right:5px;font-size:24px;font-size:1.5rem;height:18px;line-height:30px;margin-bottom:6px;vertical-align:middle}.inline-bullet-list a{font-size:inherit}.ce-list--remove-bullets{padding-left:0}.ce-list--remove-bullets__list-item{list-style:none;display:flex;margin-bottom:15px;flex-flow:row wrap}.ce-list--remove-bullets__list-item>.label{margin-right:9px;margin-top:-1px;font-size:1rem}.ce-list--remove-bullets__list-item__text{flex:90%}@media (max-width:767px){.ce-list--remove-bullets__list-item__text{flex:70%}}.inline-table{border-top:1px solid silver;border-bottom:1px solid silver;margin-top:27px;margin-bottom:25px}.inline-table__head{margin-top:30px;margin-bottom:16px;font-weight:700}.inline-table__head span{font-size:1.25rem;margin-right:10px}.inline-table__tail{margin-top:12px;margin-bottom:30px}.inline-table__footnote{font-size:.875em;font-weight:700}.inline-table .scrollable{max-width:100%;display:inline-block;max-height:600px;width:auto}.inline-table .download-links{margin-bottom:25px}.inline-table .scroallbe-table,article:not(.complexTable) .inline-table .table-with-References{display:inline-block;max-width:100%}table{line-height:1.25rem;border-collapse:separate;border-spacing:0}article:not(.complexTable) table{overflow:auto}table ul{margin:0;padding:0 0 0 16px}table sup{position:static;display:inline-block;vertical-align:text-top;z-index:0}table.bordered,table.bordered td,table.bordered th{border:1px solid #f5f4f4}table.bordered{border-right:0}table.bordered td:first-child,table.bordered th:first-child{padding-left:16px}table.bordered th{vertical-align:middle}table.bordered th.rowsep{border-bottom:2px solid #80c6ee}table td,table th{text-align:left;padding:16px}table th{border-bottom:2px solid #80c6ee;padding-top:20px;padding-bottom:15px;line-height:1.25rem;background:#fff;min-width:100px}table th:first-child,table th:first-child[rowspan="2"]+th{padding-left:0}table td{font-weight:400}table td:first-child{padding-left:0}table tr{z-index:1}.table-list li{margin-bottom:15px}.table-list .inline-table__label{font-weight:700}.table-list .inline-table__label:not(.no-caption):after{margin-right:4px;margin-left:2px;content:":"}.table-with-References{position:relative}@media (max-width:767px){.ce-list--remove-bullets__list-item__text{max-width:100%!important}}table strong,table td,table th{font-size:.875rem}.inline-table__footnote{overflow:auto}ol:not([class^=rlist]):not([class~=rlist])>li:before{color:var(--theme-headings,#005789);content:counter(li) ".";color:#005789;display:inline-block;width:1em;margin-left:-26px;margin-right:5px}.ce-list--remove-bullets li .label,ul:not([class^=rlist]):not([class~=rlist]):not(.frames__list)>li:before{color:var(--theme-headings)}h2{font-weight:700}@media (max-width:1139px){h2{font-weight:600}}[data-db-parent-of]:not(.sticko):not(.sticko__md):not(.js--not-parent):not(.fixed-element){position:relative}[data-db-target-of]{display:none;position:absolute;text-align:left}article section a:not([class*=__control]):not([class*=__ctrl]){border-bottom:2px solid #ebebeb}@media (max-width:1139px){article .download-links__figureViewer{display:none}}.article-info{font-size:1.13rem}@media (max-width:1139px){.article-info{font-size:1rem}}.article-header{position:relative;font-size:1rem}@media (max-width:1139px){.article-header{padding:20px 16px;font-size:.875rem}}.article-header .loa{font-size:1rem}@media (max-width:1139px){.article-header .loa{font-size:.88rem}}@media (min-width:1140px){.article-header{padding-top:27px}}@media (max-width:767px){.article-header ul.loa[data-number-of-author]{display:inline}.article-header ul.loa[data-number-of-author] .loa__item:not(.hide-author){display:inline-flex;flex-wrap:wrap}}@media (max-width:313px){.article-header ul.loa[data-number-of-author] .loa__item:not(.hide-author),.article-header ul.loa[data-number-of-author] .loa__item:not(.hide-author) .show-all-author{display:inline-block}.article-header ul.loa[data-number-of-author] .article-header__info{display:inline}}.article-header a:hover{color:#fff;color:hsla(0,0%,100%,.6)}.article-header .article-header__access{text-transform:capitalize;color:#f78300}.fonts-loaded .article-header .article-header__access{font-family:elsevierWordmarkRegular}.article-header .default{border-bottom:0}.article-header__info{display:inline-block}@media (max-width:1139px){.article-header__info{margin-top:0}}.article-header__info i.faded{padding-left:6px;display:inline-block}.article-header a.faded:hover{color:#fff;color:hsla(0,0%,100%,.6)}.article-header .dropBlock{position:relative}@media (max-width:1139px){.article-header .dropBlock{position:static}}.article-header__journal{margin-right:5px}.article-header__sub-title{display:block;margin-top:-9px;margin-bottom:12px;font-size:1.38rem;font-weight:300}.article-header .loa{margin-bottom:16px;line-height:29px}.article-header .loa .faded{font-size:.85rem;margin-left:4px;font-weight:300}.article-header .loa .faded:hover{color:#fff;color:hsla(0,0%,100%,.6)}.article-header .loa__item__email{margin-right:0}.article-header .loa .article-header__info{margin-top:0}.article-header__meta{text-transform:uppercase;margin-bottom:12px}@media (max-width:1139px){.article-header__meta a,.article-header__meta span{font-size:.69rem}}.article-header__middle{max-width:800px}.article-header__doi,.article-header__publish-date{margin-bottom:10px;display:inline-block}.article-header__doi__label,.article-header__publish-date__label{margin-right:5px}@media (max-width:531px){.article-header__doi__value,.article-header__publish-date__value{word-break:break-all}}.article-header__mark{font-size:.875rem;text-transform:uppercase;font-weight:700}.article-header__sep{margin-right:5px}.article-header__meta span:not(.article-header__journal),.article-header__series{color:#fff;color:hsla(0,0%,100%,.7)}.article-header__title{display:block}@media (max-width:1139px){.article-header__title{margin-bottom:15px}}@media (min-width:768px){.article-header__title{margin-bottom:22px}}.article-header__wrapper{position:relative;z-index:888}.article-header .what-image__wrapper{width:100%;overflow:hidden;position:absolute;top:0;left:0;right:0;bottom:0;z-index:0;max-height:420px}.article-header .what-image{transform:rotate(20deg) skew(-15deg);border:25px solid #fff;height:100%;right:0;opacity:.3;outline:1px solid grey;position:absolute;top:105px;width:40%;min-height:520px;z-index:0}@media (max-width:767px){.article-header .what-image{right:-450px;opacity:.15;top:165px;width:650px;max-width:650px}}.article-header .plum-jbs-theme{float:right}.article-header .plum-jbs-theme .ppp-container.ppp-badge.ppp-small .ppp-pop{top:auto;bottom:-15px}.article-header .plum-jbs-theme .ppp-container.ppp-badge.ppp-small .ppp-pop:after,.article-header .plum-jbs-theme .ppp-container.ppp-badge.ppp-small .ppp-pop:before{bottom:17px;top:auto}.article-header .PlumX-Popup .ppp-container.ppp-badge>a{font-size:1.13rem}.dropBlock [data-db-target-of]{border:16px solid hsla(0,0%,92.2%,.85);padding:20px;box-shadow:none;z-index:101}@media (max-width:767px){.dropBlock [data-db-target-of]{z-index:9999}}.dropBlock [data-db-target-of]:before{content:"";background:#fff;top:0;left:0;right:0;bottom:0;position:absolute;z-index:-1}.figure__title{margin-top:14px;font-weight:700}.figure__title .label{margin-right:5px;display:inline;color:#505050}figure{margin:24px 0;padding:30px 0;border-top:1px solid silver;border-bottom:1px solid silver}figure img{cursor:pointer}figure .figure__label,figure .figure__title__text{font-size:.875rem}@media (max-width:1139px){figure .figure__label,figure .figure__title__text{font-size:.75rem}}.figures{display:flex;flex-direction:row;max-width:100%;justify-content:flex-start;flex-wrap:wrap}.figures__thumbnail{flex:0 1 auto;margin-bottom:30px;width:100%;position:relative;display:flex;flex-direction:column}@media (min-width:532px){.figures__thumbnail{width:31%;min-width:150px;margin-right:2%}}.figures .thumbnail__image{margin-bottom:10px;border:1px solid #ccc;padding:4px;position:relative}.figures .thumbnail__image>div{max-height:200px;overflow:hidden;cursor:pointer}@media (max-width:1139px){.figures .thumbnail__image>div{height:140px}}@media (min-width:1140px) and (max-width:1499px){.figures .thumbnail__image>div{height:100px}}@media (min-width:1500px){.figures .thumbnail__image>div{height:200px}}.figures .thumbnail__image>div img{display:block;width:100%;max-width:none}.figures .thumbnail__image>div img.tall{height:auto}.figures .figure__title{margin:0;overflow:hidden;white-space:nowrap;text-overflow:ellipsis;max-width:100%}.figures .figure__title__text{font-weight:400}.linked-article__item{margin-bottom:32px}.linked-article__details{margin-bottom:4px}.linked-article__details span:before{display:inline;content:", "}.linked-article__details span:first-child:before{display:none}.linked-article__links a{color:#969696;font-size:1rem}.linked-article__links a:hover{color:#505050}.linked-article__links li{float:left}.linked-article .bulleted:after{margin-left:6px;margin-right:5px}.reference-citations{display:inline-block}.reference-citations__ctrl{border-bottom:2px solid #ebebeb}table .reference-citations.dropBlock{display:inline}.ref{position:relative;margin-top:-4px;counter-reset:refCounter;padding-left:.625rem}.ref+.ref{margin-top:34px}.ref__authors__name{font-size:1rem;line-height:1.75rem}@media (min-width:532px){.ref__authors__name{font-size:1.125rem}}.ref__title{margin:0;font-weight:700}.ref__seriesVolume{font-weight:700}.ref__controls{margin-top:.875rem;line-height:1.75rem}@media (min-width:1500px){.ref__controls{display:flex;flex-direction:row;align-items:center}}@media (min-width:1500px){.ref__controls__viewInArticle+ul{margin-left:3ex}}.ref__controls a{font-size:1rem;border-bottom:2px solid #ebebeb}@media (min-width:1500px){.ref__controls a{display:inline-flex;align-items:center;flex-wrap:nowrap}}@media (max-width:1499px){.ref__controls a{display:inline-block}}.ref__controls a i{font-size:.5rem;color:#969696;margin-left:1ex}.journal-logos{vertical-align:middle;float:left}.journal-logos img{max-height:100%}@media (max-width:767px){.journal-logos img{max-height:32px}}.supplemental-information{font-size:1rem}.supplemental-information__item{margin-bottom:18px;border-bottom:2px solid #e1e1e1;padding-bottom:20px}.supplemental-information__icon{font-size:2.48rem;color:#000;margin-bottom:22px}@media (min-width:768px){.supplemental-information__help{float:right}}.left-side-nav{left:16px;overflow-y:auto}.article__body .left-side-nav{width:8%}@media (max-width:1499px){.article__body .left-side-nav{width:16%}}@media (max-width:1139px){.left-side-nav{display:none}}.left-side-nav li{margin-bottom:15px;font-size:.875rem}.left-side-nav li a{display:block;padding-left:10px;color:#505050;border-left:2px solid transparent}.left-side-nav li a.active,.left-side-nav li a.js--active,.left-side-nav li a:hover{color:#005789;border-color:#005789}@media (max-width:1139px){.left-side-nav li a.active,.left-side-nav li a.js--active,.left-side-nav li a:hover{color:#018ddd;border-color:#018ddd}}.article-header{padding:40px 40px 40px 128px;color:var(--theme-font-color,#fff);background:var(--theme-color,#005789)}@media (max-width:1139px){.article-header{padding:18px 16px;background-position-x:center}}@media (min-width:1140px){.article-header{padding-top:28px}}@media (min-width:1140px){.article-header__title.smaller{font-size:1.625rem}.article-header__title{line-height:2.25rem;min-height:72px}.article-header__bottom{margin-top:-40px;margin-bottom:40px}.article-header__bottom .plum-jbs-theme{position:absolute;right:16px}}.article-header__overlay{position:absolute;top:0;left:0;right:0;bottom:0;background-size:cover;background-repeat:no-repeat}.article-header a{border-bottom:2px solid hsla(0,0%,100%,.2);color:var(--theme-font-color,#fff)}.article-header a:hover{color:var(--theme-font-color,#fff);opacity:.8}.article-header .loa .faded:hover{opacity:.8}.article-header .article-tools__dropblock__holder a{position:relative;display:block}.article-header .article-tools__dropblock__holder a:hover{color:#005789;color:rgba(0,87,137,.6)}.article-header .article-tools__more .dropBlock__holder a{color:#005789;border-bottom:0;margin-bottom:0}.article-header .article-tools__more .dropBlock__holder a:hover{color:var(--theme-hover-color,silver)}@media (min-width:1140px){.article-header .article-tools__more .dropBlock__holder a{color:inherit}.article-header .article-tools__more .dropBlock__holder a:hover{color:var(--theme-hover-color,#fff);color:var(--theme-hover-color,hsla(0,0%,100%,.6))}}.article-header a.faded,.article-header i.faded,.article-header span.faded{color:var(--theme-font-color,#fff);opacity:.7}.article-header a.faded:hover{color:var(--theme-font-color,#fff);opacity:.5}.article-header__meta span:not(.article-header__journal){color:var(--theme-font-color,#fff);opacity:.7}.article-header__meta span.article-header__date.faded{display:inline-block}@media (min-width:1140px){.article-header__meta{margin:10px 0 20px}}.article-header__meta a,.article-header__meta span{font-size:.875rem}@media (max-width:1139px){.article-header__meta a,.article-header__meta span{font-size:.75rem}}.article-header .PlumX-Popup .ppp-container.ppp-badge>a{font-family:Helvetica;border-bottom:0}.article-header__journal{font-weight:600}@media (max-width:313px){ul.loa[data-number-of-author] li:not(:last-child):after{line-height:20px}}@media (min-width:1140px){ul.loa[data-number-of-author]{margin-top:21px}}.article-info a,.article-info a:hover{color:var(--theme-headings)}.article-info a:hover{opacity:.6}.figures .figure__title .label{font-size:1.125rem}.refs ol:not([class^=rlist]):not([class~=rlist])>li.ref{line-height:27.008px;line-height:1.688rem}.refs ol:not([class^=rlist]):not([class~=rlist])>li.ref:before{display:inline-block;color:#505050;width:2em}.ref:before{counter-increment:refCounter;content:counter(refCounter) ".";position:absolute;left:0}.left-side-nav li a.active,.left-side-nav li a.js--active,.left-side-nav li a:hover{color:var(--theme-headings);border-left-color:var(--theme-headings)}.adplaceholder{position:relative}.adplaceholder--header{overflow:hidden}.adplaceholder--header{justify-content:center;z-index:2;margin-top:0;background-color:#f9f9f9}.adplaceholder--header.widget{margin:0}.adplaceholders{right:16px;z-index:99;max-width:350px}@media (max-width:1139px){.adplaceholders{display:none}}.article-tools{height:55px}@media (max-width:1139px){.article-tools{display:none;position:fixed;z-index:1}}.article-tools a{font-size:.875rem}@media (min-width:768px){.article-tools .article-tools__dropblock{position:relative}}@media (min-width:1140px){.article-tools__dropblock__holder{margin-top:18px}}@media (max-width:1139px){.article-tools__dropblock__holder{margin-top:15px}}@media (min-width:768px){.article-tools__dropblock__holder{right:50%;width:231px;font-size:.875rem}}@media (max-width:767px){.article-tools__dropblock__holder{width:260px;left:50%;margin-left:-130px}.article-tools__dropblock__holder:after{display:none}}.article-tools__dropblock__holder li:last-child a{margin-bottom:0}.article-tools__dropblock__holder:after{content:"";right:-16px;position:absolute;top:-30px;width:0;height:0;border-color:transparent #ebebeb #ebebeb transparent;border-color:transparent hsla(0,0%,92.2%,.95) hsla(0,0%,92.2%,.95) transparent;border-style:solid;border-width:7px}.article-tools .article-tools__ctrl{border-bottom:0;display:block}.article-tools .article-tools__ctrl i{height:25px}@media (max-width:1139px){.article-tools .article-tools__ctrl span{display:none}}.article-tools__ctrl{vertical-align:middle;text-align:center}@media (hover:hover){.article-tools .article-tools__ctrl:hover{color:var(--theme-hover-color,silver)}}@media (max-width:1139px){.article-tools .article-tools__figures{display:none}}.article-tools__holder{text-align:right}.article-tools__ctrl i,.article-tools__more i{display:block;margin-bottom:10px;font-size:1.6rem}@media (max-width:1139px){.article-tools__ctrl i,.article-tools__more i{margin-bottom:0}}.article-tools__item{margin-right:25px}.article-tools__list{display:inline-block;vertical-align:middle}.article-tools__list li{vertical-align:middle;margin-bottom:0}@media (min-width:1140px){.article-tools__more{margin-right:0}.article-tools__more .dropBlock__holder{background-color:transparent;display:inline-block;border:0;position:static;margin-top:0;padding:0;width:auto}.article-tools__more .dropBlock__holder:before{background:transparent}.article-tools__more .dropBlock__holder:after{display:none}.article-tools__more .dropBlock__holder li{display:inline-block;text-align:center;margin-right:25px}.article-tools__more .dropBlock__holder a{color:inherit;border-bottom:0;margin-bottom:0}}@media (min-width:1140px) and (hover:hover){.article-tools__more .dropBlock__holder a:hover{color:silver}}@media (max-width:1139px){.article-tools__more{margin-right:24px}.article-tools__more li{text-align:center}}.profile-links{float:right}.profile-links>li{margin-right:15px;margin-bottom:0;line-height:1;vertical-align:middle}@media (min-width:532px){.profile-links>li{margin-right:32px}}.profile-links>li:before{display:none}@media (hover:hover){.profile-links a:hover{color:silver}}@media (max-width:767px){.profile-links a{font-size:1.13rem}}@media (max-width:1139px){.profile-links .profile-links__claim,.profile-links .profile-links__logIn,.profile-links .profile-links__loginHtml,.profile-links .profile-links__register,.profile-links .profile-links__subscribe{display:none}}@media (hover:hover){.quick-search .search-drawer:hover{color:var(--theme-color,silver)}}.article__body{position:relative;font-size:1rem;line-height:1.69rem;margin-top:14px}@media (min-width:768px){.article__body{font-size:1.125rem}}.article__sections>section:first-of-type>h2{margin-top:30px}@media (min-width:1140px){.article__sections .section-paragraph>.reference-citations{position:relative}}@media (min-width:1140px){.article__sections{padding-right:100px;margin-top:-15px}}.article__sections .keywords-list a{font-size:1rem}.article__sections :target:before{content:"";display:block;z-index:-1;position:relative}@media (min-width:768px){.article__sections :target:before{height:130px;margin:-130px 0 0}}@media (min-width:1140px){.article__sections :target:before{height:170px;margin:-170px 0 0}}.OALabel{color:#f78300}.OALabel{font-size:.825rem}#open-crossmark{display:inline-block!important;margin-top:-5px;vertical-align:middle;border-bottom:0}.section-paragraph>.reference-citations{display:inline}.content-navigation a{color:#005789}.content-navigation a:focus .content-navigation__body.next,.content-navigation a:hover .content-navigation__body.next{left:-243px}.content-navigation a:focus .content-navigation__body.pre,.content-navigation a:hover .content-navigation__body.pre{right:-243px}.content-navigation a:focus i,.content-navigation a:hover i{color:var(--theme-headings,#005789);position:relative}.content-navigation__body{position:absolute;top:0;bottom:0;width:290px;background-color:#fff;line-height:1.4rem}.content-navigation__body.next{left:91px;padding:14px 50px 14px 15px;transition:left .1s}.content-navigation__body.pre{right:91px;padding:14px 15px 14px 50px;transition:right .1s}.content-navigation__body__top{font-size:.75rem}.content-navigation__body__title,.content-navigation__body__top{display:block}.content-navigation__body__title{color:#505050;max-width:225px;margin:0 auto;overflow:hidden;font-size:1rem}.content-navigation__btn__wrapper--next,.content-navigation__btn__wrapper--prev{overflow:hidden;position:absolute;top:0;bottom:1px;width:300px}.content-navigation__btn__wrapper--next{right:0}.content-navigation__btn--pre,.content-navigation__btn__wrapper--prev{left:0}.content-navigation__btn--next{right:0}@media (max-width:1139px){.content-navigation .content-navigation__body{display:none}.content-navigation .content-navigation__btn--next{right:15px}.content-navigation .content-navigation__btn--pre{right:75px;left:auto}.content-navigation .content-navigation__btn--next,.content-navigation .content-navigation__btn--pre{position:fixed;bottom:0;margin:0;top:auto;z-index:1;padding:10px 14px;background:#969696}.content-navigation .content-navigation__btn--next:hover,.content-navigation .content-navigation__btn--pre:hover{background:#969696;background:hsla(0,0%,58.8%,.7)}}.menu-drawer__ctrl{position:relative;z-index:999;display:flex;flex-direction:column;justify-content:center;align-items:center;width:64px;height:64px}@media (min-width:532px){.menu-drawer__ctrl{width:80px;height:80px}}.menu-drawer__ctrl:focus,.menu-drawer__ctrl a{color:#fff}@media (hover:hover){.menu-drawer__ctrl a:hover{color:silver}}.menu-drawer__ctrl span i{display:flex;flex-direction:column;justify-content:center;align-items:center;font-size:2rem}.menu-drawer__ctrl span i:before{width:26px;display:block;margin-top:-2px}@-moz-document url-prefix(){.registration .registration__field select{padding:20px 11px 8px;color:#000;color:transparent;text-shadow:0 0 0 #666}}@-moz-document url-prefix(){.advanced-search select{padding:6px 8px;color:#000;color:transparent;text-shadow:0 0 0 #505050}}@-moz-document url-prefix(){.audio-video--audio .audio-video__media{background:transparent}}@media not all and (min-resolution:0.001dpcm){@supports (-webkit-appearance:none) and (stroke-color:transparent){.audio-video--audio .audio-video__media{background:transparent}}}@-moz-document url-prefix(){.audio-video--audio .audio-video__media audio[style]{height:40px!important}}@media not all and (min-resolution:0.001dpcm){@supports (-webkit-appearance:none) and (stroke-color:transparent){.audio-video--audio .audio-video__media audio[style]{height:31px!important}}}.menu-drawer__ctrl a{color:var(--theme-header-font-color,var(--theme-font-color,#fff))}@media (hover:hover){.menu-drawer__ctrl a:hover{color:var(--theme-hover-color,silver)}}.quick-search .dropBlock i{padding:0;margin:0}.quick-search .dropBlock>a{border:0}.quick-search .search-drawer{color:var(--theme-header-font-color,var(--theme-font-color,#fff))}@media (hover:hover){.quick-search .search-drawer:hover{color:var(--theme-hover-color,silver)}}.profile-links a{font-size:1.25rem;color:var(--theme-header-font-color,var(--theme-font-color,#fff))}.fonts-loaded .profile-links a{font-family:Nexus Sans Pro,sans-serif}.profile-links a:hover{text-decoration:underline}@media (hover:hover){.profile-links a:hover{color:var(--theme-hover-color,silver)}}@media (max-width:767px){.profile-links a{font-size:1.13rem}}.content-navigation__btn--next,.content-navigation__btn--pre{position:absolute;top:50%;margin-top:-46px;padding:31px 16px;background:hsla(0,0%,100%,.3);z-index:888}.content-navigation__btn--next i,.content-navigation__btn--pre i{color:var(--theme-font-color);font-size:1.6rem;line-height:1.35}@media (max-width:1139px){.adplaceholders{display:block;max-width:none}}@media (hover:hover){.article-tools .article-tools__ctrl:hover{color:var(--theme-hover-color,#fff);color:var(--theme-hover-color,hsla(0,0%,100%,.6))}}.footer{position:relative;z-index:100;background-color:#fff}.footer__bottom{padding:30px 0 0;margin-bottom:-26px;overflow:hidden;position:relative;z-index:1;background:#fff}@media (min-width:532px){.footer__bottom{padding:30px 16px;margin-bottom:0}}.footer .copy-right{font-size:.875rem;padding:30px 16px!important}@media (min-width:532px){.footer .copy-right{padding:30px 32px}}header{width:100%;background-color:#fff;border-bottom:2px solid #ebebeb}header .header__wrapper{position:relative;height:64px}header .header__wrapper>div>div{height:64px}@media (min-width:532px){header .header__wrapper,header .header__wrapper>div>div{height:80px}}header .quick-search .search-drawer{display:inline-block;margin-right:22px}@media (min-width:768px){header .quick-search .search-drawer{margin-right:5px}}@media (max-width:767px){header .quick-search .search-drawer{margin-right:3px}}header .quick-search .search-drawer i{font-size:20px;display:block}header .journal-logos{display:block;margin-left:0;max-width:calc(100% - 68px)}@media (max-width:767px){header .journal-logos{max-width:100%}}@media (min-width:768px){header .journal-logos{margin-left:16px}}header .journal-logos a{display:flex}header .journal-logos-wrapper{display:flex;align-items:center}header .journal-logos-wrapper .journal-logos{position:static;top:auto;transform:none}header.fixed{position:fixed;top:0;z-index:895}@media (max-width:767px){header.fixed{position:absolute;top:0!important}}.header{box-shadow:0 2px 0 0 #ebebeb}.header__nav{display:flex;flex-direction:row-reverse;justify-content:flex-start;align-items:center}@-moz-document url-prefix(){.do-detail-media--audio,.do-item-media--audio{background:transparent;height:40px!important}}@media not all and (min-resolution:0.001dpcm){@supports (-webkit-appearance:none) and (stroke-color:transparent){.do-detail-media--audio,.do-item-media--audio{background:transparent;height:31px!important}}}@-moz-document url-prefix(){.do-detail-media--audio audio[style],.do-item-media--audio audio[style]{height:40px!important}}@media not all and (min-resolution:0.001dpcm){@supports (-webkit-appearance:none) and (stroke-color:transparent){.do-detail-media--audio audio[style],.do-item-media--audio audio[style]{height:31px!important}}}.header{color:var(--theme-font-color)}:root{--theme-journal:#736759;--theme-color:#736759;--theme-font-color:#fff;--theme-background:linear-gradient(100deg,#484038,#736759 50%,#90816f);--theme-headings:#736759}</style>
<meta http-equiv=X-UA-Compatible content="IE=edge">
<style>@keyframes onetrust-fade-in{0%{opacity:0}100%{opacity:1}}#_atssh{width:1px!important;height:1px!important;border:0!important}#MathJax_Message{position:fixed;left:1em;bottom:1.5em;background-color:#E6E6E6;border:1px solid #959595;margin:0px;padding:2px 8px;z-index:102;color:black;font-size:80%;width:auto;white-space:nowrap}</style><meta http-equiv=origin-trial content="AzoawhTRDevLR66Y6MROu167EDncFPBvcKOaQispTo9ouEt5LvcBjnRFqiAByRT+2cDHG1Yj4dXwpLeIhc98/gIAAACFeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv=origin-trial content="A6+nc62kbJgC46ypOwRsNW6RkDn2x7tgRh0wp7jb3DtFF7oEhu1hhm4rdZHZ6zXvnKZLlYcBlQUImC4d3kKihAcAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv=origin-trial content="A/9La288e7MDEU2ifusFnMg1C2Ij6uoa/Z/ylwJIXSsWfK37oESIPbxbt4IU86OGqDEPnNVruUiMjfKo65H/CQwAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta name=dc.identifier scheme=doi content=doi:10.1016/j.jval.2017.06.013 class=sf-hidden><link type=image/x-icon rel="shortcut icon" href="data:image/x-icon;base64,AAABAAEAEBAAAAEAIABoBAAAFgAAACgAAAAQAAAAIAAAAAEAIAAAAAAAAAQAABMLAAATCwAAAAAAAAAAAAD/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA=="><style>.sf-hidden{display:none!important}</style><link rel=canonical href=https://www.valueinhealthjournal.com/article/S1098-3015(17)30316-9/fulltext#relatedArticles><meta http-equiv=content-security-policy content="default-src 'none'; font-src 'self' data:; img-src 'self' data:; style-src 'unsafe-inline'; media-src 'self' data:; script-src 'unsafe-inline' data:;"></head>
<body class=pb-ui><div id=MathJax_Message style=display:none></div>
 <div class=skip>
 <a href=#pageBody id=skipNavigationLink title="Skip to Main Content" tabindex=0>Skip to Main Content</a>
 </div>
 
 <div id=pb-page-content data-ng-non-bindable>
 <div data-pb-dropzone=main data-pb-dropzone-name=Main>
 <div data-widget-def=ux3-layout-widget data-widget-id=54cf691d-1d44-49ee-922c-5ca55dc1d4af class=ux3>
 
 
 
 
 
 
 <div class="jval fonts-loaded">
 
 <div data-widget-id=54cf691d-1d44-49ee-922c-5ca55dc1d4af data-widget-name=ux3-layout-widget><div>
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 <div class="widget general-html none widget-none" id=1c43b980-a0aa-42c5-885f-23557fb2ab3f>
 
 
 <div class=wrapped>
 
 <div class="widget-body body body-none"><style class=sf-hidden>:root{--theme-background:linear-gradient(100deg,#736759 0%,#736759 50%,#736759 100%)}</style></div>
 </div>
 </div>
 
 
 
 
 
 
 <div data-widget-id=249b2c00-88e5-43c8-a274-0ec4e29f652d data-widget-name=UX3HTMLWidget><style class=sf-hidden>.ux3 .header{background:#736759!important}.article-header .content-navigation:not(.js--sticky) a:focus i,.article-header .content-navigation:not(.js--sticky) a:hover i,.article__body h2,.article__body h3,.article__body h4,.content-navigation__body__top,table th{color:#736759!important}.left-side-nav li a.active,.left-side-nav li a.js--active,.left-side-nav li a:hover{color:#736759!important;border-left-color:#736759!important}.article-header__overlay{background:linear-gradient(100deg,#564d43 0,#736759 50%,#8a7c6b 100%)!important}</style></div>
 
 
 
 
 
 
 
 <div data-widget-id=ce55ee24-5538-4b41-b162-c93a966d8add data-widget-name=UX3HTMLWidget><style class=sf-hidden>.journal-logos:nth-of-type(2) img{max-height:20px!important;height:20px}.ux3 .journal-logos+.journal-logos{margin-left:24px}.header__wrapper.clearfix .col-xs-6:first-of-type{width:55%}.header__wrapper.clearfix .col-xs-6:nth-of-type(2){width:45%}@media screen and (max-width:1000px){.ux3 .journal-logos+.journal-logos{display:none}.header__wrapper.clearfix .col-xs-6:first-of-type{width:50%}.header__wrapper.clearfix .col-xs-6:nth-of-type(2){width:50%}}</style></div>
 
 
 
 
 
 
 
 <div class=ux3-ads>
 
 <div class="pb-ad sf-hidden">
 
<style>.gpt-InScrollBox{height:100vh!important;width:100vw;cursor:pointer;max-width:100vw;position:relative;left:50%;right:50%;margin-left:-50vw;margin-right:-50vw;margin-bottom:50px;padding-top:5px;padding-bottom:5px;z-index:10001;background-color:white}</style>
 </div>
 
 </div>
 
 
 
 
 
 
 
 <div data-widget-id=53023812-5eb3-476f-8922-6f6f95be0a5c data-widget-name=ux3-layout-widget><header class="header base fixed">
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 <div class="widget literatumAd none adplaceholder adplaceholder--header js__adToHide widget-horizontalAd" id=ad532c9c-4e0f-4b0d-8b27-9bd0ddbdb190 style=display:none>
 
 
 
 </div>
 
 <div data-widget-def=ux3-layout-widget data-widget-id=3bd430f7-bd17-4546-89a2-5b0ca3b18cdf class="header__wrapper clearfix" data-db-parent-of=quickSearch>
 
 
 
 
 
 
 <div data-widget-id=3bd430f7-bd17-4546-89a2-5b0ca3b18cdf data-widget-name=ux3-layout-widget><div class="col-xs-6 col-lg-6 journal-logos-wrapper">
 
 
 
 
 
 <div class=journal-logos>
 
 <span data-widget-id=ecdbcba0-b4aa-4389-a4c7-33705333b11e data-widget-name=ux3-general-image><a href=https://www.valueinhealthjournal.com/home title="Value in Health"><img alt="Value in Health" src="data:image/svg+xml;base64,<?xml version="1.0" encoding="utf-8"?>
<svg version="1.1" id="jval" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px"
	 viewBox="0 0 101.2 50" style="enable-background:new 0 0 101.2 50;" xml:space="preserve" width="101.2" height="50">
<style type="text/css">
	.st0{fill:#DFBE4D;}
</style>
<g>
	<g>
		<path class="st0" d="M10.2,22.9c0.4,0,0.8,0,1.1,0c0.2,0,0.2,0,0.3-0.2c2.2-5.8,4.5-11.6,6.7-17.5l2-5.1c0,0,0-0.1,0-0.1l-0.4,0
			c-0.5,0-1,0-1.5,0c-0.2,0-0.2,0-0.3,0.2c-1.9,5-3.7,9.9-5.6,14.9l-0.6,1.7c-0.3,0.9-0.7,1.8-1,2.7L10.2,21L10,20.5
			c0-0.1-0.1-0.1-0.1-0.2L5.1,7.4C4.2,5,3.3,2.6,2.4,0.2C2.3,0.1,2.2,0,2.2,0C1.6,0,1,0,0.4,0L0,0c0,0.1,0,0.1,0.1,0.2L3,7.8
			c1.9,5,3.8,9.9,5.7,14.9c0.1,0.1,0.1,0.2,0.2,0.2C9.4,22.9,9.8,22.9,10.2,22.9z"/>
	</g>
	<g>
		<path class="st0" d="M61.9,5.8c-0.4,0-0.9,0-1.3,0.1c-2.5,0.3-4.3,1.6-5.6,3.8c-1.3,2.2-1.6,4.7-0.9,7.4c0.8,3.1,2.7,5,5.8,5.9
			c1.4,0.4,2.9,0.4,4.7,0.1c1.3-0.2,2.3-0.6,3.2-1.3c0.1-0.1,0.1-0.1,0.1-0.1c0-0.6,0-1.1,0-1.7v-0.3l-0.1,0
			c-0.1,0.1-0.2,0.1-0.3,0.2c-2.1,1.4-4.5,1.9-7,1.3c-2.3-0.5-4.3-2.7-4.7-5.1c-0.1-0.3-0.1-0.7-0.1-1c0-0.2,0-0.3,0-0.5l0-0.2h12.9
			c0-0.2,0-0.4,0-0.6c0-1.1,0-2.1-0.2-3.1c-0.4-1.9-1.4-3.3-3-4.2C64.4,6.1,63.2,5.8,61.9,5.8z M66.7,12.8H56l0-0.2
			c0.4-2.7,2.3-4.7,4.7-5c1-0.2,2-0.1,2.9,0.2c1.6,0.5,2.6,1.8,2.9,3.6c0,0.3,0.1,0.5,0.1,0.8c0,0.1,0,0.3,0,0.4L66.7,12.8z"/>
	</g>
	<g>
		<path class="st0" d="M27.3,13.4c0,0-0.1,0-0.1,0c-0.3,0-0.7,0-1,0c-0.7,0-1.5,0-2.2,0.1c-1.2,0.1-2.4,0.3-3.5,0.8
			c-1.9,0.8-2.9,2.1-3,4c-0.1,1.9,0.8,3.3,2.5,4.2c1.1,0.5,2.3,0.7,3.4,0.8c2,0.2,4,0,6.1-0.5c0.2,0,0.2-0.1,0.2-0.2
			c0-1.3,0-2.6,0-3.8c0-2.7,0-5.6-0.1-8.4c0-2.3-1.2-3.7-3.4-4.3c-2.3-0.6-4.6-0.2-7.1,1c0,0-0.1,0.1-0.1,0.1c0,0.5,0,1,0,1.6l0,0.3
			l0.1-0.1c0.3-0.1,0.5-0.2,0.7-0.3c1.7-0.8,3.4-1,5-0.8c1.4,0.2,2.4,1.2,2.6,2.6c0.1,0.6,0.1,1.3,0,1.9c0,0.3,0,0.6,0,0.9v0.1
			l-0.2,0C27.4,13.4,27.3,13.4,27.3,13.4z M25,21.5c-1,0-2.1-0.1-3.2-0.4c-0.4-0.1-0.7-0.3-1.1-0.5c-0.8-0.5-1.2-1.3-1.2-2.3
			c0-1,0.5-1.9,1.4-2.4c0.9-0.5,1.8-0.8,2.9-0.8c0.8-0.1,1.6-0.1,2.4-0.1c0.3,0,0.7,0,1,0c0.1,0,0.1,0,0.2,0l0.2,0v6.3l-0.1,0
			c-0.2,0-0.5,0-0.7,0.1C26.3,21.5,25.7,21.5,25,21.5C25.1,21.5,25.1,21.5,25,21.5z"/>
	</g>
	<g>
		<path class="st0" d="M38.4,6.2l0,2.9c0,2.6,0,5.1,0,7.7c0,0.6,0,1.2,0.1,1.8c0.2,1.7,1,2.9,2.5,3.7c1.2,0.6,2.6,0.9,4.3,0.9
			c1.1,0,2.3,0,3.6-0.1c0.7-0.1,1.4-0.2,2.1-0.3c0.3,0,0.5-0.1,0.8-0.1V6.2h-2v15.2l-0.1,0c-0.4,0-0.8,0-1.2,0.1
			c-0.9,0-1.9,0.1-2.9,0.1c-0.6,0-1.4-0.1-2.2-0.3c-1.1-0.3-1.8-0.8-2.4-1.6c-0.3-0.6-0.5-1.2-0.5-2c0-2.7,0-5.5,0-8.2l0-3.2H38.4z"
			/>
	</g>
	<g>
		<path class="st0" d="M32.9,22.9h2V0h-2V22.9z"/>
	</g>
	<g>
		<g>
			<path class="st0" d="M89.7,23.3h1.7l0-2.5c0-2.1,0-4.2,0-6.3c0-0.7,0-1.3-0.1-1.9c-0.1-1.1-0.6-1.9-1.3-2.5
				c-0.9-0.7-2-1.1-3.4-1.2c-2.1-0.1-4.3,0.2-6.6,1c-0.1,0.1-0.2,0.1-0.2,0.2c0,3.7,0,7.3,0,11v2.2h1.7V11.8c0-0.7,0-0.8,0.7-0.9
				c1.8-0.4,3.3-0.5,4.7-0.2c1.3,0.2,2.4,1.1,2.6,2.4c0.1,0.4,0.1,0.9,0.1,1.4c0,2.2,0,4.3,0,6.5L89.7,23.3z"/>
		</g>
		<g>
			<path class="st0" d="M74.4,23.3h1.7v-14h-1.7V23.3z"/>
		</g>
		<g>
			<path class="st0" d="M75.2,3.3c-0.3,0-0.7,0.2-0.9,0.4c-0.3,0.3-0.4,0.6-0.4,0.9c0,0.7,0.6,1.3,1.3,1.3c0,0,0,0,0,0
				c0.7,0,1.3-0.6,1.3-1.3c0-0.4-0.1-0.7-0.4-1C75.9,3.4,75.6,3.3,75.2,3.3C75.2,3.3,75.2,3.3,75.2,3.3L75.2,3.3z"/>
		</g>
	</g>
	<g>
		<g>
			<path class="st0" d="M35.6,49.6h2V26.7h-2v10.3H20.8V26.7h-2v22.8h2V38.8h14.8V49.6z"/>
		</g>
	</g>
	<g>
		<g>
			<g>
				<path class="st0" d="M87.5,49.6h1.9l0-2.6c0-3.8,0-7.6,0-11.3c0-0.2,0-0.5,0.4-0.6c2-0.6,3.9-0.8,5.7-0.6
					c2.3,0.3,3.7,1.8,3.7,4.1c0,2.6,0,5.4,0,7.6c0,1.1,0,2.2,0,3.3v0.1h1.9c0-1,0-2,0-3c0-2.8,0-6,0-9c0-0.9-0.2-1.7-0.7-2.5
					c-0.6-1-1.6-1.7-3-2.1c-1.8-0.5-3.7-0.5-5.9,0c-0.4,0.1-0.8,0.2-1.2,0.3l-0.1,0c-0.2,0-0.3,0.1-0.5,0.1l-0.3,0.1v-6.7h-1.9V49.6
					z"/>
			</g>
		</g>
	</g>
	<g>
		<g>
			<g>
				<path class="st0" d="M65.2,40.1l-0.1,0c-0.3,0-0.6,0-0.8,0l-0.1,0c-0.7,0-1.5,0-2.3,0.1c-1.4,0.1-2.6,0.3-3.7,0.8
					c-1.7,0.8-2.6,2-2.7,3.7c-0.1,1.9,0.6,3.2,2.2,4.1c1.1,0.6,2.3,0.9,3.8,1c1.9,0.2,3.9,0,6-0.5c0.2,0,0.2-0.1,0.2-0.3
					c0-2,0-3.9,0-5.9c0-1.5,0-3,0-4.6v0c0-0.6,0-1.3-0.1-1.9c-0.2-1.9-1.1-3.1-2.9-3.7c-1.2-0.4-2.5-0.5-4.1-0.3
					c-1.2,0.2-2.3,0.5-3.4,1.1c-0.1,0-0.1,0.1-0.1,0.1c0,0.5,0,1,0,1.5v0.2l0.1-0.1c0.3-0.1,0.5-0.3,0.8-0.4c1.7-0.7,3.3-1,4.9-0.7
					c1.5,0.2,2.5,1.2,2.7,2.6c0.1,0.7,0.1,1.3,0.1,2c0,0.3,0,0.6,0,0.9l0,0.2L65.2,40.1z M62.9,48.4c-1.2,0-2.2-0.1-3.1-0.5
					c-0.8-0.2-1.3-0.6-1.7-1.1c-0.5-0.7-0.7-1.4-0.6-2.2c0.2-0.8,0.7-1.6,1.5-2c0.8-0.5,1.8-0.7,2.8-0.8c0.8-0.1,1.7-0.1,2.5-0.1
					c0.3,0,0.7,0,1,0c0.1,0,0.1,0,0.2,0c0,0,0.1,0,0.1,0l0.2,0v6.4l-0.2,0c-0.1,0-0.2,0-0.3,0l-0.1,0c-0.3,0-0.5,0.1-0.8,0.1
					C63.8,48.3,63.3,48.4,62.9,48.4z"/>
			</g>
		</g>
	</g>
	<g>
		<g>
			<g>
				<path class="st0" d="M71.1,49.6H73V26.7h-1.9V49.6z"/>
			</g>
		</g>
	</g>
	<g>
		<g>
			<path class="st0" d="M75.3,34.5h2.6l0,3.8c0,2.3,0,4.5,0,6.8c0,0.8,0,1.6,0.3,2.3c0.4,1.3,1.2,2.1,2.4,2.4
				c0.4,0.1,0.8,0.1,1.2,0.2c0,0,0.1,0,0.1,0l0,0c1.1,0.1,2.2,0,3.7-0.2v-1.6c-0.1,0-0.2,0-0.3,0l0,0c-0.3,0-0.5,0.1-0.8,0.1
				c-0.8,0.1-1.6,0.1-2.3,0c-0.4,0-1-0.1-1.5-0.5c-0.6-0.5-0.9-1.2-0.9-2.1c0-2.7,0-5.5,0-8.2l0-2.6c0-0.1,0-0.1,0-0.2
				c0,0,0-0.1,0-0.1l0-0.2h4.7v-1.5h-4.8v-4.1h-1.9v4.1h-2.6V34.5z"/>
		</g>
	</g>
	<g>
		<path class="st0" d="M48,32.5c-0.4,0-0.9,0-1.3,0.1c-2.5,0.3-4.3,1.6-5.6,3.8c-1.3,2.2-1.6,4.7-0.9,7.4c0.8,3.1,2.7,5,5.8,5.9
			c1.4,0.4,2.9,0.4,4.7,0.1c1.3-0.2,2.3-0.6,3.2-1.3c0.1-0.1,0.1-0.1,0.1-0.1c0-0.6,0-1.1,0-1.7v-0.3l-0.1,0
			c-0.1,0.1-0.2,0.1-0.3,0.2c-2.1,1.4-4.5,1.9-7,1.3c-2.3-0.5-4.3-2.7-4.7-5.1c-0.1-0.3-0.1-0.7-0.1-1c0-0.2,0-0.3,0-0.5l0-0.2h12.9
			c0-0.2,0-0.4,0-0.6c0-1.1,0-2.1-0.2-3.1c-0.4-1.9-1.4-3.3-3-4.2C50.5,32.8,49.3,32.5,48,32.5z M52.8,39.5H42.1l0-0.2
			c0.4-2.7,2.3-4.7,4.7-5c1-0.2,2-0.1,2.9,0.2c1.6,0.5,2.6,1.8,2.9,3.6c0,0.3,0.1,0.5,0.1,0.8c0,0.1,0,0.3,0,0.4L52.8,39.5z"/>
	</g>
</g>
</svg>
"></a></span>
 
 </div>
 
 
 
 
 
 
 
 <div class=journal-logos>
 
 <span data-widget-id=d439245e-9928-4ff3-b2a7-6520166a27f2 data-widget-name=ux3-general-image><a href=http://www.ispor.org/ title=ISPOR target=_blank><img alt=ISPOR src=data:image/svg+xml;base64,<?xml version="1.0" encoding="utf-8"?>
<svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px"
	 viewBox="0 0 219.6 50" style="enable-background:new 0 0 219.6 50;" xml:space="preserve" width="219.6" height="50">
<style type="text/css">
	.st0{display:none;}
	.st1{display:inline;fill:#27AAE1;}
	.st2{display:inline;fill:#FFFFFF;}
	.st3{fill:#FFFFFF;}
	.st4{fill:#25A9E0;}
	.st5{fill:#A6A8AB;}
</style>
<g id="vhri" class="st0">
	<path class="st1" d="M-272.8,2.6c1,0,1.9,0,2.7,0c0.4,0,0.6-0.1,0.8-0.5c5.5-14.3,11-28.6,16.5-42.9l4.8-12.5
		c0-0.1,0.1-0.2,0.1-0.3l-1.1,0c-1.3,0-2.5,0-3.8,0c-0.5,0-0.6,0.1-0.8,0.5c-4.6,12.2-9.1,24.4-13.7,36.6l-1.6,4.2
		c-0.8,2.2-1.6,4.3-2.5,6.6l-1.4,3.6l-0.5-1.1c-0.1-0.2-0.2-0.4-0.2-0.5l-11.9-31.7c-2.2-5.9-4.4-11.8-6.7-17.7
		c-0.1-0.2-0.3-0.4-0.4-0.5c-1.5,0-2.9,0-4.5,0l-0.9,0c0.1,0.2,0.1,0.3,0.2,0.5l7.2,18.8c4.7,12.2,9.4,24.4,14.1,36.6
		c0.1,0.3,0.2,0.4,0.6,0.4C-274.7,2.6-273.7,2.6-272.8,2.6"/>
	<path class="st1" d="M-134.1-22.1h-26.2l0.1-0.4c1-6.6,5.5-11.4,11.4-12.3c2.5-0.4,4.9-0.2,7.2,0.6c4,1.3,6.4,4.3,7.1,8.8
		c0.1,0.7,0.2,1.3,0.3,2c0,0.3,0.1,0.6,0.1,1L-134.1-22.1z M-145.8-39.4c-1,0-2.1,0.1-3.2,0.2c-6,0.8-10.6,4-13.8,9.4
		c-3.2,5.5-3.9,11.6-2.3,18.2c1.9,7.5,6.7,12.3,14.2,14.4c3.4,0.9,7.2,1,11.6,0.2c3.3-0.6,5.8-1.6,7.9-3.1c0.3-0.2,0.3-0.3,0.3-0.3
		c0-1.4,0-2.8,0-4.2v-0.6l-0.2,0.1c-0.2,0.2-0.5,0.3-0.7,0.5c-5.3,3.5-11,4.6-17.1,3.2c-5.7-1.3-10.6-6.5-11.5-12.5
		c-0.1-0.8-0.2-1.6-0.3-2.5c0-0.4-0.1-0.8-0.1-1.2l0-0.4h31.7c0-0.5,0-0.9,0-1.4c0-2.7,0-5.2-0.5-7.7c-1-4.8-3.5-8.1-7.4-10.3
		C-139.7-38.7-142.6-39.4-145.8-39.4"/>
	<path class="st1" d="M-236.3-0.7c-2.4,0-5.1-0.1-7.8-1.1c-0.9-0.3-1.8-0.8-2.7-1.3c-1.9-1.2-3-3.3-2.9-5.6c0-2.4,1.3-4.6,3.4-5.8
		c2.1-1.2,4.5-1.9,7.1-2.1c2-0.1,4-0.2,6-0.2c0.8,0,1.6,0,2.4-0.1c0.2,0,0.3,0,0.5,0l0.5,0v15.5l-0.3,0c-0.6,0.1-1.2,0.1-1.8,0.2
		c-1.4,0.1-2.8,0.3-4.2,0.3H-236.3z M-230.8-20.8c-0.1,0-0.2,0-0.3,0c-0.8,0-1.6,0-2.4,0c-1.8,0-3.7,0.1-5.5,0.1
		c-3,0.2-5.9,0.8-8.5,1.9c-4.8,2-7.1,5.2-7.3,9.7c-0.1,4.7,2,8.2,6.2,10.2c2.7,1.3,5.7,1.7,8.4,2c4.8,0.4,9.8,0,15-1.2
		c0.4-0.1,0.4-0.1,0.4-0.4c0-3.1,0-6.3,0-9.4c0-6.7,0-13.7-0.1-20.5c-0.1-5.7-2.9-9.1-8.4-10.4c-5.6-1.4-11.3-0.6-17.4,2.4
		c-0.1,0-0.2,0.2-0.2,0.2c0,1.3,0,2.5,0,3.8v0.7l0.4-0.2c0.6-0.3,1.2-0.6,1.8-0.8c4.3-1.9,8.3-2.5,12.4-1.9c3.5,0.6,5.9,3,6.3,6.4
		c0.2,1.5,0.1,3.1,0.1,4.7c0,0.7,0,1.5,0,2.2v0.4l-0.6,0C-230.6-20.8-230.7-20.8-230.8-20.8"/>
	<path class="st1" d="M-203.6-38.4l0,7.2c0,6.3,0,12.6,0,18.9c0,1.5,0,3,0.2,4.5c0.5,4.2,2.6,7.2,6.2,9c3,1.5,6.4,2.2,10.5,2.3
		c2.7,0.1,5.5-0.1,8.7-0.3c1.7-0.1,3.4-0.4,5.1-0.7c0.7-0.1,1.3-0.2,2-0.3v-40.6h-5v37.2l-0.3,0c-1,0-2,0.1-3,0.1
		c-2.3,0.1-4.7,0.2-7.1,0.2c-1.6,0-3.3-0.2-5.3-0.7c-2.6-0.6-4.5-2-5.8-4c-0.9-1.4-1.3-3-1.3-4.9c0-6.7,0-13.4,0-20.1l0-7.8H-203.6z
		"/>
	<rect x="-217.1" y="-53.6" class="st1" width="4.9" height="56.1"/>
	<path class="st1" d="M-77.5,3.6h4.2l0-6.2c0-5.2,0-10.4,0-15.6c0-1.8-0.1-3.3-0.3-4.6c-0.3-2.7-1.4-4.7-3.3-6.1
		c-2.2-1.7-4.8-2.6-8.4-2.8c-5.2-0.3-10.4,0.5-16.1,2.4c-0.4,0.1-0.4,0.2-0.4,0.6c0,9,0,17.9,0,26.9v5.4h4.2v-28.3
		c0-1.7,0.1-1.9,1.8-2.2c4.5-1,8.1-1.1,11.5-0.6c3.3,0.5,5.8,2.8,6.5,5.9c0.2,1,0.3,2.2,0.4,3.5c0,5.3,0,10.7,0,16L-77.5,3.6z"/>
	<rect x="-115.1" y="-30.9" class="st1" width="4.1" height="34.5"/>
	<path class="st1" d="M-113.1-45.6c-0.9,0-1.7,0.4-2.3,1c-0.6,0.6-1,1.5-1,2.3c0,1.7,1.6,3.3,3.3,3.3c0,0,0,0,0,0
		c1.7,0,3.3-1.6,3.3-3.3c0-0.9-0.3-1.7-1-2.3C-111.4-45.3-112.2-45.6-113.1-45.6L-113.1-45.6z"/>
	<polygon class="st1" points="-210.3,68 -205.5,68 -205.5,12 -210.4,12 -210.4,37.4 -246.7,37.4 -246.7,12 -251.5,12 -251.5,68 
		-246.6,68 -246.6,41.7 -210.3,41.7 	"/>
	<path class="st1" d="M-82.8,68h4.6l0-6.4c0-9.3,0-18.6,0-27.8c0-0.5,0-1.3,1-1.6c5-1.5,9.6-2,14-1.5c5.7,0.7,9.2,4.5,9.2,10.2
		c0,6.5,0,13.2,0,18.7c0,2.7,0,5.4,0,8V68h4.7c0-2.5,0-5,0-7.5c0-6.9,0-14.7-0.1-22.2c0-2.2-0.6-4.3-1.7-6.2c-1.5-2.5-4-4.2-7.5-5.2
		c-4.4-1.2-9.1-1.2-14.5,0.1c-1,0.2-1.9,0.5-3,0.8l-0.3,0.1c-0.4,0.1-0.8,0.2-1.2,0.3l-0.7,0.2V12h-4.6V68z"/>
	<path class="st1" d="M-143.4,65.1c-2.8,0-5.4-0.4-7.7-1.1c-1.9-0.6-3.3-1.5-4.3-2.7c-1.3-1.6-1.8-3.5-1.4-5.5
		c0.4-2,1.7-3.8,3.7-4.9c2.1-1.2,4.4-1.8,6.9-2c2.1-0.1,4.1-0.2,6.2-0.2c0.9,0,1.7,0,2.5-0.1c0.1,0,0.2,0,0.4,0c0.1,0,0.1,0,0.2,0
		l0.5,0v15.8l-0.4,0.1c-0.2,0-0.4,0.1-0.6,0.1l-0.3,0c-0.6,0.1-1.3,0.2-2,0.3C-141.1,65.1-142.3,65.1-143.4,65.1 M-137.6,44.9
		l-0.3,0c-0.7,0-1.4,0-2,0l-0.3,0c-1.7,0-3.7,0-5.6,0.1c-3.3,0.2-6.3,0.9-9,2.1c-4.3,1.9-6.5,4.9-6.7,9c-0.3,4.5,1.5,7.8,5.3,10.1
		c2.7,1.6,5.6,2.1,9.2,2.4c4.7,0.4,9.6,0.1,14.9-1.1c0.5-0.1,0.5-0.1,0.5-0.6c0-4.8,0-9.7,0-14.5c0-3.7,0-7.5,0-11.2V41
		c0-1.6,0-3.2-0.2-4.8c-0.5-4.7-2.7-7.6-7-9.1c-2.9-1-6.2-1.2-10.1-0.7c-2.8,0.4-5.6,1.3-8.3,2.6c-0.1,0.1-0.2,0.2-0.3,0.2
		c0,1.2,0,2.5,0,3.8v0.4l0.3-0.1c0.7-0.3,1.3-0.6,2-0.9c4.2-1.8,8.1-2.4,12.1-1.7c3.6,0.6,6.1,3.1,6.6,6.5c0.2,1.6,0.2,3.2,0.2,4.8
		c0,0.7,0,1.5,0,2.2l0,0.5L-137.6,44.9z"/>
	<rect x="-123.1" y="12" class="st1" width="4.6" height="56.1"/>
	<path class="st1" d="M-113,31h6.4l0,9.4c0,5.6,0,11.1,0,16.7c0,1.8,0.1,3.8,0.7,5.6c1.1,3.2,3.1,5.1,6,5.8c1,0.2,1.9,0.4,2.9,0.4
		c0.1,0,0.1,0,0.2,0l0.1,0c2.6,0.1,5.5,0,9.1-0.5v-3.9c-0.2,0-0.4,0.1-0.6,0.1l0,0c-0.7,0.1-1.3,0.2-2,0.3c-2,0.2-3.9,0.2-5.6,0.1
		c-1.1-0.1-2.5-0.3-3.7-1.3c-1.5-1.2-2.2-2.9-2.2-5.2c-0.1-6.7-0.1-13.6-0.1-20.2l0-6.4c0-0.1,0-0.3,0.1-0.4c0-0.1,0-0.1,0-0.2
		l0.1-0.4h11.6v-3.8h-11.8V17.1h-4.8v10.2h-6.3V31z"/>
	<path class="st1" d="M-168.3,43.4h-26.2l0.1-0.4c1-6.6,5.5-11.4,11.4-12.3c2.5-0.4,4.9-0.2,7.2,0.6c4,1.3,6.4,4.3,7.1,8.8
		c0.1,0.7,0.2,1.3,0.3,2c0,0.3,0.1,0.6,0.1,1L-168.3,43.4z M-179.9,26.1c-1,0-2.1,0.1-3.2,0.2c-6,0.8-10.6,4-13.8,9.4
		c-3.2,5.5-3.9,11.6-2.3,18.2c1.9,7.5,6.7,12.3,14.2,14.4c3.4,0.9,7.2,1,11.6,0.2c3.3-0.6,5.8-1.6,7.9-3.1c0.3-0.2,0.3-0.3,0.3-0.3
		c0-1.4,0-2.8,0-4.2v-0.6l-0.2,0.1c-0.2,0.2-0.5,0.3-0.7,0.5c-5.3,3.5-11,4.6-17.1,3.2c-5.7-1.3-10.6-6.5-11.5-12.5
		c-0.1-0.8-0.2-1.6-0.3-2.5c0-0.4-0.1-0.8-0.1-1.2l0-0.4h31.7c0-0.5,0-0.9,0-1.4c0-2.7,0-5.2-0.5-7.7c-1-4.8-3.5-8.1-7.4-10.3
		C-173.8,26.8-176.7,26.1-179.9,26.1"/>
	<path class="st2" d="M-48.8,89.8c-0.7-0.8-1.9-1.6-3.8-2.3c-1.1-0.4-1.9-0.8-2.4-1.2c-0.5-0.4-0.9-0.7-1.1-1.2
		c-0.2-0.4-0.3-1-0.3-1.6c0-0.9,0.3-1.6,0.9-2.1c0.6-0.5,1.4-0.8,2.5-0.8c1.4,0,2.7,0.3,4.2,1l0.6-2c-1.4-0.7-3-1.1-4.8-1.1
		c-1.7,0-3,0.4-4,1.3c-1,0.9-1.5,2.1-1.5,3.5c0,1.4,0.3,2.6,1,3.4c0.7,0.9,1.8,1.6,3.5,2.3c1.2,0.5,2,0.9,2.6,1.2
		c0.6,0.4,1,0.8,1.2,1.2c0.2,0.4,0.4,1,0.4,1.6c0,1-0.3,1.8-1,2.4c-0.7,0.6-1.7,0.8-3,0.8c-0.8,0-1.7-0.1-2.5-0.3
		c-0.8-0.2-1.6-0.5-2.3-0.8v2.2c1.1,0.6,2.7,0.9,4.7,0.9c1.9,0,3.4-0.5,4.5-1.4c1.1-0.9,1.7-2.3,1.7-4
		C-47.8,91.6-48.2,90.6-48.8,89.8 M-61.9,96.1h-7.7V89h7.2v-2h-7.2v-6.2h7.7v-2h-9.7v19.3h9.7V96.1z M-78.5,78.8v12.6
		c0,1.6-0.4,2.9-1.2,3.7c-0.8,0.9-1.9,1.3-3.4,1.3c-1.5,0-2.7-0.4-3.5-1.3c-0.8-0.9-1.2-2.1-1.2-3.7V78.8h-2v12.4
		c0,2.2,0.6,4,1.7,5.2c1.1,1.3,2.8,1.9,4.8,1.9c2.1,0,3.7-0.6,4.9-1.9c1.2-1.3,1.8-3,1.8-5.2V78.8H-78.5z M-94.3,89.8
		c-0.7-0.8-1.9-1.6-3.8-2.3c-1.1-0.4-1.9-0.8-2.4-1.2c-0.5-0.4-0.9-0.7-1.1-1.2c-0.2-0.4-0.3-1-0.3-1.6c0-0.9,0.3-1.6,0.9-2.1
		s1.4-0.8,2.5-0.8c1.4,0,2.7,0.3,4.2,1l0.6-2c-1.4-0.7-3-1.1-4.8-1.1c-1.7,0-3,0.4-4,1.3c-1,0.9-1.5,2.1-1.5,3.5
		c0,1.4,0.3,2.6,1,3.4c0.7,0.9,1.8,1.6,3.5,2.3c1.2,0.5,2,0.9,2.6,1.2c0.6,0.4,1,0.8,1.2,1.2c0.2,0.4,0.4,1,0.4,1.6
		c0,1-0.3,1.8-1,2.4c-0.7,0.6-1.7,0.8-3,0.8c-0.8,0-1.7-0.1-2.5-0.3c-0.8-0.2-1.6-0.5-2.3-0.8v2.2c1.1,0.6,2.7,0.9,4.7,0.9
		c1.9,0,3.4-0.5,4.5-1.4c1.1-0.9,1.7-2.3,1.7-4C-93.2,91.6-93.6,90.6-94.3,89.8 M-108.1,89.8c-0.7-0.8-1.9-1.6-3.8-2.3
		c-1.1-0.4-1.9-0.8-2.4-1.2c-0.5-0.4-0.9-0.7-1.1-1.2c-0.2-0.4-0.3-1-0.3-1.6c0-0.9,0.3-1.6,0.9-2.1c0.6-0.5,1.4-0.8,2.5-0.8
		c1.4,0,2.7,0.3,4.2,1l0.6-2c-1.4-0.7-3-1.1-4.8-1.1c-1.7,0-3,0.4-4,1.3c-1,0.9-1.5,2.1-1.5,3.5c0,1.4,0.3,2.6,1,3.4
		c0.7,0.9,1.8,1.6,3.5,2.3c1.2,0.5,2,0.9,2.6,1.2c0.6,0.4,1,0.8,1.2,1.2c0.2,0.4,0.4,1,0.4,1.6c0,1-0.3,1.8-1,2.4
		c-0.7,0.6-1.7,0.8-3,0.8c-0.8,0-1.7-0.1-2.5-0.3c-0.8-0.2-1.6-0.5-2.3-0.8v2.2c1.1,0.6,2.7,0.9,4.7,0.9c1.9,0,3.4-0.5,4.5-1.4
		c1.1-0.9,1.7-2.3,1.7-4C-107.1,91.6-107.4,90.6-108.1,89.8 M-121.9,78.8h-2v19.3h2V78.8z M-134.2,98.1v-2h-7.7V78.8h-2v19.3H-134.2
		z M-157.4,89.9l2-6c0.3-1,0.6-1.9,0.7-2.8c0.3,1.1,0.5,2,0.8,2.8l2,6H-157.4z M-146.9,98.1l-6.8-19.4h-1.7l-6.9,19.4h2l2.1-6.1h7
		l2.2,6.1H-146.9z M-165.3,78.8h-1.9v11.1c0,0.6,0,1.5,0.1,2.8c0.1,1.3,0.1,2,0.1,2.3h-0.1l-9.5-16.1h-2.3v19.3h1.9v-11
		c0-1.6-0.1-3.3-0.2-5.2h0.1l9.5,16.2h2.3V78.8z M-195.3,82.5c1-1.3,2.5-2,4.4-2c1.9,0,3.4,0.7,4.3,2c1,1.3,1.5,3.3,1.5,5.9
		c0,2.6-0.5,4.6-1.5,5.9c-1,1.3-2.4,2-4.4,2c-1.9,0-3.4-0.7-4.4-2c-1-1.3-1.5-3.3-1.5-5.9C-196.8,85.9-196.3,83.9-195.3,82.5
		 M-185.1,81.2c-1.4-1.8-3.3-2.6-5.8-2.6c-2.6,0-4.5,0.9-5.9,2.6c-1.4,1.7-2.1,4.2-2.1,7.3c0,3.2,0.7,5.6,2.1,7.3
		c1.4,1.7,3.4,2.6,5.9,2.6c2.5,0,4.5-0.9,5.9-2.7c1.4-1.8,2.1-4.2,2.1-7.3C-183,85.3-183.7,82.9-185.1,81.2 M-203.2,78.8h-2v19.3h2
		V78.8z M-215.6,90h3.9v5.9c-1.1,0.3-2.3,0.5-3.5,0.5c-2.2,0-3.9-0.7-5-2c-1.1-1.3-1.7-3.3-1.7-5.9c0-2.5,0.6-4.4,1.8-5.8
		c1.2-1.4,2.8-2.1,4.9-2.1c1.4,0,3,0.4,4.5,1.1l0.8-2c-1.6-0.8-3.3-1.1-5.2-1.1c-1.8,0-3.4,0.4-4.8,1.2c-1.4,0.8-2.4,1.9-3.1,3.5
		c-0.7,1.5-1.1,3.3-1.1,5.3c0,3.1,0.7,5.6,2.2,7.3c1.5,1.7,3.5,2.6,6.1,2.6c1.3,0,2.4-0.1,3.3-0.3s1.9-0.4,2.8-0.7V88h-5.9V90z
		 M-227.2,96.1h-7.7V89h7.2v-2h-7.2v-6.2h7.7v-2h-9.7v19.3h9.7V96.1z M-250.3,80.8h2.6c1.5,0,2.6,0.3,3.3,0.8c0.7,0.6,1,1.5,1,2.8
		c0,1.3-0.3,2.2-1,2.8c-0.7,0.6-1.7,0.9-3.1,0.9h-2.8V80.8z M-246.7,90.1l4.2,8h2.4l-4.7-8.7c2.3-0.9,3.5-2.6,3.5-5.2
		c0-1.8-0.5-3.2-1.5-4.1c-1-0.9-2.6-1.4-4.7-1.4h-4.8v19.3h2v-8H-246.7z"/>
</g>
<g id="vhri_copy" class="st0">
	<path class="st2" d="M-126.2-17.7c0.3,0,0.6,0,0.9,0c0.1,0,0.2,0,0.2-0.2c1.8-4.7,3.6-9.4,5.4-14.1l1.6-4.1c0,0,0-0.1,0-0.1l-0.4,0
		c-0.4,0-0.8,0-1.2,0c-0.2,0-0.2,0-0.3,0.2c-1.5,4-3,8-4.5,12l-0.5,1.4c-0.3,0.7-0.5,1.4-0.8,2.2l-0.5,1.2l-0.2-0.4
		c0-0.1-0.1-0.1-0.1-0.2l-3.9-10.4c-0.7-1.9-1.5-3.9-2.2-5.8c0-0.1-0.1-0.1-0.1-0.2c-0.5,0-1,0-1.5,0l-0.3,0c0,0.1,0,0.1,0.1,0.2
		l2.4,6.2c1.5,4,3.1,8,4.6,12c0,0.1,0.1,0.1,0.2,0.1C-126.8-17.7-126.5-17.7-126.2-17.7"/>
	<path class="st2" d="M-80.6-25.8h-8.6l0-0.1c0.3-2.2,1.8-3.8,3.8-4.1c0.8-0.1,1.6-0.1,2.4,0.2c1.3,0.4,2.1,1.4,2.4,2.9
		c0,0.2,0.1,0.4,0.1,0.7c0,0.1,0,0.2,0,0.3L-80.6-25.8z M-84.4-31.5c-0.3,0-0.7,0-1.1,0.1c-2,0.3-3.5,1.3-4.5,3.1
		c-1,1.8-1.3,3.8-0.7,6c0.6,2.5,2.2,4.1,4.7,4.7c1.1,0.3,2.4,0.3,3.8,0.1c1.1-0.2,1.9-0.5,2.6-1c0.1-0.1,0.1-0.1,0.1-0.1
		c0-0.4,0-0.9,0-1.4v-0.2l-0.1,0c-0.1,0.1-0.2,0.1-0.2,0.2c-1.7,1.1-3.6,1.5-5.6,1.1c-1.9-0.4-3.5-2.2-3.8-4.1
		c0-0.3-0.1-0.5-0.1-0.8c0-0.1,0-0.3,0-0.4l0-0.1h10.4c0-0.2,0-0.3,0-0.4c0-0.9,0-1.7-0.2-2.5c-0.3-1.6-1.1-2.7-2.4-3.4
		C-82.4-31.3-83.3-31.5-84.4-31.5"/>
	<path class="st2" d="M-114.2-18.8c-0.8,0-1.7,0-2.6-0.4c-0.3-0.1-0.6-0.3-0.9-0.4c-0.6-0.4-1-1.1-1-1.8c0-0.8,0.4-1.5,1.1-1.9
		c0.7-0.4,1.5-0.6,2.3-0.7c0.7,0,1.3-0.1,2-0.1c0.3,0,0.5,0,0.8,0c0.1,0,0.1,0,0.2,0l0.2,0v5.1l-0.1,0c-0.2,0-0.4,0-0.6,0.1
		C-113.2-18.8-113.7-18.8-114.2-18.8L-114.2-18.8z M-112.4-25.4C-112.4-25.4-112.4-25.4-112.4-25.4c-0.4,0-0.6,0-0.9,0
		c-0.6,0-1.2,0-1.8,0c-1,0.1-1.9,0.3-2.8,0.6c-1.6,0.7-2.3,1.7-2.4,3.2c0,1.5,0.7,2.7,2,3.4c0.9,0.4,1.9,0.6,2.8,0.7
		c1.6,0.1,3.2,0,4.9-0.4c0.1,0,0.1,0,0.1-0.1c0-1,0-2.1,0-3.1c0-2.2,0-4.5,0-6.8c0-1.9-0.9-3-2.8-3.4c-1.8-0.5-3.7-0.2-5.7,0.8
		c0,0-0.1,0.1-0.1,0.1c0,0.4,0,0.8,0,1.3v0.2l0.1-0.1c0.2-0.1,0.4-0.2,0.6-0.3c1.4-0.6,2.7-0.8,4.1-0.6c1.2,0.2,2,1,2.1,2.1
		c0.1,0.5,0,1,0,1.5c0,0.2,0,0.5,0,0.7v0.1L-112.4-25.4C-112.3-25.4-112.3-25.4-112.4-25.4"/>
	<path class="st2" d="M-103.4-31.2l0,2.4c0,2.1,0,4.2,0,6.2c0,0.5,0,1,0.1,1.5c0.2,1.4,0.8,2.4,2,3c1,0.5,2.1,0.7,3.5,0.7
		c0.9,0,1.8,0,2.9-0.1c0.6,0,1.1-0.1,1.7-0.2c0.2,0,0.4-0.1,0.7-0.1v-13.4h-1.6v12.2l-0.1,0c-0.3,0-0.6,0-1,0
		c-0.8,0-1.5,0.1-2.3,0.1c-0.5,0-1.1-0.1-1.7-0.2c-0.9-0.2-1.5-0.7-1.9-1.3c-0.3-0.5-0.4-1-0.4-1.6c0-2.2,0-4.4,0-6.6l0-2.6H-103.4z
		"/>
	<rect x="-107.9" y="-36.2" class="st2" width="1.6" height="18.5"/>
	<path class="st2" d="M-61.9-17.4h1.4l0-2c0-1.7,0-3.4,0-5.1c0-0.6,0-1.1-0.1-1.5c-0.1-0.9-0.5-1.5-1.1-2c-0.7-0.6-1.6-0.9-2.8-0.9
		c-1.7-0.1-3.4,0.1-5.3,0.8c-0.1,0-0.1,0.1-0.1,0.2c0,3,0,5.9,0,8.9v1.8h1.4v-9.3c0-0.6,0-0.6,0.6-0.7c1.5-0.3,2.7-0.4,3.8-0.2
		c1.1,0.2,1.9,0.9,2.1,1.9c0.1,0.3,0.1,0.7,0.1,1.2c0,1.8,0,3.5,0,5.3L-61.9-17.4z"/>
	<rect x="-74.3" y="-28.7" class="st2" width="1.3" height="11.3"/>
	<path class="st2" d="M-73.6-33.6c-0.3,0-0.6,0.1-0.8,0.3c-0.2,0.2-0.3,0.5-0.3,0.8c0,0.6,0.5,1.1,1.1,1.1c0,0,0,0,0,0
		c0.6,0,1.1-0.5,1.1-1.1c0-0.3-0.1-0.6-0.3-0.8C-73.1-33.4-73.3-33.6-73.6-33.6L-73.6-33.6z"/>
	<polygon class="st2" points="-105.6,3.8 -104,3.8 -104,-14.6 -105.7,-14.6 -105.7,-6.3 -117.6,-6.3 -117.6,-14.6 -119.2,-14.6 
		-119.2,3.8 -117.6,3.8 -117.6,-4.8 -105.6,-4.8 	"/>
	<path class="st2" d="M-63.7,3.8h1.5l0-2.1c0-3.1,0-6.1,0-9.2c0-0.2,0-0.4,0.3-0.5c1.6-0.5,3.1-0.7,4.6-0.5c1.9,0.2,3,1.5,3,3.3
		c0,2.1,0,4.4,0,6.1c0,0.9,0,1.8,0,2.6v0.1h1.6c0-0.8,0-1.6,0-2.5c0-2.3,0-4.8,0-7.3c0-0.7-0.2-1.4-0.6-2c-0.5-0.8-1.3-1.4-2.5-1.7
		c-1.4-0.4-3-0.4-4.8,0c-0.3,0.1-0.6,0.2-1,0.3l-0.1,0c-0.1,0-0.3,0.1-0.4,0.1l-0.2,0.1v-5.4h-1.5V3.8z"/>
	<path class="st2" d="M-83.6,2.9c-0.9,0-1.8-0.1-2.5-0.4c-0.6-0.2-1.1-0.5-1.4-0.9C-88,1.1-88.2,0.5-88-0.2c0.1-0.7,0.6-1.3,1.2-1.6
		c0.7-0.4,1.4-0.6,2.3-0.7c0.7,0,1.4-0.1,2-0.1c0.3,0,0.6,0,0.8,0c0,0,0.1,0,0.1,0c0,0,0,0,0.1,0l0.2,0v5.2l-0.1,0
		c-0.1,0-0.1,0-0.2,0l-0.1,0c-0.2,0-0.4,0.1-0.7,0.1C-82.9,2.9-83.3,2.9-83.6,2.9 M-81.7-3.8l-0.1,0c-0.2,0-0.4,0-0.7,0l-0.1,0
		c-0.6,0-1.2,0-1.8,0c-1.1,0.1-2.1,0.3-3,0.7c-1.4,0.6-2.1,1.6-2.2,3c-0.1,1.5,0.5,2.6,1.7,3.3c0.9,0.5,1.9,0.7,3,0.8
		c1.6,0.1,3.2,0,4.9-0.4c0.1,0,0.2,0,0.2-0.2c0-1.6,0-3.2,0-4.8c0-1.2,0-2.5,0-3.7v0c0-0.5,0-1-0.1-1.6c-0.2-1.6-0.9-2.5-2.3-3
		c-1-0.3-2-0.4-3.3-0.2c-0.9,0.1-1.8,0.4-2.7,0.9c0,0-0.1,0.1-0.1,0.1c0,0.4,0,0.8,0,1.2v0.1l0.1,0c0.2-0.1,0.4-0.2,0.7-0.3
		c1.4-0.6,2.7-0.8,4-0.6c1.2,0.2,2,1,2.2,2.1c0.1,0.5,0.1,1,0.1,1.6c0,0.2,0,0.5,0,0.7l0,0.2L-81.7-3.8z"/>
	<rect x="-76.9" y="-14.6" class="st2" width="1.5" height="18.5"/>
	<path class="st2" d="M-73.6-8.3h2.1l0,3.1c0,1.8,0,3.7,0,5.5c0,0.6,0,1.3,0.2,1.9c0.4,1.1,1,1.7,2,1.9c0.3,0.1,0.6,0.1,1,0.1
		c0,0,0,0,0.1,0l0,0c0.9,0,1.8,0,3-0.2V2.7c-0.1,0-0.1,0-0.2,0l0,0c-0.2,0-0.4,0.1-0.7,0.1c-0.7,0.1-1.3,0.1-1.9,0
		c-0.4,0-0.8-0.1-1.2-0.4c-0.5-0.4-0.7-1-0.7-1.7c0-2.2,0-4.5,0-6.6l0-2.1c0,0,0-0.1,0-0.1c0,0,0,0,0-0.1l0-0.1h3.8v-1.2h-3.9v-3.3
		h-1.6v3.3h-2.1V-8.3z"/>
	<path class="st2" d="M-91.8-4.2h-8.6l0-0.1c0.3-2.2,1.8-3.8,3.8-4.1c0.8-0.1,1.6-0.1,2.4,0.2c1.3,0.4,2.1,1.4,2.4,2.9
		c0,0.2,0.1,0.4,0.1,0.7c0,0.1,0,0.2,0,0.3L-91.8-4.2z M-95.6-9.9c-0.3,0-0.7,0-1.1,0.1c-2,0.3-3.5,1.3-4.5,3.1
		c-1,1.8-1.3,3.8-0.7,6c0.6,2.5,2.2,4.1,4.7,4.7c1.1,0.3,2.4,0.3,3.8,0.1c1.1-0.2,1.9-0.5,2.6-1c0.1-0.1,0.1-0.1,0.1-0.1
		c0-0.4,0-0.9,0-1.4V1.3l-0.1,0C-90.9,1.4-91,1.5-91,1.5c-1.7,1.1-3.6,1.5-5.6,1.1c-1.9-0.4-3.5-2.2-3.8-4.1c0-0.3-0.1-0.5-0.1-0.8
		c0-0.1,0-0.3,0-0.4l0-0.1h10.4c0-0.1,0-0.3,0-0.4c0-0.9,0-1.7-0.2-2.5c-0.3-1.6-1.1-2.7-2.4-3.4C-93.6-9.7-94.6-9.9-95.6-9.9"/>
	<path class="st2" d="M-52.5,11c-0.2-0.3-0.6-0.5-1.2-0.8c-0.4-0.1-0.6-0.3-0.8-0.4c-0.2-0.1-0.3-0.2-0.4-0.4C-55,9.3-55,9.1-55,8.9
		c0-0.3,0.1-0.5,0.3-0.7C-54.5,8-54.3,8-53.9,8c0.4,0,0.9,0.1,1.4,0.3l0.2-0.6c-0.5-0.2-1-0.3-1.6-0.3c-0.5,0-1,0.1-1.3,0.4
		c-0.3,0.3-0.5,0.7-0.5,1.2c0,0.5,0.1,0.8,0.3,1.1c0.2,0.3,0.6,0.5,1.1,0.8c0.4,0.2,0.7,0.3,0.8,0.4c0.2,0.1,0.3,0.2,0.4,0.4
		c0.1,0.1,0.1,0.3,0.1,0.5c0,0.3-0.1,0.6-0.3,0.8c-0.2,0.2-0.6,0.3-1,0.3c-0.3,0-0.5,0-0.8-0.1c-0.3-0.1-0.5-0.2-0.8-0.3v0.7
		c0.4,0.2,0.9,0.3,1.6,0.3c0.6,0,1.1-0.2,1.5-0.5c0.4-0.3,0.5-0.7,0.5-1.3C-52.2,11.6-52.3,11.3-52.5,11z"/>
	<polygon class="st2" points="-60,13.7 -56.8,13.7 -56.8,13.1 -59.3,13.1 -59.3,10.7 -57,10.7 -57,10.1 -59.3,10.1 -59.3,8 -56.8,8 
		-56.8,7.4 -60,7.4 	"/>
	<path class="st2" d="M-62.3,11.5c0,0.5-0.1,0.9-0.4,1.2c-0.3,0.3-0.6,0.4-1.1,0.4c-0.5,0-0.9-0.1-1.1-0.4c-0.3-0.3-0.4-0.7-0.4-1.2
		V7.4H-66v4.1c0,0.7,0.2,1.3,0.6,1.7c0.4,0.4,0.9,0.6,1.6,0.6c0.7,0,1.2-0.2,1.6-0.6c0.4-0.4,0.6-1,0.6-1.7V7.4h-0.7V11.5z"/>
	<path class="st2" d="M-68.7,10.2c-0.4-0.1-0.6-0.3-0.8-0.4c-0.2-0.1-0.3-0.2-0.4-0.4C-69.9,9.3-70,9.1-70,8.9
		c0-0.3,0.1-0.5,0.3-0.7C-69.5,8-69.2,8-68.8,8c0.4,0,0.9,0.1,1.4,0.3l0.2-0.6c-0.5-0.2-1-0.3-1.6-0.3c-0.5,0-1,0.1-1.3,0.4
		c-0.3,0.3-0.5,0.7-0.5,1.2c0,0.5,0.1,0.8,0.3,1.1c0.2,0.3,0.6,0.5,1.1,0.8c0.4,0.2,0.7,0.3,0.8,0.4c0.2,0.1,0.3,0.2,0.4,0.4
		c0.1,0.1,0.1,0.3,0.1,0.5c0,0.3-0.1,0.6-0.3,0.8c-0.2,0.2-0.6,0.3-1,0.3c-0.3,0-0.5,0-0.8-0.1c-0.3-0.1-0.5-0.2-0.8-0.3v0.7
		c0.4,0.2,0.9,0.3,1.6,0.3c0.6,0,1.1-0.2,1.5-0.5c0.4-0.3,0.5-0.7,0.5-1.3c0-0.4-0.1-0.8-0.3-1.1C-67.7,10.7-68.1,10.5-68.7,10.2z"
		/>
	<path class="st2" d="M-73.2,10.2c-0.4-0.1-0.6-0.3-0.8-0.4c-0.2-0.1-0.3-0.2-0.4-0.4c-0.1-0.1-0.1-0.3-0.1-0.5
		c0-0.3,0.1-0.5,0.3-0.7C-74,8-73.7,8-73.4,8c0.4,0,0.9,0.1,1.4,0.3l0.2-0.6c-0.5-0.2-1-0.3-1.6-0.3c-0.5,0-1,0.1-1.3,0.4
		C-75,8-75.2,8.4-75.2,8.9c0,0.5,0.1,0.8,0.3,1.1c0.2,0.3,0.6,0.5,1.1,0.8c0.4,0.2,0.7,0.3,0.8,0.4c0.2,0.1,0.3,0.2,0.4,0.4
		c0.1,0.1,0.1,0.3,0.1,0.5c0,0.3-0.1,0.6-0.3,0.8c-0.2,0.2-0.6,0.3-1,0.3c-0.3,0-0.5,0-0.8-0.1c-0.3-0.1-0.5-0.2-0.8-0.3v0.7
		c0.4,0.2,0.9,0.3,1.6,0.3c0.6,0,1.1-0.2,1.5-0.5c0.4-0.3,0.5-0.7,0.5-1.3c0-0.4-0.1-0.8-0.3-1.1C-72.2,10.7-72.6,10.5-73.2,10.2z"
		/>
	<rect x="-77.2" y="7.4" class="st2" width="0.7" height="6.3"/>
	<polygon class="st2" points="-83.1,7.4 -83.8,7.4 -83.8,13.7 -80.6,13.7 -80.6,13.1 -83.1,13.1 	"/>
	<path class="st2" d="M-87,7.4h-0.6l-2.3,6.4h0.7l0.7-2h2.3l0.7,2h0.7L-87,7.4z M-88.2,11.1l0.7-2c0.1-0.3,0.2-0.6,0.2-0.9
		c0.1,0.4,0.2,0.7,0.3,0.9l0.7,2H-88.2z"/>
	<path class="st2" d="M-91.4,11c0,0.2,0,0.5,0,0.9c0,0.4,0,0.7,0,0.8h0l-3.1-5.3h-0.7v6.3h0.6v-3.6c0-0.5,0-1.1-0.1-1.7h0l3.1,5.3
		h0.8V7.4h-0.6V11z"/>
	<path class="st2" d="M-97.3,8.2c-0.5-0.6-1.1-0.9-1.9-0.9c-0.8,0-1.5,0.3-2,0.9s-0.7,1.4-0.7,2.4c0,1,0.2,1.8,0.7,2.4
		c0.5,0.6,1.1,0.9,1.9,0.9c0.8,0,1.5-0.3,1.9-0.9c0.5-0.6,0.7-1.4,0.7-2.4C-96.6,9.5-96.9,8.7-97.3,8.2z M-97.8,12.5
		c-0.3,0.4-0.8,0.7-1.4,0.7c-0.6,0-1.1-0.2-1.4-0.7c-0.3-0.4-0.5-1.1-0.5-2c0-0.8,0.2-1.5,0.5-1.9c0.3-0.4,0.8-0.7,1.4-0.7
		c0.6,0,1.1,0.2,1.4,0.7c0.3,0.4,0.5,1.1,0.5,1.9C-97.3,11.4-97.5,12.1-97.8,12.5z"/>
	<rect x="-103.9" y="7.4" class="st2" width="0.7" height="6.3"/>
	<path class="st2" d="M-107.4,11.1h1.3v2c-0.4,0.1-0.8,0.2-1.2,0.2c-0.7,0-1.3-0.2-1.7-0.7c-0.4-0.4-0.6-1.1-0.6-1.9
		c0-0.8,0.2-1.5,0.6-1.9c0.4-0.5,0.9-0.7,1.6-0.7c0.5,0,1,0.1,1.5,0.4l0.3-0.7c-0.5-0.2-1.1-0.4-1.7-0.4c-0.6,0-1.1,0.1-1.6,0.4
		c-0.4,0.3-0.8,0.6-1,1.1c-0.2,0.5-0.4,1.1-0.4,1.7c0,1,0.2,1.8,0.7,2.4c0.5,0.6,1.2,0.9,2,0.9c0.4,0,0.8,0,1.1-0.1
		c0.3-0.1,0.6-0.1,0.9-0.2v-3.1h-1.9V11.1z"/>
	<polygon class="st2" points="-114.4,13.7 -111.2,13.7 -111.2,13.1 -113.7,13.1 -113.7,10.7 -111.3,10.7 -111.3,10.1 -113.7,10.1 
		-113.7,8 -111.2,8 -111.2,7.4 -114.4,7.4 	"/>
	<path class="st2" d="M-117,10.9c0.8-0.3,1.1-0.9,1.1-1.7c0-0.6-0.2-1-0.5-1.3c-0.3-0.3-0.9-0.4-1.6-0.4h-1.6v6.3h0.7v-2.6h1.2
		l1.4,2.6h0.8L-117,10.9z M-117.9,10.5h-0.9V8h0.9c0.5,0,0.8,0.1,1.1,0.3c0.2,0.2,0.3,0.5,0.3,0.9c0,0.4-0.1,0.7-0.3,0.9
		C-117.1,10.4-117.4,10.5-117.9,10.5z"/>
</g>
<g id="ISPOR">
	<path class="st3" d="M69.1,48.8h-4.6V1.4h4.6V48.8z"/>
	<path class="st3" d="M98.1,9c-1-1.4-2.2-2.6-3.8-3.4s-3.4-1.3-5.6-1.3c-1.1,0-2.3,0.2-3.4,0.5c-1.2,0.4-2.2,0.9-3.1,1.6
		c-0.9,0.7-1.7,1.7-2.3,2.8c-0.6,1.1-0.9,2.4-0.9,3.9c0,1.5,0.3,2.8,0.8,3.7c0.6,1,1.3,1.8,2.2,2.5c0.9,0.7,2,1.3,3.1,1.7
		c1.2,0.4,2.4,0.9,3.7,1.3c1.6,0.5,3.2,1.1,4.8,1.7c1.6,0.6,3,1.4,4.3,2.4c1.3,1,2.3,2.3,3.1,3.8c0.8,1.5,1.2,3.5,1.2,5.9
		c0,2.4-0.4,4.4-1.3,6.1c-0.9,1.7-2,3.1-3.4,4.2c-1.4,1.1-3,1.9-4.7,2.5c-1.8,0.5-3.6,0.8-5.4,0.8c-1.4,0-2.7-0.1-4.1-0.4
		c-1.4-0.3-2.7-0.7-3.9-1.3c-1.2-0.6-2.4-1.3-3.5-2.2c-1.1-0.9-2-1.9-2.8-3.1l4-3.1c1,1.7,2.4,3.1,4.1,4.2c1.8,1.1,3.9,1.7,6.3,1.7
		c1.2,0,2.3-0.2,3.5-0.6c1.2-0.4,2.3-1,3.2-1.7c1-0.8,1.8-1.7,2.4-2.9c0.6-1.1,0.9-2.5,0.9-4c0-1.6-0.3-3-0.9-4.1
		c-0.6-1.1-1.4-2-2.5-2.7c-1-0.7-2.2-1.3-3.5-1.8c-1.3-0.5-2.7-1-4.2-1.5c-1.5-0.5-3-1-4.4-1.7c-1.5-0.6-2.8-1.4-3.9-2.4
		c-1.2-1-2.1-2.2-2.8-3.7c-0.7-1.5-1.1-3.3-1.1-5.4c0-2.3,0.4-4.2,1.3-5.9c0.9-1.6,2-3,3.4-4.1c1.4-1.1,3-1.8,4.7-2.3
		c1.7-0.5,3.4-0.7,5.1-0.7c3.1,0,5.7,0.6,7.9,1.7c2.2,1.1,3.8,2.5,4.9,4L98.1,9z"/>
	<path class="st3" d="M107.3,1.4h12.9c2.3,0,4.4,0.3,6.3,0.8c1.9,0.5,3.5,1.3,4.9,2.3c1.3,1,2.4,2.4,3.1,3.9
		c0.7,1.6,1.1,3.4,1.1,5.6s-0.4,4-1.1,5.6c-0.8,1.6-1.8,2.9-3.1,3.9c-1.3,1-3,1.8-4.9,2.4c-1.9,0.5-4,0.8-6.3,0.8h-8.1v22h-4.6V1.4z
		 M111.9,22.7h7.8c3.6,0,6.4-0.7,8.3-2.2c1.9-1.5,2.8-3.6,2.8-6.4c0-2.9-1-5.1-2.9-6.5c-2-1.4-4.7-2-8.2-2h-7.8V22.7z"/>
	<path class="st3" d="M184.5,25.1c0,3.6-0.6,6.9-1.8,10c-1.2,3-2.9,5.7-5,7.9c-2.1,2.2-4.6,3.9-7.5,5.2c-2.9,1.2-6,1.9-9.4,1.9
		c-3.4,0-6.5-0.6-9.4-1.9c-2.9-1.2-5.4-3-7.5-5.2c-2.1-2.2-3.8-4.8-5-7.9c-1.2-3-1.8-6.4-1.8-10c0-3.6,0.6-6.9,1.8-10
		c1.2-3,2.9-5.7,5-7.9c2.1-2.2,4.6-3.9,7.5-5.2c2.9-1.2,6-1.9,9.4-1.9c3.4,0,6.5,0.6,9.4,1.9c2.9,1.2,5.4,3,7.5,5.2
		c2.1,2.2,3.8,4.8,5,7.9C183.9,18.2,184.5,21.5,184.5,25.1z M179.6,25.1c0-2.8-0.4-5.4-1.3-7.9c-0.9-2.5-2.1-4.7-3.7-6.6
		c-1.6-1.9-3.6-3.4-5.9-4.5c-2.3-1.1-5-1.7-7.9-1.7c-2.9,0-5.5,0.6-7.9,1.7c-2.3,1.1-4.3,2.6-5.9,4.5c-1.6,1.9-2.9,4.1-3.7,6.6
		c-0.9,2.5-1.3,5.1-1.3,7.9c0,2.8,0.4,5.4,1.3,7.9c0.9,2.5,2.1,4.7,3.7,6.5c1.6,1.9,3.6,3.4,5.9,4.5c2.3,1.1,5,1.7,7.9,1.7
		c2.9,0,5.5-0.6,7.9-1.7c2.3-1.1,4.3-2.6,5.9-4.5c1.6-1.9,2.9-4,3.7-6.5C179.1,30.5,179.6,27.9,179.6,25.1z"/>
	<path class="st3" d="M193.6,48.8H189V1.4h13.4c2.2,0,4.3,0.2,6.2,0.7c1.9,0.4,3.6,1.2,4.9,2.2c1.4,1,2.5,2.3,3.2,3.9
		c0.8,1.6,1.2,3.6,1.2,5.9c0,1.7-0.3,3.3-0.9,4.7c-0.6,1.4-1.4,2.7-2.4,3.7c-1,1-2.2,1.9-3.7,2.5c-1.4,0.6-3,1-4.6,1.2l13.3,22.5
		H214l-12.6-22.1h-7.7V48.8z M193.6,22.5h8c3.7,0,6.6-0.7,8.6-2.1c2-1.4,3-3.5,3-6.3c0-1.6-0.3-2.9-0.8-3.9
		c-0.6-1.1-1.3-1.9-2.3-2.6c-1-0.7-2.2-1.2-3.6-1.5c-1.4-0.3-3-0.5-4.7-0.5h-8.2V22.5z"/>
	<g>
		<ellipse class="st4" cx="24.1" cy="14.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="34.2" cy="14.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="44.4" cy="14.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="3.8" cy="14.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="13.9" cy="14.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="24.1" cy="3.9" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="34.2" cy="3.9" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="13.9" cy="3.9" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="34.2" cy="25" rx="3.8" ry="3.9"/>
		<ellipse class="st4" cx="44.4" cy="25" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="3.8" cy="25" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="13.9" cy="25" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="24.1" cy="35.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="34.2" cy="35.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="44.4" cy="35.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="3.8" cy="35.5" rx="3.8" ry="3.9"/>
		<ellipse class="st4" cx="13.9" cy="35.5" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="24.1" cy="46.1" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="34.2" cy="46.1" rx="3.8" ry="3.9"/>
		<ellipse class="st5" cx="13.9" cy="46.1" rx="3.8" ry="3.9"/>
	</g>
</g>
</svg>
></a></span>
 
 </div>
 
 
</div><div class="col-xs-6 col-lg-6">
 
 
 
 
 
 <div data-widget-id=27014d70-9f94-467d-857b-805d256132d2 data-widget-name=ux3-layout-widget><div class="header__nav row menu--desk">
 
 
 
 
 
 <div data-widget-id=0a3e2e4b-cb1c-443a-929e-4a71f1f9f6e3 data-widget-name=UX3MenuWidget class="main-nav menu-drawer"><div class=menu-drawer__ctrl><a href=#main-menu data-target=main-menu data-toggle=nav title="Explore Journal" aria-controls=main-menu aria-expanded=false><span class=menu-drawer--open><i aria-hidden=true class=icon-gizmo-hamburger></i></span><span class="menu-drawer--close sf-hidden"></span></a></div><nav role=navigation id=main-menu data-ctrl-res=screen-sm class="menu-drawer__nav drawer__nav gutterless sf-hidden" style=top:82px></nav></div><div class=header__dropzone><div class=pb-dropzone data-pb-dropzone=menuDropzone title=menuDropzone></div></div>
 
 
 
 
 
 
 
 <div data-widget-id=4b13527a-8285-4636-ac31-0e0ddddf175f data-widget-name=UX3QuickSearchWidget class=quick-search><div class=dropBlock><a href=# title=Search data-db-target-for=quickSearch aria-expanded=false aria-controls=quick-search-holder class=search-drawer><i aria-hidden=true class=icon-search></i></a><div data-db-target-of=quickSearch id=quick-search-holder class="dropBlock__holder quick-search__holder sf-hidden"></div></div></div>
 
 
 
 
 
 
 
 <ul data-widget-id=337ee8a8-34c0-420d-84ae-7906e01fd189 data-widget-name=UX3ProfileLinksWidget class="rlist rlist--inline profile-links"><li class=profile-links__loginHtml><a href=https://mc.manuscriptcentral.com/valueinhealth target=_blank>Submit</a><li class=profile-links__logIn><a href="https://www.valueinhealthjournal.com/action/showLogin?redirectUri=https%3A%2F%2Fwww.valueinhealthjournal.com%2Farticle%2FS1098-3015%2817%2930316-9%2Ffulltext&amp;pii=S1098-3015%2817%2930316-9" title="Log in" class=show-login>Log in</a><li class=profile-links__register><a href="https://www.valueinhealthjournal.com/action/registration?redirectUri=https%3A%2F%2Fwww.valueinhealthjournal.com%2Farticle%2FS1098-3015%2817%2930316-9%2Ffulltext&amp;directReg=true" title="Register a username and password for free">Register</a><li class="hidden-lg sf-hidden"><li class=profile-links__subscribe><a href=https://www.valueinhealthjournal.com/action/ecommerce title=Subscribe>Subscribe</a><li class=profile-links__claim><a href=https://www.valueinhealthjournal.com/action/activateClaim title="Claim your online subscription">Claim</a></ul>
 
 
</div></div>
 
 
</div></div>
 
 
 </div>
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 <div class="widget csasInstitutionBanner none widget-none" id=ee8e0108-277d-418e-a042-5980d028efd5 style=display:none>
 
 
 <div class="wrapped sf-hidden">
 
 <div class="widget-body body body-none sf-hidden">
</div>
 </div>
 </div>
 
</header></div>
 
 
 
 
 
 
 
 <div data-widget-id=cce513c3-ede2-454b-83a2-b235c17a37ed data-widget-name=UX3HTMLWidget></div>
 
 
 
 
 
 
 
 <div id=6ee85045-2441-4b5c-8a4b-4c078d548375 class="widget loginPopup none widget-none widget-compact-all"><div class=wrapped><div class="widget-body body body-none body-compact-all"><div role=dialog aria-modal=true aria-label=Login class="popup login-popup hidden sf-hidden"></div></div></div></div>
 
 
 
 
 
 
 
 <div role=dialog aria-modal=true aria-label="Reset password" class="popup top-drawer request-reset-password-drawer hidden sf-hidden"></div>
 
 
 <main data-widget-def=UX3articleContent data-widget-id=a5be6016-1e69-4924-852e-9f24ff70fb94 class=content style=padding-top:82px>
 
 
 
 
 
 
 <article data-widget-id=a5be6016-1e69-4924-852e-9f24ff70fb94 data-widget-name=UX3articleContent data-pii=S1098-3015(17)30316-9><div id=articleHeader class="article__header low-height"><div class=article-header><div class=article-header__overlay></div><div class=what-image__wrapper><img aria-hidden=true class="what-image b-lazy b-loaded ux-lazyloaded wide img-aspect-ratio-checked" loading=lazy src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="562" height="395"><rect fill-opacity="0"/></svg>' style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-15)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"></div><div class=article-header__wrapper><div class=article-header__top><div class=row><div class=col-md-6><div class=article-header__meta><span class=article-header__journal>Full length article</span><span class=article-header__sep>|</span><a href=https://www.valueinhealthjournal.com/issue/S1098-3015(18)X0005-9 class="article-header__vol faded">
 Volume 21, ISSUE 6</a><span></span><span>, </span><span class="article-header__pages faded">P677-684, </span><span class="article-header__date faded">June 01, 2018</span></div></div><div class=col-md-6><div class="article-header__dropZone pb-dropzone" data-pb-dropzone=articleTools-dropzone><div data-widget-id=456b8a45-7ff3-433c-b2f1-84eabc846406 data-widget-name=UX3ArticleToolsWidget class=article-tools><div class=article-tools__wrapper style=top:0px><span class="article-tools__header sf-hidden">A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses</span><div class="article-tools__holder pull-right"><ul class="rlist rlist--inline article-tools__list"><li class="article-tools__item article-tools__pdf"><a href="https://www.valueinhealthjournal.com/action/showPdf?pii=S1098-3015%2817%2930316-9" title="Standard PDF (opens in a new tab)" target=_blank aria-hidden=false class="article-tools__ctrl article-tools__item__pdf"><i aria-hidden=true class=icon-gizmo-pdf-file></i><span class=basic>PDF [579 KB]</span><span class="alternative sf-hidden">PDF [579 KB]</span></a><li class="article-tools__item article-tools__figures"><div aria-hidden=true class="dropBlock article-tools__dropblock article-tools__figures"><a href=# title="open Figures menu" data-db-target-for=article-tools-figures aria-expanded=false class="article-tools__ctrl article-tools__item__figures"><i aria-hidden=true class=icon-gizmo-image_figure></i><span>Figures</span></a><div data-db-target-of=article-tools-figures class="dropBlock__holder article-tools__dropblock__holder sf-hidden"></div></div><li class="article-tools__item article-tools__save"><div aria-hidden=false class="dropBlock article-tools__dropblock article-tools__save"><a href=# title="open Save menu" data-db-target-for=article-tools-save aria-expanded=false class="article-tools__ctrl article-tools__item__save"><i aria-hidden=true class=icon-gizmo-folder-in></i><span>Save</span></a><div data-db-target-of=article-tools-save class="dropBlock__holder article-tools__dropblock__holder sf-hidden"></div></div><li class=article-tools__item>
 
 
 
 
 
 <div data-widget-id=eb69bac3-4f48-4142-a6e4-3ba1b70e518e data-widget-name=UX3share class="dropBlock article-tools__dropblock article-tools__share"><a href=# data-db-target-for=eb69bac3-4f48-4142-a6e4-3ba1b70e518e aria-expanded=false title="open Share menu" class="article-tools__ctrl share__ctrl"><i aria-hidden=true class=icon-gizmo-share></i><span>Share</span></a><div data-db-target-of=eb69bac3-4f48-4142-a6e4-3ba1b70e518e id=eb69bac3-4f48-4142-a6e4-3ba1b70e518e_Pop class="share__block dropBlock__holder article-tools__dropblock__holder sf-hidden"></div></div>
 
 
<li><div class="dropBlock article-tools__dropblock article-tools__more"><a href=# title="Show more tools menu" data-db-target-for=article-tools-more aria-expanded=false class="article-tools__ctrl sf-hidden"></a><div data-db-target-of=article-tools-more class="dropBlock__holder article-tools__dropblock__holder"><ul class=rlist><li><a href="http://www.medreprints.com/?pii=S1098301517303169&amp;issn=10983015&amp;source=jbs" title=Reprints class=article-tools__item__reprints><i aria-hidden=true class=icon-gizmo-reprints></i><span>Reprints</span></a><li><a href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S1098301517303169&amp;orderBeanReset=true&amp;orderSource=Phoenix" title=Request class=article-tools__item__request><i aria-hidden=true class=icon-copyright></i><span>Request</span></a></ul></div></div><li><a href=# class="back-to-top sf-hidden"></a></ul></div></div></div></div></div></div></div><div class=article-header__middle><h1 class="article-header__title smaller">A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses</h1><span class=article-header__sub-title></span><ul class="rlist loa inline-bullet-list ellipsis-dot" data-number-of-author=6><li class="loa__item author"><div class="dropBlock article-header__info"><a href=# data-db-target-for=au0005-authorcard aria-expanded=false aria-controls=au0005 class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Joseph Levy, BS ">Joseph Levy, BS <i aria-hidden=true class="icon-gizmo-person faded"></i></a><div data-db-target-of=au0005-authorcard class="dropBlock__holder article-header__info__holder lefted sf-hidden"></div></div><div class="dropBlock article-header__info"><a title="Send email to Joseph Levy" class="loa__item__name loa__item__email" href=mailto:jlevy1@rx.umaryland.edu><i aria-hidden=true class="icon-Email faded"></i></a></div><li class="loa__item author"><div class="dropBlock article-header__info"><a href=# data-db-target-for=au0010-authorcard aria-expanded=false aria-controls=au0010 class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Marjorie Rosenberg, PhD, FSA ">Marjorie Rosenberg, PhD, FSA </a><div data-db-target-of=au0010-authorcard class="dropBlock__holder article-header__info__holder lefted sf-hidden"></div></div><li class="loa__item author"><div class="dropBlock article-header__info"><a href=# data-db-target-for=au0015-authorcard aria-expanded=false aria-controls=au0015 class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author David Vanness, PhD ">David Vanness, PhD </a><div data-db-target-of=au0015-authorcard class="dropBlock__holder article-header__info__holder lefted sf-hidden"></div></div></li> </ul><div class=inline-it><span class=bulleted><span><span class=article-header__access>Open Archive</span></span></span><span class="article-header__publish-date bulleted"><span class=article-header__publish-date__label>Published:</span><span class=article-header__publish-date__value>September 07, 2017</span></span><span class="article-header__doi bulleted"><span class=article-header__doi__label>DOI:</span><a class=article-header__doi__value href=https://doi.org/10.1016/j.jval.2017.06.013>https://doi.org/10.1016/j.jval.2017.06.013</a></span><span class="article-header__mark bulleted"><a id=open-crossmark data-target=crossmark href="https://crossmark.crossref.org/dialog?doi=10.1016%2Fj.jval.2017.06.013&amp;domain=www.valueinhealthjournal.com&amp;uri_scheme=https%3A&amp;cm_version=v2.0" style=cursor:pointer><img id=crossmark-icon width=150 src=data:null;base64, loading=lazy title alt></a></span></div></div><div class="article-header__bottom clearfix row"><div class="col-md-6 static-md"></div><div class="col-md-6 static-md"><div class=plum-jbs-theme><div class=PlumX-Popup><div class="ppp-container ppp-small ppp-badge"><a target=_blank class=plx-wrapping-print-link href="https://plu.mx/plum/a/?doi=10.1016/j.jval.2017.06.013&amp;theme=plum-jbs-theme&amp;hideUsage=true" title="PlumX Metrics Detail Page"><div class=plx-print><svg viewBox="0 0 100 100" width=100% height=100% aria-labelledby=widget-plumprint-1><title id=widget-plumprint-1 class=sf-hidden>Plum Print visual indicator of research metrics</title><path fill=#6e1a62 stroke=#6e1a62 stroke-width=1 d="M 34.25647995972439,62.701219986343176 C 46.330714315081664,46.92110373510095 53.22258276539442,52.01369320408618 45.90423977855504,66.13211781824477 L 54.09576022144496,66.13211781824477 C 46.77741723460558,52.01369320408618 54.03506449855641,46.61417886748478 66.54742636083053,64.54421717178356 L 71.93602549879321,47.95981431643905 C 51.27430002413852,55.11093824041902 47.830602651064346,44.630553141813195 71.14082924377277,38.54294099079976 L 54.36343511677333,26.35345064842729 C 55.77702807175218,50.4039691555658 44.93657281826103,50.35406932032712 44.98800462990401,29.295092779870068 L 31.857254814097068,38.835140945652356 C 51.9014249832547,45.293808021189015 48.841215341530386,54.64763141426376 29.797634942039544,48.978306080598635 Z"></path><circle fill=#13b7ea stroke=#6e1a62 stroke-width=1 r=8.807354922057604 cx=27.22261356937938 cy=57.40082148001677></circle><circle fill=none stroke=#ffffff stroke-width=1.5 r=7.307354922057604 cx=27.22261356937938 cy=57.40082148001677></circle><circle fill=#f3c316 stroke=#6e1a62 stroke-width=1 r=5 cx=50 cy=69></circle><circle fill=none stroke=#ffffff stroke-width=1.5 r=3.5 cx=50 cy=69></circle><circle fill=#c43bf3 stroke=#6e1a62 stroke-width=1 r=10.643856189774723 cx=75.0479878778213 cy=58.138584612507216></circle><circle fill=none stroke=#ffffff stroke-width=1.5 r=9.143856189774723 cx=75.0479878778213 cy=58.138584612507216></circle><circle fill=#6dd54d stroke=#6e1a62 stroke-width=1 r=12.658211482751796 cx=67.01971869260488 cy=26.574366899993365></circle><circle fill=none stroke=#ffffff stroke-width=1.5 r=11.158211482751796 cx=67.01971869260488 cy=26.574366899993365></circle><circle fill=#fd5704 stroke=#6e1a62 stroke-width=1 r=9.90689059560852 cx=35.0826229017183 cy=29.467991861074328></circle><circle fill=none stroke=#ffffff stroke-width=1.5 r=8.40689059560852 cx=35.0826229017183 cy=29.467991861074328></circle></svg></div>PlumX Metrics</a><div class="ppp-pop ppp-pop-left" style=display:none></div></div></div></div></div></div></div><div class="article-header__dropZone pb-dropzone" data-pb-dropzone=articleNavigation-Dropzone><div data-widget-id=6a165565-112b-475f-8cb2-c98055bc417f data-widget-name=UX3ArticleNavigation class="content-navigation clearfix"><div class=content-navigation__btn__wrapper--prev><a href=https://www.valueinhealthjournal.com/article/S1098-3015(17)33616-1/fulltext title="Previous Article" class="content-navigation__btn--pre default"><span class="content-navigation__body pre"><span class=content-navigation__body__top>Previous Article</span><span class=content-navigation__body__title>Expert Elicitation of Multinomial Probabilities for<span class=ellipsis> … </span></span></span><i aria-hidden=true class=icon-arrow_l></i></a></div><div class=content-navigation__extra></div><div class=content-navigation__btn__wrapper--next><a href=https://www.valueinhealthjournal.com/article/S1098-3015(17)33564-7/fulltext title="Next Article" class="content-navigation__btn--next default"><span class="content-navigation__body next"><span class=content-navigation__body__top>Next Article</span><span class=content-navigation__body__title>Cost-Effectiveness Analysis of a Navigation Program for<span class=ellipsis> … </span></span></span><i aria-hidden=true class=icon-arrow_r></i></a></div></div></div></div></div><div class=article__body><button title="open table of sections" aria-label="open table of sections" type=button class="left-side-nav__ctrl sf-hidden"></button><div class="left-side-nav col-md-2 col-lg-1" style=height:20843.8px;position:absolute;top:20px><ul class="rlist left-side-nav__upper"><li role=menuitem><a class=w-slide__hide href=#secsect0005><span>Abstract</span></a><li role=menuitem><a class=w-slide__hide href=#secsect0035><span>Keywords</span></a><li role=menuitem><a class=w-slide__hide href=#secsect0040><span>Introduction</span></a><li role=menuitem><a class=w-slide__hide href=#secsect0070><span>Methods</span></a><li role=menuitem><a class=w-slide__hide href=#secsect0090><span>Results</span></a><li role=menuitem><a class=w-slide__hide href=#secsect0100><span>Discussion</span></a><li role=menuitem><a class=w-slide__hide href=#secsect0115><span>Conclusions</span></a><li role=menuitem><a class=w-slide__hide href=#supplementaryMaterial><span>Supplementary material</span></a><li role=menuitem><a class=w-slide__hide href=#secsect0135><span>References</span></a><li role=menuitem><a class=w-slide__hide href=#articleInformation><span>Article Info</span></a><li role=menuitem><a class=w-slide__hide href=#figures><span>Figures</span></a><li role=menuitem><a class=w-slide__hide href=#tables><span>Tables</span></a><li role=menuitem><a class=w-slide__hide href=#relatedArticles><span>Related Articles</span></a></ul><ul class="rlist left-side-nav__bottom hidden sf-hidden"></ul></div><div class="adplaceholders hidden-xs hidden-sm" style=position:absolute;top:0px;bottom:auto>
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 <div class="widget literatumAd none adplaceholder widget-verticalAd sf-hidden" id=80e61381-d1dc-4a1f-98c4-59c9e22b2cf2>
 
 
 
 </div>
 
</div><div class=container><div class=row><div class="col-md-2 col-lg-1 hidden-sm"></div><div class="col-md-7 col-lg-9 article__sections"><section><h2 class=top id=secsect0005 data-left-hand-nav=Abstract tabindex=0><span class=top__sub></span><span class=top__text>Abstract</span></h2><div class=section-paragraph><h3>Background</h3><div class=section-paragraph>Assessment of drug costs for cost-effectiveness analyses (CEAs) in the United States is not straightforward because the prices paid for drugs are not publicly available and differ between payers. CEAs have relied on list prices that do not reflect the rebates and discounts known to be associated with these purchases.</div><h3>Objectives</h3><div class=section-paragraph>To review available cost measures and propose a novel strategy that is transparent, consistent, and applicable to all CEAs taking a US health care sector perspective or a societal payer’s perspective.</div><h3>Methods</h3><div class=section-paragraph>We propose using the National Average Drug Acquisition Cost (NADAC), the Veterans Affairs Federal Supply Schedule (VAFSS), and their midpoint as the upper bound, lower bound, and base case, respectively, to estimate net drug prices for various payers. We compare this approach with wholesale acquisition cost (WAC), the most common measure observed in our literature review. The minimum WAC is used to provide the most conservative comparison.</div><h3>Results</h3><div class=section-paragraph>Our sample consists of 1436 brand drugs and 1599 generic drugs. On average, the upper bound (NADAC) is 1% and 9.8% lower than the WAC for brand and generic drugs respectively, whereas the lower bound (VAFSS) is 48.3% and 54.2% lower than the WAC. The NADAC is less than the WAC in 89.6% of drug groups. The distributions of these relationships do not show a clear mode and have wide variation.</div><h3>Conclusions</h3><div class=section-paragraph>Our study suggests that the WAC may be an overestimate for the base case because the minimum WAC is higher than the NADAC for most drugs. Our approach balances uncertainty and lack of data for the cost of pharmaceuticals with the need for a transparent and consistent approach for valid CEAs.</div></div><div id=gpt-Interscroller class=gpt-InScrollBox style=display:none>
 
 
 
</div></section><section><h2 class=top id=secsect0035 data-left-hand-nav=Keywords tabindex=0><span class=top__sub></span><span class=top__text>Keywords</span></h2><ul class="rlist keywords-list inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/action/doSearch?AllField=%22cost-effectiveness%20analysis%22&amp;journalCode=jval">cost-effectiveness analysis</a><li><a href="https://www.valueinhealthjournal.com/action/doSearch?AllField=%22drug%20cost%22&amp;journalCode=jval">drug cost</a><li><a href="https://www.valueinhealthjournal.com/action/doSearch?AllField=%22health%20economic%20methods%22&amp;journalCode=jval">health economic methods</a><li><a href="https://www.valueinhealthjournal.com/action/doSearch?AllField=%22United%20States%22&amp;journalCode=jval">United States</a></ul></section><div data-pb-dropzone=relatedItems-dropzone class="relatedItems-dropzone pb-dropzone"></div><section id=s0005 data-locator=s0005 tabindex=0><h2 class=top id=secsect0040 data-left-hand-nav=Introduction tabindex=0><span class=top__sub></span><span class=top__text>Introduction</span></h2><div class=section-paragraph>Prescription drug costs, which totaled more than $300 billion in the United States in 2015, are an essential input for cost-effectiveness analyses (CEAs) [<div class="dropBlock reference-citations"><a href=# id=back-bib1 data-db-target-for=bib1-d1592139e822 class=reference-citations__ctrl aria-expanded=false aria-controls=bib1>1</a><div data-db-target-of=bib1-d1592139e822 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib2 data-db-target-for=bib2-d1592139e822 class=reference-citations__ctrl aria-expanded=false aria-controls=bib2>2</a><div data-db-target-of=bib2-d1592139e822 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib3 data-db-target-for=bib3-d1592139e822 class=reference-citations__ctrl aria-expanded=false aria-controls=bib3>3</a><div data-db-target-of=bib3-d1592139e822 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib4 data-db-target-for=bib4-d1592139e822 class=reference-citations__ctrl aria-expanded=false aria-controls=bib4>4</a><div data-db-target-of=bib4-d1592139e822 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib5 data-db-target-for=bib5-d1592139e822 class=reference-citations__ctrl aria-expanded=false aria-controls=bib5>5</a><div data-db-target-of=bib5-d1592139e822 class="dropBlock__holder sf-hidden"></div></div>]. A lack of transparency in actual transacted amounts complicates the process of obtaining reasonable drug cost estimates for US-based CEAs [<div class="dropBlock reference-citations"><a href=# id=back-bib6 data-db-target-for=bib6-d1592139e825 class=reference-citations__ctrl aria-expanded=false aria-controls=bib6>6</a><div data-db-target-of=bib6-d1592139e825 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib7 data-db-target-for=bib7-d1592139e825 class=reference-citations__ctrl aria-expanded=false aria-controls=bib7>7</a><div data-db-target-of=bib7-d1592139e825 class="dropBlock__holder sf-hidden"></div></div>]. Traditionally, the drug manufacturer’s list price or the wholesale acquisition cost (WAC) of pharmaceuticals published in commercially available drug pricing compendia has been used in CEAs [<div class="dropBlock reference-citations"><a href=# id=back-bib8 data-db-target-for=bib8-d1592139e828 class=reference-citations__ctrl aria-expanded=false aria-controls=bib8>8</a><div data-db-target-of=bib8-d1592139e828 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib9 data-db-target-for=bib9-d1592139e828 class=reference-citations__ctrl aria-expanded=false aria-controls=bib9>9</a><div data-db-target-of=bib9-d1592139e828 class="dropBlock__holder sf-hidden"></div></div>]. These list prices do not reflect the actual cost paid for drugs, because there are numerous discounts and rebates known to be granted to various entities throughout the drug supply chain [<div class="dropBlock reference-citations"><a href=# id=back-bib7 data-db-target-for=bib7-d1592139e831 class=reference-citations__ctrl aria-expanded=false aria-controls=bib7>7</a><div data-db-target-of=bib7-d1592139e831 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib10 data-db-target-for=bib10-d1592139e831 class=reference-citations__ctrl aria-expanded=false aria-controls=bib10>10</a><div data-db-target-of=bib10-d1592139e831 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib11 data-db-target-for=bib11-d1592139e831 class=reference-citations__ctrl aria-expanded=false aria-controls=bib11>11</a><div data-db-target-of=bib11-d1592139e831 class="dropBlock__holder sf-hidden"></div></div>]. Accounting for these rebates and discounts is necessary to reflect costs from any payer’s perspective [<div class="dropBlock reference-citations"><a href=#bib8 id=back-bib8 data-db-target-for=bib8-d1592139e834 class=reference-citations__ctrl aria-expanded=false aria-controls=bib8>[8]</a><div data-db-target-of=bib8-d1592139e834 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>The goal of this work was to describe a consistent, transparent, and empirically based approach for estimating a plausible range of drug costs for US-based CEAs taking an all-payer’s perspective such as the US health care sector perspective or the societal perspective. We then compare our approach with standard practice. Our approach relies on two publicly available price measures, the National Average Drug Acquisition Cost (NADAC) and the Department of Veterans Affairs Federal Supply Schedule (VAFSS), which are used to form the bounds of our drug cost parameter estimates. The range of net costs excludes pharmacy dispensing fees, which, although relevant for CEA, are not easily estimated. Our method does not incorporate dispensing fees, but does suggest assigning a separate parameter in the final analysis.</div><div class=section-paragraph>Our approach diverges from current practice that specifies a base case on the basis of either a list price or a prespecified fixed percent reduction from the list price, and then adds and subtracts a percent of the base case to cover the range of likely transaction costs for sensitivity analyses [<div class="dropBlock reference-citations"><a href=# id=back-bib12 data-db-target-for=bib12-d1592139e841 class=reference-citations__ctrl aria-expanded=false aria-controls=bib12>12</a><div data-db-target-of=bib12-d1592139e841 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib13 data-db-target-for=bib13-d1592139e841 class=reference-citations__ctrl aria-expanded=false aria-controls=bib13>13</a><div data-db-target-of=bib13-d1592139e841 class="dropBlock__holder sf-hidden"></div></div>]. We focus instead on defining plausible extremes of the range and assign the base case as the midpoint of this interval. We compare our approach to using the WAC for more than 3000 drugs covered by Medicaid and examine subsets of highly used and costly drugs.</div><div class=section-paragraph>To provide some background, we review existing recommendations for best practices in assessing drug costs for CEAs, and then we conduct a systematic review of recent CEAs to understand whether, and how, the recommendations are being followed. Next, we summarize the drug supply chain and highlight vital features including the discounts available to pharmacies and rebates available to payers (health insurers or pharmacy benefit managers) that reduce the cost of pharmaceuticals compared with their list prices to motivate our approach.</div><section id=s0010 data-locator=s0010 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Current Recommendations and Current Practice</span></h3><div class=section-paragraph>To promote quality and uniformity in drug costing for CEA studies, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a series titled Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses [<div class="dropBlock reference-citations"><a href=# id=back-bib8 data-db-target-for=bib8-d1592139e851 class=reference-citations__ctrl aria-expanded=false aria-controls=bib8>8</a><div data-db-target-of=bib8-d1592139e851 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib14 data-db-target-for=bib14-d1592139e851 class=reference-citations__ctrl aria-expanded=false aria-controls=bib14>14</a><div data-db-target-of=bib14-d1592139e851 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib15 data-db-target-for=bib15-d1592139e851 class=reference-citations__ctrl aria-expanded=false aria-controls=bib15>15</a><div data-db-target-of=bib15-d1592139e851 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib16 data-db-target-for=bib16-d1592139e851 class=reference-citations__ctrl aria-expanded=false aria-controls=bib16>16</a><div data-db-target-of=bib16-d1592139e851 class="dropBlock__holder sf-hidden"></div></div>]. ISPOR guidelines for costing drugs adopt the perspective of five different types of payers: societal, managed care organizations, US government, industry, and international. The guidelines state that “CEAs performed from a payer’s perspective should use drug prices actually paid by the relevant payer net of all rebates, co-pays, or other adjustments [discounts]” [<div class="dropBlock reference-citations"><a href=#bib8 id=back-bib8 data-db-target-for=bib8-d1592139e854 class=reference-citations__ctrl aria-expanded=false aria-controls=bib8>[8]</a><div data-db-target-of=bib8-d1592139e854 class="dropBlock__holder sf-hidden"></div></div>]. The ISPOR guidelines provide limited guidance as to how to account for these discounts and rebates, but suggest a generic average discount by some percent of the list price. In the chapter on the managed care organization perspective, the guidelines suggest a range of 5% to 25% for the manufacturer’s rebate [<div class="dropBlock reference-citations"><a href=#bib15 id=back-bib15 data-db-target-for=bib15-d1592139e857 class=reference-citations__ctrl aria-expanded=false aria-controls=bib15>[15]</a><div data-db-target-of=bib15-d1592139e857 class="dropBlock__holder sf-hidden"></div></div>]. This suggestion, however, is based only on a subset of highly used drugs from calendar year 2003 [<div class="dropBlock reference-citations"><a href=# id=back-bib11 data-db-target-for=bib11-d1592139e860 class=reference-citations__ctrl aria-expanded=false aria-controls=bib11>11</a><div data-db-target-of=bib11-d1592139e860 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib17 data-db-target-for=bib17-d1592139e860 class=reference-citations__ctrl aria-expanded=false aria-controls=bib17>17</a><div data-db-target-of=bib17-d1592139e860 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>To assess the impact of the recommendations, we conducted a literature search of US-based CEAs published between 2011 and 2015 that explicitly estimated cost for at least one outpatient drug. Forty-four of 81 studies adopted a US health system or generic third-party payer’s perspective, whereas 19 of 81 adopted the broader societal perspective.</div><div class=section-paragraph>Of the 81 studies, 43 used full nondiscounted WAC for the base case, 17 studies used nondiscounted average wholesale price (AWP), and 9 studies accounted for rebates/discounts by applying some discount to the AWP or the WAC. Twenty of the 81 studies used measures other than the AWP or the WAC for the base case, 19 studies used the VAFSS, and 1 study used the NADAC. Uncertainty of these estimates for sensitivity analyses was typically reflected by some percentage addition and subtraction, with a mode of ±25% (n = 19). Nevertheless, studies varied greatly, from as low as ±5% to as high as ±100%.</div></section><section id=s0015 data-locator=s0015 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Key Transactions in the Drug Supply Chain</span></h3><div class=section-paragraph>In a CEA, the relevant entities in the drug supply chain include drug manufacturers, drug wholesalers, pharmacies, and payers. Manufacturers produce drugs and sell these drugs to wholesalers, who, in turn, sell the drugs to pharmacies. Pharmacies dispense the drugs to patients and are usually paid by a health insurer or pharmacy benefit manager (herein “payer”) [<div class="dropBlock reference-citations"><a href=#bib18 id=back-bib18 data-db-target-for=bib18-d1592139e872 class=reference-citations__ctrl aria-expanded=false aria-controls=bib18>[18]</a><div data-db-target-of=bib18-d1592139e872 class="dropBlock__holder sf-hidden"></div></div>]. The manufacturer’s sale to the wholesaler is represented by the manufacturer’s suggested list price known as the WAC. These purchases, however, are often made at less than the WAC, because manufacturers grant discounts to wholesalers [<div class="dropBlock reference-citations"><a href=#bib19 id=back-bib19 data-db-target-for=bib19-d1592139e875 class=reference-citations__ctrl aria-expanded=false aria-controls=bib19>[19]</a><div data-db-target-of=bib19-d1592139e875 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>The second transaction is the sale from the wholesaler to the pharmacy. In theory, this purchase is also represented by a manufacturer-reported number, the AWP. It is well documented that discounts are often available for this purchase, for larger quantity and prompt pay [<div class="dropBlock reference-citations"><a href=# id=back-bib1 data-db-target-for=bib1-d1592139e880 class=reference-citations__ctrl aria-expanded=false aria-controls=bib1>1</a><div data-db-target-of=bib1-d1592139e880 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib7 data-db-target-for=bib7-d1592139e880 class=reference-citations__ctrl aria-expanded=false aria-controls=bib7>7</a><div data-db-target-of=bib7-d1592139e880 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib20 data-db-target-for=bib20-d1592139e880 class=reference-citations__ctrl aria-expanded=false aria-controls=bib20>20</a><div data-db-target-of=bib20-d1592139e880 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib21 data-db-target-for=bib21-d1592139e880 class=reference-citations__ctrl aria-expanded=false aria-controls=bib21>21</a><div data-db-target-of=bib21-d1592139e880 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>The third transaction is payer purchases of the drug from the pharmacy on behalf of the patient. This amount is negotiated between the pharmacy and the payer and is supposed to capture the amount the pharmacy paid to acquire the drug plus a dispensing fee. After the payer pays the pharmacy, the payer receives a rebate from the manufacturer independent of what they paid the pharmacy [<div class="dropBlock reference-citations"><a href=# id=back-bib22 data-db-target-for=bib22-d1592139e885 class=reference-citations__ctrl aria-expanded=false aria-controls=bib22>22</a><div data-db-target-of=bib22-d1592139e885 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib23 data-db-target-for=bib23-d1592139e885 class=reference-citations__ctrl aria-expanded=false aria-controls=bib23>23</a><div data-db-target-of=bib23-d1592139e885 class="dropBlock__holder sf-hidden"></div></div>]. This rebate, the final key transaction, effectively lowers the price of the drug to the payer below what they paid the pharmacy. The details of the manufacturer rebate or final negotiated price for almost all payers are confidential and vary not only by different drugs and manufacturers but also by different payers and their market power to negotiate these rebates [<div class="dropBlock reference-citations"><a href=#bib7 id=back-bib7 data-db-target-for=bib7-d1592139e888 class=reference-citations__ctrl aria-expanded=false aria-controls=bib7>[7]</a><div data-db-target-of=bib7-d1592139e888 class="dropBlock__holder sf-hidden"></div></div>].</div></section><section id=s0020 data-locator=s0020 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Cost Measures</span></h3><div class=section-paragraph>Our method proposes two cost measures to represent the range of plausible net costs likely encountered by all payers. The NADAC defines the upper bound, whereas the VAFSS defines the lower bound. We describe these measures in sufficient detail to motivate why they can represent these respective bounds for CEA.</div><section id=s0025 data-locator=s0025 tabindex=0><h4 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>National Average Drug Acquisition Cost</span></h4><div class=section-paragraph>The amount that fee-for-service Medicaid (distinct from Medicaid managed care) spends for a certain outpatient drug has two components—the payment to the pharmacy, which itself comprises ingredient costs and dispensing fee, and the rebates Medicaid eventually receives from the drug manufacturer [<div class="dropBlock reference-citations"><a href=#bib24 id=back-bib24 data-db-target-for=bib24-d1592139e901 class=reference-citations__ctrl aria-expanded=false aria-controls=bib24>[24]</a><div data-db-target-of=bib24-d1592139e901 class="dropBlock__holder sf-hidden"></div></div>]. The ingredient cost estimation varies by state, but is generally a fixed percent reduction or addition to the drug list price (either the AWP or the WAC) [<div class="dropBlock reference-citations"><a href=#bib25 id=back-bib25 data-db-target-for=bib25-d1592139e904 class=reference-citations__ctrl aria-expanded=false aria-controls=bib25>[25]</a><div data-db-target-of=bib25-d1592139e904 class="dropBlock__holder sf-hidden"></div></div>]. The second component comprises the rebates that are received by the state from the manufacturers after the drug has been dispensed and the pharmacy has been paid. The Medicaid Drug Rebate Program sets the amount and grants these rebates automatically, although the rebates can be larger if the state has negotiated an additional supplements rebate for individual drugs [<div class="dropBlock reference-citations"><a href=# id=back-bib24 data-db-target-for=bib24-d1592139e907 class=reference-citations__ctrl aria-expanded=false aria-controls=bib24>24</a><div data-db-target-of=bib24-d1592139e907 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib26 data-db-target-for=bib26-d1592139e907 class=reference-citations__ctrl aria-expanded=false aria-controls=bib26>26</a><div data-db-target-of=bib26-d1592139e907 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>In 2012, in an effort to aid state Medicaid agencies in modernizing their reimbursement, to pharmacies, the Centers for Medicare &amp; Medicaid Services conceived of the NADAC as a new price measure for use in fee-for-service Medicaid [<div class="dropBlock reference-citations"><a href=# id=back-bib19 data-db-target-for=bib19-d1592139e912 class=reference-citations__ctrl aria-expanded=false aria-controls=bib19>19</a><div data-db-target-of=bib19-d1592139e912 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib27 data-db-target-for=bib27-d1592139e912 class=reference-citations__ctrl aria-expanded=false aria-controls=bib27>27</a><div data-db-target-of=bib27-d1592139e912 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib28 data-db-target-for=bib28-d1592139e912 class=reference-citations__ctrl aria-expanded=false aria-controls=bib28>28</a><div data-db-target-of=bib28-d1592139e912 class="dropBlock__holder sf-hidden"></div></div>]. The goal of the NADAC is to estimate what pharmacies pay to acquire all outpatient pharmaceuticals reimbursed by Medicaid to better estimate their ingredient costs [<div class="dropBlock reference-citations"><a href=#bib27 id=back-bib27 data-db-target-for=bib27-d1592139e915 class=reference-citations__ctrl aria-expanded=false aria-controls=bib27>[27]</a><div data-db-target-of=bib27-d1592139e915 class="dropBlock__holder sf-hidden"></div></div>]. To compute the NADAC, an accounting firm contracted by the Centers for Medicare &amp; Medicaid Services (CMS) conducts a monthly nationwide survey of a random sample of pharmacies to assess their drug acquisition cost for purchases using invoices from the last 30 days. A weighted average is computed using the number of times each product, by unique National Drug Code (NDC), is observed in the sample. NDCs are grouped into therapeutically equivalent “drug groups,” that is, the same active ingredient, strength, and formulation. The survey yields a single weighted average cost for each drug group that may be used by states as the basis for reimbursement. Of the roughly 67,000 pharmacies in the United States, approximately 2000 to 2500 are sampled monthly [<div class="dropBlock reference-citations"><a href=# id=back-bib19 data-db-target-for=bib19-d1592139e918 class=reference-citations__ctrl aria-expanded=false aria-controls=bib19>19</a><div data-db-target-of=bib19-d1592139e918 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib27 data-db-target-for=bib27-d1592139e918 class=reference-citations__ctrl aria-expanded=false aria-controls=bib27>27</a><div data-db-target-of=bib27-d1592139e918 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib28 data-db-target-for=bib28-d1592139e918 class=reference-citations__ctrl aria-expanded=false aria-controls=bib28>28</a><div data-db-target-of=bib28-d1592139e918 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>We define the NADAC as an upper bound for sensitivity analyses, because it is an estimate of the net amount paid by payers before manufacturer rebates. We assume that the amount paid by the pharmacy to acquire the drug is the amount the payer will pay to acquire it, excluding the dispensing fee. The details of the NADAC are presented in <a href=#t0005 id=back-t0005 class=scroll-into-link>Table 1</a>.</div><div class=floatDisplay><div id=t0005 class=inline-table tabindex=0><div class=inline-table__head><span class=inline-table__label>Table 1</span><span class=inline-table__title>Drug cost measures’ descriptions and suggestions to inform CEA</span></div><div class=table-with-References> <table width=100% cellpadding=0 cellspacing=0 border=0 class="scrollable bordered"><thead><tr><th class=rowsep><strong>Cost measure</strong><th class=rowsep><strong>Description</strong><th class=rowsep><strong>Suggestion for inclusion in CEA</strong><tbody><tr><td>National Average Drug Acquisition Cost (NADAC)<td><ul class=ce-list--remove-bullets id=li0005><li class=ce-list--remove-bullets__list-item id=u0005><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Guides Medicaid on what to reimburse pharmacies</div><li class=ce-list--remove-bullets__list-item id=u0010><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Weighted average pharmacies pay to acquire a unit of a given drug group (unique combination of active ingredient, strength, and formulation)</div><li class=ce-list--remove-bullets__list-item id=u0015><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Based on monthly national survey that collects invoices from pharmacies, made publicly available online</div><li class=ce-list--remove-bullets__list-item id=u0020><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>The NADAC does not reflect the payers’ dispensing fee or rebates provided by drug manufacturers</div><li class=ce-list--remove-bullets__list-item id=u0025><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>The NADAC is updated weekly and published online; it lists only one cost for NDCs that contain identical ingredients.</div></ul><td><ul class=ce-list--remove-bullets id=li0010><li class=ce-list--remove-bullets__list-item id=u0030><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Use the NADAC as the upper bound of drug cost</div></ul><tr><td>Veterans Affairs Federal Supply Schedule (VAFSS)<td><ul class=ce-list--remove-bullets id=li0015><li class=ce-list--remove-bullets__list-item id=u0035><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>The FSS is the price negotiated by the Department of Veterans Affairs (VA) with drug manufacturers on behalf of all federal direct payers</div><li class=ce-list--remove-bullets__list-item id=u0040><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>For certain drugs the VA receives additional rebates on behalf of the Big 4 public payers (Big 4 price)</div><li class=ce-list--remove-bullets__list-item id=u0045><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>In addition, in some cases the VA can achieve even lower prices for the VA only on the basis of preferred placement on the VA formulary; this is called the national contract price (the NC price)</div><li class=ce-list--remove-bullets__list-item id=u0050><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>We define the VAFSS as the lowest price available to the VA (i.e., minimum FSS, Big 4, or the NC price) of any drug in a drug group (VAFSS)<div class="dropBlock reference-citations"><a href=# id=back-tbl1fnStar data-db-target-for=tbl1fnStar-d1592139e106 class="reference-citations__ctrl scroll-into-link" aria-expanded=false aria-controls=tbl1fnStar><sup>*</sup></a><div data-db-target-of=tbl1fnStar-d1592139e106 class="dropBlock__holder sf-hidden"></div></div></div><li class=ce-list--remove-bullets__list-item id=u0055><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Believed to be one of the lowest if not the lowest final price any payer (public or private) pays</div><li class=ce-list--remove-bullets__list-item id=u0060><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Contracts are publicly available and published online</div><li class=ce-list--remove-bullets__list-item id=u0065><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Prices can vary within drug group depending on the NDC</div></ul><td><ul class=ce-list--remove-bullets id=li0020><li class=ce-list--remove-bullets__list-item id=u0070><span class=label>•</span><div class=ce-list--remove-bullets__list-item__text>Use the VAFSS as the lower bound of drug cost</div></ul></table></div><div class=inline-table__tail><div class=section-paragraph>CEA, cost-effectiveness ratio; NDC, National Drug Code.</div><div class=inline-table__footnote><span><img src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="10" height="21"><rect fill-opacity="0"/></svg>' alt="low asterisk" border=0 class=entity style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-17)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"> </span><span>According to a 2011 report, the VA uses the FSS in 78% of prescriptions, a Big 4 price in 15%, and 7% in other negotiated situations that include the NC price.</span></div></div><ul class="rlist--inline separator download-links"><li><a title="Open Full Table" class=table__open__ctrl target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0005&amp;pii=S1098-3015%2817%2930316-9">
 Open table in a new tab
 </a></ul></div></div></section><section id=s0030 data-locator=s0030 tabindex=0><h4 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Veterans Affairs Federal Supply Schedule</span></h4><div class=section-paragraph>The US Department of Veterans Affairs (VA) Health Administration, an integrated care system with roughly 9 million enrollees, is able to negotiate the price of drugs with manufacturers. Unlike virtually all other US payers, these contract details, including the final negotiated prices, are publicly available [<div class="dropBlock reference-citations"><a href=# id=back-bib13 data-db-target-for=bib13-d1592139e932 class=reference-citations__ctrl aria-expanded=false aria-controls=bib13>13</a><div data-db-target-of=bib13-d1592139e932 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib21 data-db-target-for=bib21-d1592139e932 class=reference-citations__ctrl aria-expanded=false aria-controls=bib21>21</a><div data-db-target-of=bib21-d1592139e932 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib26 data-db-target-for=bib26-d1592139e932 class=reference-citations__ctrl aria-expanded=false aria-controls=bib26>26</a><div data-db-target-of=bib26-d1592139e932 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib29 data-db-target-for=bib29-d1592139e932 class=reference-citations__ctrl aria-expanded=false aria-controls=bib29>29</a><div data-db-target-of=bib29-d1592139e932 class="dropBlock__holder sf-hidden"></div></div>]. The pricing process for the VA is complex, because the VA is charged with negotiating prices, called the Federal Supply Schedule (FSS), for all federal direct health care payer agencies (notably not Medicare and Medicaid). The FSS price is no more than the price manufacturers charge their most favored nonfederal customers under similar market conditions [<div class="dropBlock reference-citations"><a href=#bib30 id=back-bib30 data-db-target-for=bib30-d1592139e935 class=reference-citations__ctrl aria-expanded=false aria-controls=bib30>[30]</a><div data-db-target-of=bib30-d1592139e935 class="dropBlock__holder sf-hidden"></div></div>]. In addition to the FSS, the VA can receive additional statutorily defined rebates through their shared purchasing power with other large agencies (the Big 4 price) and additional rebates for themselves through preferred formulary placement (national contract price) [<div class="dropBlock reference-citations"><a href=#bib31 id=back-bib31 data-db-target-for=bib31-d1592139e938 class=reference-citations__ctrl aria-expanded=false aria-controls=bib31>[31]</a><div data-db-target-of=bib31-d1592139e938 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>We define the VAFSS as the lowest of all these prices available to the VA for every covered drug. A recent Department of Health and Human Services report to Congress described the large rebates the VA receives: “The national formulary allows the VA to purchase prescription drugs at some of the lowest prices available to any buyer in the US based on its ability to drive utilization to the most cost-effective drugs” [<div class="dropBlock reference-citations"><a href=#bib32 id=back-bib32 data-db-target-for=bib32-d1592139e943 class=reference-citations__ctrl aria-expanded=false aria-controls=bib32>[32]</a><div data-db-target-of=bib32-d1592139e943 class="dropBlock__holder sf-hidden"></div></div>]. The other key feature of the VAFSS is that it is excluded from the computation of the statutorily defined best price used in computing Medicaid’s manufacturer rebates [<div class="dropBlock reference-citations"><a href=#bib32 id=back-bib32 data-db-target-for=bib32-d1592139e946 class=reference-citations__ctrl aria-expanded=false aria-controls=bib32>[32]</a><div data-db-target-of=bib32-d1592139e946 class="dropBlock__holder sf-hidden"></div></div>]. Thus, the VAFSS exclusion from the computation of best price allows manufacturers to offer larger rebates to the VA without having to allow a larger rebate to Medicaid [<div class="dropBlock reference-citations"><a href=# id=back-bib32 data-db-target-for=bib32-d1592139e949 class=reference-citations__ctrl aria-expanded=false aria-controls=bib32>32</a><div data-db-target-of=bib32-d1592139e949 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib33 data-db-target-for=bib33-d1592139e949 class=reference-citations__ctrl aria-expanded=false aria-controls=bib33>33</a><div data-db-target-of=bib33-d1592139e949 class="dropBlock__holder sf-hidden"></div></div>]. A 2005 Congressional Budget Office report found that the VA paid on average 42% of the AWP, whereas the average best price of all pharmaceuticals was 63% of the AWP [<div class="dropBlock reference-citations"><a href=# id=back-bib17 data-db-target-for=bib17-d1592139e952 class=reference-citations__ctrl aria-expanded=false aria-controls=bib17>17</a><div data-db-target-of=bib17-d1592139e952 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib31 data-db-target-for=bib31-d1592139e952 class=reference-citations__ctrl aria-expanded=false aria-controls=bib31>31</a><div data-db-target-of=bib31-d1592139e952 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>The VAFSS price can vary by the NDC within drug groups if more than one therapeutically equivalent product is reimbursed. The details of VA pricing are presented in <a href=#t0005 id=back-t0005 class=scroll-into-link>Table 1</a>.</div></section></section></section><section id=s0035 data-locator=s0035 tabindex=0><h2 class=top id=secsect0070 data-left-hand-nav=Methods tabindex=0><span class=top__sub></span><span class=top__text>Methods</span></h2><section id=s0040 data-locator=s0040 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Approach</span></h3><div class=section-paragraph>Our approach focuses on defining plausible values of the minimum and maximum net price [<div class="dropBlock reference-citations"><a href=#bib34 id=back-bib34 data-db-target-for=bib34-d1592139e968 class=reference-citations__ctrl aria-expanded=false aria-controls=bib34>[34]</a><div data-db-target-of=bib34-d1592139e968 class="dropBlock__holder sf-hidden"></div></div>]. We define the NADAC as an upper bound estimate of the net price for payers. We define the minimum VAFSS price by drug group as the lower bound estimate of the lowest net price available to any US payer. The midpoint between the upper and lower bounds is designated as the base case. The tutorial in <a href=#s0085 class=scroll-into-link>Appendix I in Supplemental Materials</a> found at <a href=http://dx.doi.org/10.1016/j.jval.2017.06.013 target=_blank>doi:10.1016/j.jval.2017.06.013</a> provides further details with two completed examples using our approach. <a href=#s0085 class=scroll-into-link>Appendix II in Supplemental Materials</a> found at <a href=http://dx.doi.org/10.1016/j.jval.2017.06.013 target=_blank>doi:10.1016/j.jval.2017.06.013</a> details how to make adjustments if the cost metrics do not follow their anticipated ordering, that is, if the NADAC is lower than the VAFSS. This reverse ordering may occur because VAFSS prices are updated less frequently than NADACs [<div class="dropBlock reference-citations"><a href=#bib35 id=back-bib35 data-db-target-for=bib35-d1592139e984 class=reference-citations__ctrl aria-expanded=false aria-controls=bib35>[35]</a><div data-db-target-of=bib35-d1592139e984 class="dropBlock__holder sf-hidden"></div></div>].</div></section><section id=s0045 data-locator=s0045 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Comparison</span></h3><div class=section-paragraph>We compared a wide range of pharmaceuticals using the current approach represented by the WAC and our approach represented by the NADAC and the VAFSS. We selected the WAC as our comparator because it was revealed to be the most prevalent strategy currently being used in CEAs. The minimum WAC by drug group was used to be as conservative as possible in our comparisons [<div class="dropBlock reference-citations"><a href=#bib3 id=back-bib3 data-db-target-for=bib3-d1592139e992 class=reference-citations__ctrl aria-expanded=false aria-controls=bib3>[3]</a><div data-db-target-of=bib3-d1592139e992 class="dropBlock__holder sf-hidden"></div></div>].</div><div class=section-paragraph>The WAC, NADAC, and VAFSS databases were accessed on April 1, 2015. To select our set of drug groups (unique ingredient, strength, and formulation), we used the NDCs representing each drug group reported in the NADAC. We included NDCs of single- and multi-ingredient tablet and capsule formulated drugs as well as single-ingredient non–tablet and capsule formulated drugs that had a reported cost in all three databases. We converted the unit cost for each NDC into the units used by the NADAC drug group for each product.</div></section><section id=s0050 data-locator=s0050 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Data Analysis</span></h3><div class=section-paragraph>We calculated the following ratios: 1) the NADAC to the WAC, 2) the VAFSS to the WAC, and 3) the base case to the WAC. The ratio of the NADAC to the WAC explains how much the WAC fails to account for discounts pharmacies receive when acquiring the drug. The ratio of the VAFSS to the WAC explains how much using the WAC fails to account for the maximum rebate available to any payer. The ratio of the midpoint to the WAC compares our strategies’ base case with the most common approach for CEAs. We examined these ratios separately for brand and generic drugs and created histograms to examine the consistency of the relationships between price measures.</div><div class=section-paragraph>Finally, we examined the unit cost of each price measure for 20 drug groups with the highest utilization and 20 drug groups with the highest overall spending as identified in the 2015 utilization report published by IMS Health [<div class="dropBlock reference-citations"><a href=#bib36 id=back-bib36 data-db-target-for=bib36-d1592139e1004 class=reference-citations__ctrl aria-expanded=false aria-controls=bib36>[36]</a><div data-db-target-of=bib36-d1592139e1004 class="dropBlock__holder sf-hidden"></div></div>].</div></section></section><section id=s0055 data-locator=s0055 tabindex=0><h2 class=top id=secsect0090 data-left-hand-nav=Results tabindex=0><span class=top__sub></span><span class=top__text>Results</span></h2><div class=section-paragraph>We included 3035 drug groups with a reported NADAC, VAFSS, and WAC. The average unit costs by the NADAC, the VAFSS, and the WAC for 1436 brand drug groups and 1599 generic drug groups are presented in <a href=#t0010 id=back-t0010 class=scroll-into-link>Table 2</a>. As expected, these average unit costs show that the WAC is the highest and the VAFSS is the lowest.<div class=floatDisplay><div id=t0010 class=inline-table tabindex=0><div class=inline-table__head><span class=inline-table__label>Table 2</span><span class=inline-table__title>Average unit cost and average ratio between price measures by brand designation</span></div><table width=100% cellpadding=0 cellspacing=0 border=0 class="scrollable bordered"><thead><tr><th class=rowsep><th class=rowsep><strong>Brand (N = 1436)</strong><th class=rowsep><strong>Generic (N = 1599)</strong><tbody><tr><td>Unit cost<td><td><tr><td> WAC<td>67.42<td>4.47<tr><td> NADAC<td>65.22<td>3.58<tr><td> VAFSS<td>34.05<td>1.69<tr><td>Ratio of price measure to the WAC<td><td><tr><td> NADAC (upper bound)<td>0.991<td>0.902<tr><td> VAFSS (lower bound)<td>0.517<td>0.458<tr><td> Proposed base case<td>0.754<td>0.680</table><div class=inline-table__tail><div class=section-paragraph>NADAC, National Average Drug Acquisition Cost; VAFSS, Veterans Affairs Federal Supply Schedule; WAC, wholesale acquisition cost.</div></div><ul class="rlist--inline separator download-links"><li><a title="Open Full Table" class=table__open__ctrl target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0010&amp;pii=S1098-3015%2817%2930316-9">
 Open table in a new tab
 </a></ul></div></div></div><div class=section-paragraph>The lower panel of <a href=#t0010 id=back-t0010 class=scroll-into-link>Table 2</a> indicates that on average the NADAC is 99.1% of the WAC for brand drugs and 90.2% of the WAC for generics. The VAFSS cost is 51.7% of the WAC for brand drugs and 45.8% of the WAC for generics. Finally, the ratio of the base case to the WAC is on average 75.4% for brand drugs and 68% for generics. The smaller ratios for generics than for brand drugs suggests that the extent of discounts and rebates available to pharmacies and payers from wholesalers and manufacturers is greater for generic drugs than for brand drugs.</div><div class=section-paragraph>The histograms of these ratios are shown in <a data-link=modal data-target=#image-S1098-3015(17)30316-9gr1 href=#gr1 data-locator=f0005 id=back-gr1 class="figure-link scroll-into-link">Fig. 1</a>, <a data-link=modal data-target=#image-S1098-3015(17)30316-9gr2 href=#gr2 data-locator=f0010 id=back-gr2 class="figure-link scroll-into-link">Fig. 2</a>, <a data-link=modal data-target=#image-S1098-3015(17)30316-9gr3 href=#gr3 data-locator=f0015 id=back-gr3 class="figure-link scroll-into-link">Fig. 3</a>. The left-hand panel of <a data-link=modal data-target=#image-S1098-3015(17)30316-9gr1 href=#gr1 data-locator=f0005 id=back-gr1 class="figure-link scroll-into-link">Figure 1</a> shows strong concentration around 97% and few observations above 100% (n = 75). There is much greater uncertainty for generics, with a mode of 95% and a surprisingly large number of drug groups over 100% (n = 238).<div class=floatDisplay><figure id=gr1><img class="b-lazy b-loaded ux-lazyloaded tall img-aspect-ratio-checked" loading=lazy alt="Fig. 1" data-locator=f0005 data-high-res=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9392f847-b862-4663-b245-61884ed9c1a7/gr1_lrg.jpg data-large-image=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6218808c-f2e4-4b02-98dc-b6c5c21b6ddd/gr1.jpg src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="562" height="395"><rect fill-opacity="0"/></svg>' style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-15)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"><figcaption><div class=figure__caption__body><div class=figure__title><span data-fv-label="Fig. 1" class="label figure__label">Fig. 1</span><span class=figure__title__text>Histograms of NADAC/Minimum WAC Ratio.</span></div><ul class="rlist--inline separator download-links"><li><a target=_blank href=https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6218808c-f2e4-4b02-98dc-b6c5c21b6ddd/gr1.jpg title="View Large Image in a new tab">View Large
 Image
 </a><li class=download-links__figureViewer><a href=# class=figure__open__ctrl>Figure Viewer</a><li><a href=https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9392f847-b862-4663-b245-61884ed9c1a7/gr1_lrg.jpg class=download-links__download-Hi-res target=_blank download>Download Hi-res
 image
 </a><li class=hidden-xs><a href="https://www.valueinhealthjournal.com/action/downloadFigures?pii=S1098-3015(17)30316-9&amp;id=gr1.jpg" class=download-links__download-This>Download (PPT)</a></ul></div></figcaption></figure></div><div class=floatDisplay><figure id=gr2><img class="b-lazy b-loaded ux-lazyloaded tall img-aspect-ratio-checked" loading=lazy alt="Fig. 2" data-locator=f0010 data-high-res=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c5e76630-f8ad-4db2-b707-0de6ae691e07/gr2_lrg.jpg data-large-image=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/082ddeaf-a0a6-4217-b656-ca8ea9adc9df/gr2.jpg src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="562" height="396"><rect fill-opacity="0"/></svg>' style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-18)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"><figcaption><div class=figure__caption__body><div class=figure__title><span data-fv-label="Fig. 2" class="label figure__label">Fig. 2</span><span class=figure__title__text>Histogram of VAFSS/Minimum WAC Ratio.</span></div><ul class="rlist--inline separator download-links"><li><a target=_blank href=https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/082ddeaf-a0a6-4217-b656-ca8ea9adc9df/gr2.jpg title="View Large Image in a new tab">View Large
 Image
 </a><li class=download-links__figureViewer><a href=# class=figure__open__ctrl>Figure Viewer</a><li><a href=https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c5e76630-f8ad-4db2-b707-0de6ae691e07/gr2_lrg.jpg class=download-links__download-Hi-res target=_blank download>Download Hi-res
 image
 </a><li class=hidden-xs><a href="https://www.valueinhealthjournal.com/action/downloadFigures?pii=S1098-3015(17)30316-9&amp;id=gr2.jpg" class=download-links__download-This>Download (PPT)</a></ul></div></figcaption></figure></div><div class=floatDisplay><figure id=gr3><img class="b-lazy b-loaded ux-lazyloaded tall img-aspect-ratio-checked" loading=lazy alt="Fig. 3" data-locator=f0015 data-high-res=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2df9c122-3f70-4859-a0af-4411b9f32ea4/gr3_lrg.jpg data-large-image=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a69732d5-d234-4edf-b83d-73dc1f3f26a1/gr3.jpg src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="565" height="395"><rect fill-opacity="0"/></svg>' style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-19)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"><figcaption><div class=figure__caption__body><div class=figure__title><span data-fv-label="Fig. 3" class="label figure__label">Fig. 3</span><span class=figure__title__text>Histogram of Basecase/Minimum WAC Ratio. NADAC, National Average Drug Acquisition Cost; VAFSS, Veterans Affairs Federal Supply Schedule; WAC, wholesale acquisition cost</span></div><ul class="rlist--inline separator download-links"><li><a target=_blank href=https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a69732d5-d234-4edf-b83d-73dc1f3f26a1/gr3.jpg title="View Large Image in a new tab">View Large
 Image
 </a><li class=download-links__figureViewer><a href=# class=figure__open__ctrl>Figure Viewer</a><li><a href=https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2df9c122-3f70-4859-a0af-4411b9f32ea4/gr3_lrg.jpg class=download-links__download-Hi-res target=_blank download>Download Hi-res
 image
 </a><li class=hidden-xs><a href="https://www.valueinhealthjournal.com/action/downloadFigures?pii=S1098-3015(17)30316-9&amp;id=gr3.jpg" class=download-links__download-This>Download (PPT)</a></ul></div></figcaption></figure></div></div><div class=section-paragraph><a data-link=modal data-target=#image-S1098-3015(17)30316-9gr2 href=#gr2 data-locator=f0010 id=back-gr2 class="figure-link scroll-into-link">Figure 2</a> displays the ratio of the VAFSS to the WAC. Most ratios for brand drugs fall between 40% and 60%, with a mode of 50% and few observations over 100% (n = 16). The relationship for generics is much less consistent with an almost uniform distribution between 15% and 35%, and more drug groups above 100% (n = 62).</div><div class=section-paragraph>Finally, <a data-link=modal data-target=#image-S1098-3015(17)30316-9gr3 href=#gr3 data-locator=f0015 id=back-gr3 class="figure-link scroll-into-link">Figure 3</a> compares the ratio between base case estimates. A single mode of 75% for brand drugs is found with few observations above 100% (n = 56). Generic drugs indicate a mode of 50% with larger uncertainty and more ratios above 100% (n = 171).</div><section id=s0060 data-locator=s0060 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Top Drug Groups</span></h3><div class=section-paragraph>We identified the top 20 prescription drugs by total US spending and by overall utilization per number of prescriptions written. <a href=#t0015 id=back-t0015 class=scroll-into-link>Table 3</a> presents the unit price reported in each price measure for the top 20 drugs by frequency (all generics) and the top 20 drugs by total spending (all brand drugs).<div class=floatDisplay><div id=t0015 class=inline-table tabindex=0><div class=inline-table__head><span class=inline-table__label>Table 3</span><span class=inline-table__title>Unit cost of top 20 drug groups by the number of prescriptions in the United States in 2015</span></div><div class=table-with-References> <table width=100% cellpadding=0 cellspacing=0 border=0 class="scrollable bordered"><thead><tr><th rowspan=2><strong>Drug group</strong><th class=rowsep colspan=3><strong>Proposed approach</strong><th class=rowsep><strong>Standard</strong><tr><th class=rowsep><strong>NADAC (upper bound) ($)</strong><th class=rowsep><strong>VAFSS (lower bound) ($)</strong><th class=rowsep><strong>Base case ($)</strong><th class=rowsep><strong>WAC ($)</strong><tbody><tr><td>Levothyroxine 50 μg tablet<td>0.375<td>0.021<td>0.198<td>0.413<tr><td>Lisinopril 20 mg tablet<td>0.026<td>0.020<td>0.023<td>0.037<tr><td>Hydrocodone/acetaminophen 10 mg/325 mg tablet<td>0.273<td>0.081<td>0.177<td>0.137<tr><td>Atorvastatin 40 mg tablet<td>0.180<td>0.059<td>0.120<td>0.294<tr><td>Metoprolol tartrate 25 mg tablet<td>0.027<td>0.016<td>0.022<td>0.027<tr><td>Amlodipine besylate 10 mg tablet<td>0.027<td>0.014<td>0.021<td>0.030<tr><td>Metformin hydrochloride 500 mg tablet<td>0.016<td>0.012<td>0.014<td>0.028<tr><td>Omeprazole DR 20 mg capsule<td>0.063<td>0.080<td>NA<div class="dropBlock reference-citations"><a href=# id=back-tbl3fnStar data-db-target-for=tbl3fnStar-d1592139e331 class="reference-citations__ctrl scroll-into-link" aria-expanded=false aria-controls=tbl3fnStar><sup>*</sup></a><div data-db-target-of=tbl3fnStar-d1592139e331 class="dropBlock__holder sf-hidden"></div></div><td>0.224<tr><td>Albuterol sulfate 2.5 mg/3 ml solution<td>0.044<td>0.034<td>0.039<td>0.053<tr><td>Simvastatin 20 mg tablet<td>0.028<td>0.020<td>0.024<td>0.031<tr><td>Gabapentin 300 mg capsule<td>0.049<td>0.024<td>0.037<td>0.067<tr><td>Amoxicillin 500 mg capsule<td>0.070<td>0.017<td>0.044<td>0.079<tr><td>Fluticasone propionate 50 μg spray<td>0.354<td>0.103<td>0.229<td>1.375<tr><td>Hydrochlorothiazide 25 mg tablet<td>0.013<td>0.008<td>0.011<td>0.011<tr><td>Alprazolam 1 mg tablet<td>0.024<td>0.008<td>0.016<td>0.045<tr><td>Azithromycin 250 mg tablet<td>0.605<td>0.363<td>0.484<td>1.287<tr><td>Furosemide 40 mg tablet<td>0.011<td>0.006<td>0.009<td>0.012<tr><td>Sertraline hydrochloride 100 mg tablet<td>0.062<td>0.077<td>0.070<td>0.086<tr><td>Losartan potassium 50 mg tablet<td>0.064<td>0.060<td>0.062<td>0.115<tr><td>Tramadol hydrochloride 50 mg tablet<td>0.030<td>0.014<td>0.022<td>0.045</table></div><div class=inline-table__tail><div class=section-paragraph>NA, not applicable; NADAC, National Average Drug Acquisition Cost; VAFSS, Veterans Affairs Federal Supply Schedule; WAC, wholesale acquisition cost.</div><div class=inline-table__footnote><span><img src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="10" height="21"><rect fill-opacity="0"/></svg>' alt="low asterisk" border=0 class=entity style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-17)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"> </span><span>VAFSS &gt; NADAC (see <a href=#s0090 class=scroll-into-link>Appendix II in Supplemental Materials</a> for further explanation).</span></div></div><ul class="rlist--inline separator download-links"><li><a title="Open Full Table" class=table__open__ctrl target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0015&amp;pii=S1098-3015%2817%2930316-9">
 Open table in a new tab
 </a></ul></div></div></div><div class=section-paragraph>The most used drug, 50 μg levothroxine, has an NADAC of $0.375, a minimum VAFSS of $0.021, and a minimum WAC of $0.413. Our approach sets the base case as $0.198, with a range of $0.021 to $0.375. Compared with using the WAC as the base case, our value is half of the WAC. We see a similar pattern in the rest of the table. In all but hydrocodone-acetaminophen, the base case using our approach is lower than the WAC. The WAC is generally closer to the NADAC than the midpoint between the NADAC and the VAFSS. The VAFSS of omeprazole is larger than its NADAC. <a href=#s0090 class=scroll-into-link>Appendix II in Supplemental Materials</a> offers our suggested adjustment.</div><div class=section-paragraph><a href=#t0020 id=back-t0020 class=scroll-into-link>Table 4</a> presents the subset of the top 20 drugs by spending in the United States, except for 3 drugs that are physician-administered and not included in the NADAC. The WAC for Harvoni is $1125 per tablet and the range using our approach is $675 to $1091 per tablet with a base case of $883. All the drugs have the expected rank orderings by price measure; the proportional differences, however, vary by drug.<div class=floatDisplay><div id=t0020 class=inline-table tabindex=0><div class=inline-table__head><span class=inline-table__label>Table 4</span><span class=inline-table__title>Unit cost of top 20 drug groups by spending in the United States in 2015<div class="dropBlock reference-citations"><a href=# id=back-tbl4fnStar data-db-target-for=tbl4fnStar-d1592139e484 class="reference-citations__ctrl scroll-into-link" aria-expanded=false aria-controls=tbl4fnStar><sup>*</sup></a><div data-db-target-of=tbl4fnStar-d1592139e484 class="dropBlock__holder sf-hidden"></div></div></span></div><table width=100% cellpadding=0 cellspacing=0 border=0 class="scrollable bordered"><thead><tr><th rowspan=2><strong>Drug group</strong><th class=rowsep colspan=3><strong>Proposed approach</strong><th class=rowsep><strong>Standard</strong><tr><th class=rowsep><strong>NADAC (upper bound) ($)</strong><th class=rowsep><strong>VAFSS (lower bound) ($)</strong><th class=rowsep><strong>Base case ($)</strong><th class=rowsep><strong>WAC ($)</strong><tbody><tr><td>Harvoni 90/400 mg tablet<td>1,091.23<td>675.00<td>883.12<td>1,125.00<tr><td>Humira 40 mg/0.8 ml pen<td>1,415.19<td>687.54<td>1,051.37<td>1,456.82<tr><td>Enbrel 50 mg/ml SureClick syringe<td>728.67<td>415.66<td>572.16<td>743.41<tr><td>Crestor 20 mg tablet<td>6.73<td>2.65<td>4.69<td>13.72<tr><td>Lantus solostar 100 units/ml<td>24.06<td>8.58<td>16.32<td>24.85<tr><td>Remicade 100 mg vial<td>890.37<td>532.89<td>711.63<td>973.72<tr><td>Advair diskus 250/50 μg (60 doses)<td>4.87<td>3.23<td>4.05<td>4.97<tr><td>Abilify 5 mg tablet<td>28.72<td>17.12<td>22.92<td>29.73<tr><td>Copaxone 20 mg/ml syringe<td>196.34<td>124.34<td>160.34<td>203.68<tr><td>Januvia 100 mg tablet<td>10.82<td>5.91<td>8.36<td>11.02<tr><td>Neulasta 6 mg/0.6 ml syringe<td>7,248.35<td>2,341.98<td>4,795.17<td>7,808.67<tr><td>Lyrica 150 mg capsule<td>4.71<td>2.92<td>3.82<td>5.04<tr><td>Lantus 100 units/ml vial<td>24.22<td>7.16<td>15.69<td>24.85<tr><td>Nexium DR 40 mg capsule<td>7.64<td>4.86<td>6.25<td>7.89<tr><td>Spiriva 18 μg CP-handihaler (30 doses)<td>9.61<td>5.60<td>7.61<td>9.93<tr><td>Sovaldi 400 mg tablet<td>981.50<td>593.57<td>787.54<td>1,000.00<tr><td>Atripla 600 mg/200 mg/300 mg tablet<td>68.71<td>43.08<td>55.90<td>70.89</table><div class=inline-table__tail><div class=section-paragraph>NADAC, National Average Drug Acquisition Cost; VAFSS, Veterans Affairs Federal Supply Schedule; WAC, wholesale acquisition cost.</div><div class=inline-table__footnote><span><img src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="10" height="21"><rect fill-opacity="0"/></svg>' alt="low asterisk" border=0 class=entity style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-17)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"> </span><span>Three physician-administered drugs are excluded because they are not included in the NADAC.</span></div></div><ul class="rlist--inline separator download-links"><li><a title="Open Full Table" class=table__open__ctrl target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0020&amp;pii=S1098-3015%2817%2930316-9">
 Open table in a new tab
 </a></ul></div></div></div></section></section><section id=s0065 data-locator=s0065 tabindex=0><h2 class=top id=secsect0100 data-left-hand-nav=Discussion tabindex=0><span class=top__sub></span><span class=top__text>Discussion</span></h2><div class=section-paragraph>Our new method for estimating drug costs for CEAs adopting a US health care sector or a societal payer’s perspective relies on two measures—the NADAC and the VAFSS. These metrics represent the plausible range of drug costs likely experienced by payers in the United States. When conducting a CEA, we propose the midpoint between the NADAC and the VAFSS as the base case and the NADAC and the VAFSS form the bounds used for deterministic sensitivity analysis and probabilistic sensitivity analysis. For probabilistic sensitivity analysis, we advocate using a uniform distribution between the bounds, because there is not a strong theoretical basis for selecting a different distribution.</div><div class=section-paragraph>We compared our approach with the WAC, because it is currently the most commonly used measure for assessing drug costs in US-based CEAs. We used the minimum WAC by drug group to compare our approach with a conservative choice of the base case. Our analysis showed that using the WAC as the base case overstates net drug costs. In 94.7% of brand drugs and 85.1% of generics, the minimum WAC is larger than our proposed upper bound. Thus, we proposed the NADAC, instead of the WAC, as the upper bound. The variation observed in the ratios of the NADAC to the minimum WAC indicates that a single discount rate is not appropriate when applied to all drugs to account for the impact of rebates and discounts.</div><section id=s0070 data-locator=s0070 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Assumptions of Approach</span></h3><div class=section-paragraph>Our approach relies on several assumptions, which should be communicated clearly in any analysis adopting this approach. By proposing the NADAC as an upper bound, we assume that the pharmacy average acquisition cost is a proxy for the highest net cost paid by some payers. The NADAC is an average cost, with some pharmacies paying more than the average. Nevertheless, all payers receive rebates that effectively lower their final price below what they pay the pharmacy.</div><div class=section-paragraph>We also assume that the VAFSS price is the lowest price likely paid by any payer. We supported this assumption with details of the computation of federally mandated manufacturer rebates for fee-for-service Medicaid purchases as well as previous work from the Congressional Budget Office that used proprietary data on prices paid by private payers.</div><div class=section-paragraph>We define the base case as the midpoint between the NADAC and the WAC. This measure was simply defined, because there is no other obvious metric to represent the base case. More transparency in net price paid by all payers, both public and private, and their relative market share would help us improve how we select the base case.</div></section><section id=s0075 data-locator=s0075 tabindex=0><h3 class=sectionTitle><span class=top__sub>&nbsp;</span><span class=top__text>Study Limitations</span></h3><div class=section-paragraph>A limitation of the NADAC is the extent to which it accurately represents the pharmacy acquisition cost. During the public comments phase of the NADACs release, several individuals and organizations identified discounts that are not included in the NADAC computation, such as discounts tied to achieving certain volumes purchased over time [<div class="dropBlock reference-citations"><a href=#bib28 id=back-bib28 data-db-target-for=bib28-d1592139e1081 class=reference-citations__ctrl aria-expanded=false aria-controls=bib28>[28]</a><div data-db-target-of=bib28-d1592139e1081 class="dropBlock__holder sf-hidden"></div></div>]. Similarly, because participation in the NADAC survey is not mandatory, pharmacies that are receiving a lower price than the current NADAC price may be disincentivized from participating, because it could lower the amount they are reimbursed by Medicaid in certain states [<div class="dropBlock reference-citations"><a href=#bib25 id=back-bib25 data-db-target-for=bib25-d1592139e1084 class=reference-citations__ctrl aria-expanded=false aria-controls=bib25>[25]</a><div data-db-target-of=bib25-d1592139e1084 class="dropBlock__holder sf-hidden"></div></div>]. Although we cannot evaluate the impact of these two potential biases directly, both result in an overestimate of the NADAC. The NADAC represents an upper bound. Because the NADAC remains lower than the minimum WAC for most drugs and is based on actual transactions instead of list prices, the NADAC, although imperfect, is an improvement over current practice to represent the upper bound of drug cost.</div><div class=section-paragraph>The comparison with minimum WAC revealed several issues that warrant discussion. We chose the minimum WAC as our comparator to define the most conservative comparison. As a result, there are instances when the minimum WAC by drug group was lower than the NADAC. Had we chosen the median WAC within drug group, there would have been only 4.7% as compared with 10.4% of WAC drug groups below the NADAC. The difficulty in choosing a representative WAC or whether it is appropriate to take some summary of the distribution of WACs (mean, median, minimum, etc.) is a further limitation of using the WAC to estimate cost parameters.</div><div class=section-paragraph>Our analysis revealed cases of the NADAC being lower than the VAFSS. Although it happened in relatively few cases (84 of 3035 drug groups), this discrepancy occurred once among the top 20 prescribed generics. The NADAC is updated weekly on the basis of survey updates and list price changes. For a VAFSS price change to occur, a manufacturer needs to submit a proposal, which can take several months to be approved.</div><div class=section-paragraph>Our approach does not account for dispensing fees or fees paid to pharmacy benefit managers, because they are nonpublic and best practices do not exist for their estimation [<div class="dropBlock reference-citations"><a href=# id=back-bib37 data-db-target-for=bib37-d1592139e1093 class=reference-citations__ctrl aria-expanded=false aria-controls=bib37>37</a><div data-db-target-of=bib37-d1592139e1093 class="dropBlock__holder sf-hidden"></div></div>, <div class="dropBlock reference-citations"><a href=# id=back-bib38 data-db-target-for=bib38-d1592139e1093 class=reference-citations__ctrl aria-expanded=false aria-controls=bib38>38</a><div data-db-target-of=bib38-d1592139e1093 class="dropBlock__holder sf-hidden"></div></div>]. Dispensing fees are recommended for inclusion in CEAs and we suggest including a separate parameter in the model independent of the unit cost of the drug.</div><div class=section-paragraph>A final limitation of our methodology is that it is unable to address an unresolved issue in CEA—that analysis from a true societal perspective, costs of drugs or otherwise, should represent opportunity costs. Opportunity costs of drugs are distinct and lower than what the market price of patented drugs represents because patented drugs are granted patent exclusivity, allowing manufacturers to extract producer surplus. Our method only improves the estimates of the market price and does not suggest an additional reduction to approach social marginal costs of brand drugs. The ISPOR Drug Cost Task Force Report–Part II contains a detailed discussion of this problem [<div class="dropBlock reference-citations"><a href=#bib16 id=back-bib16 data-db-target-for=bib16-d1592139e1098 class=reference-citations__ctrl aria-expanded=false aria-controls=bib16>[16]</a><div data-db-target-of=bib16-d1592139e1098 class="dropBlock__holder sf-hidden"></div></div>].</div></section></section><section id=s0080 data-locator=s0080 tabindex=0><h2 class=top id=secsect0115 data-left-hand-nav=Conclusions tabindex=0><span class=top__sub></span><span class=top__text>Conclusions</span></h2><div class=section-paragraph>Our article provides a clear methodology that improves on current practice to specify metrics that do not rely on a particular NDC list price. Overall, our approach improves transparency in drug cost estimates, because we rely on two publicly available reasonable extremes. This is in contrast to the WAC, in which selection of a single NDC is hard to justify, and ranges for sensitivity analysis are frequently based on best guesses and arbitrary assumptions about uncertainty rather than on data.</div><div class=section-paragraph>Our method is consistent with the 2016 recommendations of the Second Panel on Cost Effectiveness in Health and Medicine that advocate that all CEAs conduct analysis from two reference cases, the societal and the health care sector perspectives [<div class="dropBlock reference-citations"><a href=#bib5 id=back-bib5 data-db-target-for=bib5-d1592139e1108 class=reference-citations__ctrl aria-expanded=false aria-controls=bib5>[5]</a><div data-db-target-of=bib5-d1592139e1108 class="dropBlock__holder sf-hidden"></div></div>]. For each reference case, drug costs are meant to represent the costs most likely to be paid by various payers, but some consideration should be given to estimating the opportunity cost when using the societal perspective [<div class="dropBlock reference-citations"><a href=#bib16 id=back-bib16 data-db-target-for=bib16-d1592139e1111 class=reference-citations__ctrl aria-expanded=false aria-controls=bib16>[16]</a><div data-db-target-of=bib16-d1592139e1111 class="dropBlock__holder sf-hidden"></div></div>]. The panel further recommends the use of sensitivity analysis to account for uncertainty in this parameter estimate. This is exactly what our method has captured, with the ranges available for various types of sensitivity analyses.</div><div class=section-paragraph>The true distribution of US drug costs is not known. Our approach relies on publicly available data. Although our method is not perfect, it is well defined and transparent. Embedding consistency and transparency in the definition of the base case and the bounds of drug costs bolsters the credibility of CEA findings and aids comparability between studies. Our approach represents the current best available recommendations to measure drug costs in the United States and provides consistency in computing results to inform decision makers.</div><div class=section-paragraph>Source of financial support: This work was supported by the National Institutes of Health under Ruth L. Kirschstein (National Research Service Award No. T32 MH18029) from the National Institute of Mental Health.</div></section><section id=s0090 data-locator=s0090 tabindex=0><h2 class=top id=supplementaryMaterial data-left-hand-nav="Supplementary material" tabindex=0><span class=top__sub>Appendix A. </span><span class=top__text>Supplementary material</span></h2><div class="section-paragraph supplemental-information"><ul class=rlist><li class=supplemental-information__item id=ec0005><div class="supplemental-information__icon icon-gizmo-pdf-file2"></div><div class="supplemental-information__links clearfix"><div class="col-sm-6 gutterless"><a href=https://www.valueinhealthjournal.com/cms/10.1016/j.jval.2017.06.013/attachment/64e34d6d-4cec-43fe-b795-2282ba42c030/mmc1.pdf class=supplemental-information__download target=_blank>
 Download .pdf (.26
 MB)
 </a></div><div class="col-sm-6 gutterless"><a href=https://service.elsevier.com/app/answers/detail/a_id/19286/supporthub/sciencedirect/ class=supplemental-information__help target=_blank>
 Help with
 pdf files
 </a></div></div><div class=supplemental-information__description><p>Supplementary material</p></div></ul></div></section><div data-pb-dropzone=extra-dropzone class="extra-dropzone pb-dropzone"></div><section class=refs><h2 class=top id=secsect0135 data-left-hand-nav=References tabindex=0><span class=top__sub></span><span class=top__text>References</span></h2><ol class=ref__wrapper><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Glick H.A. <li class=ref__authors__name>Doshi J.A. <li class=ref__authors__name>Sonnad S.S. <li>et al.</ul><div class=ref__title>Economic Evaluation in Clinical Trials.</div> <span class=refPublisherName>Oxford University Press</span>,
 <span class=refPublisherLoc>Oxford, UK</span><span class=refDate>2014</span><div class=ref__controls><a href=#back-bib1 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1093%2Fmed%2F9780199685028.001.0001&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2014&amp;author=Glick+H.A.&amp;author=Doshi+J.A.&amp;author=Sonnad+S.S.&amp;title=Economic+Evaluation+in+Clinical+Trials">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Briggs A.H. <li class=ref__authors__name>Claxton K. <li class=ref__authors__name>Sculpher M.J. </ul><div class=ref__title>Decision Modelling for Health Economic Evaluation.</div> <span class=refPublisherName>Oxford University Press</span>,
 <span class=refPublisherLoc>Oxford, UK</span><span class=refDate>2006</span><div class=ref__controls><a href=#back-bib2 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2006&amp;author=Briggs+A.H.&amp;author=Claxton+K.&amp;author=Sculpher+M.J.&amp;title=Decision+Modelling+for+Health+Economic+Evaluation">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Levy J.F. <li class=ref__authors__name>Meek P.D. <li class=ref__authors__name>Rosenberg M.A. </ul><div class=ref__title>US-based drug cost parameter estimation for economic evaluations.</div><span class=ref__series><i>Med Decis Making.</i> <span class=ref__seriesDate>2015; </span><span class=ref__seriesVolume>35</span></span>: <span class=ref__seriesPages>622-632</span><div class=ref__controls><a href=#back-bib3 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-84931450803&amp;cf=">Scopus (4)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=25532826&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1177%2F0272989X14563987&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=35&amp;publication_year=2015&amp;pages=622-632&amp;journal=Med+Decis+Making&amp;author=Levy+J.F.&amp;author=Meek+P.D.&amp;author=Rosenberg+M.A.&amp;title=US-based+drug+cost+parameter+estimation+for+economic+evaluations">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Keehan S.P. <li class=ref__authors__name>Poisal J.A. <li class=ref__authors__name>Cuckler G.A. <li>et al.</ul><div class=ref__title>National health expenditure projections, 2015–25: economy, prices, and aging expected to shape spending and enrollment.</div><span class=ref__series><i>Health Aff (Millwood).</i> <span class=ref__seriesDate>2016; </span><span class=ref__seriesVolume>35</span></span>: <span class=ref__seriesPages>1522-1531</span><div class=ref__controls><a href=#back-bib4 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-84982284248&amp;cf=">Scopus (58)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=27411572&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1377%2Fhlthaff.2016.0459&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=35&amp;publication_year=2016&amp;pages=1522-1531&amp;journal=Health+Aff+%28Millwood%29&amp;author=Keehan+S.P.&amp;author=Poisal+J.A.&amp;author=Cuckler+G.A.&amp;title=National+health+expenditure+projections%2C+2015%E2%80%9325%3A+economy%2C+prices%2C+and+aging+expected+to+shape+spending+and+enrollment">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Neumann P.J. <li class=ref__authors__name>Sanders G.D. <li class=ref__authors__name>Russell L.B. <li>et al.</ul><div class=ref__title>Cost-Effectiveness in Health and Medicine.</div> <span class=refPublisherName>Oxford University Press</span>,
 <span class=refPublisherLoc>Oxford, UK</span><span class=refDate>2016</span><div class=ref__controls><a href=#back-bib5 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1093%2Facprof%3Aoso%2F9780190492939.001.0001&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2016&amp;author=Neumann+P.J.&amp;author=Sanders+G.D.&amp;author=Russell+L.B.&amp;title=Cost-Effectiveness+in+Health+and+Medicine">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Glick H.A. </ul><div class=ref__title>What’s in a perspective?.</div><span class=ref__series><i>Value Health.</i> <span class=ref__seriesDate>2010; </span><span class=ref__seriesVolume>13</span></span>: <span class=ref__seriesPages>2</span><div class=ref__controls><a href=#back-bib6 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-72949110588&amp;cf=">Scopus (1)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=19912594&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00674.x&amp;cf=abstract&amp;site=jval-site">Abstract</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00674.x&amp;cf=pdf&amp;site=jval-site">Full Text PDF</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2010&amp;pages=2&amp;journal=Value+Health&amp;author=Glick+H.A.&amp;title=What%E2%80%99s+in+a+perspective%3F">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Willke R.J. </ul><div class=ref__title>Beyond AWP … way beyond.</div><span class=ref__series><i>Value Health.</i> <span class=ref__seriesDate>2010; </span><span class=ref__seriesVolume>13</span></span>: <span class=ref__seriesPages>1</span><div class=ref__controls><a href=#back-bib7 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-72949102648&amp;cf=">Scopus (3)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=19912595&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00673.x&amp;cf=abstract&amp;site=jval-site">Abstract</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00673.x&amp;cf=pdf&amp;site=jval-site">Full Text PDF</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2010&amp;pages=1&amp;journal=Value+Health&amp;author=Willke+R.J.&amp;title=Beyond+AWP+%E2%80%A6+way+beyond">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Hay J.W. <li class=ref__authors__name>Smeeding J. <li class=ref__authors__name>Carroll N.V. <li>et al.</ul><div class=ref__title>Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report–Part I.</div><span class=ref__series><i>Value Health.</i> <span class=ref__seriesDate>2010; </span><span class=ref__seriesVolume>13</span></span>: <span class=ref__seriesPages>3-7</span><div class=ref__controls><a href=#back-bib8 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-72949124442&amp;cf=">Scopus (69)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=19874571&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00663.x&amp;cf=abstract&amp;site=jval-site">Abstract</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00663.x&amp;cf=pdf&amp;site=jval-site">Full Text PDF</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2010&amp;pages=3-7&amp;journal=Value+Health&amp;author=Hay+J.W.&amp;author=Smeeding+J.&amp;author=Carroll+N.V.&amp;title=Good+research+practices+for+measuring+drug+costs+in+cost+effectiveness+analyses%3A+issues+and+recommendations%3A+the+ISPOR+Drug+Cost+Task+Force+Report%E2%80%93Part+I">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Kesselheim A.S. <li class=ref__authors__name>Avorn J. <li class=ref__authors__name>Sarpatwari A. </ul><div class=ref__title>The high cost of prescription drugs in the United States: origins and prospects for reform.</div><span class=ref__series><i>JAMA.</i> <span class=ref__seriesDate>2016; </span><span class=ref__seriesVolume>316</span></span>: <span class=ref__seriesPages>858-871</span><div class=ref__controls><a href=#back-bib9 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-84985864585&amp;cf=">Scopus (332)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=27552619&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1001%2Fjama.2016.11237&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=316&amp;publication_year=2016&amp;pages=858-871&amp;journal=JAMA&amp;author=Kesselheim+A.S.&amp;author=Avorn+J.&amp;author=Sarpatwari+A.&amp;title=The+high+cost+of+prescription+drugs+in+the+United+States%3A+origins+and+prospects+for+reform">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Gottlieb S. </ul><div class=ref__title>How Congress can make drug pricing more rational.</div><span class=ref__series><i>Forbes.</i> <span class=ref__seriesDate>2016; </span><span class=ref__seriesVolume></span> (<span class=refComment>https://www.forbes.com/sites/scottgottlieb/2016/09/12/how-congress-can-make-drug-pricing-more-rational/#6f35710d3e3b. [Accessed June 22, 2017]</span>)</span><div class=ref__controls><a href=#back-bib10 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2016&amp;journal=Forbes&amp;author=Gottlieb+S.&amp;title=How+Congress+can+make+drug+pricing+more+rational">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Somers J. <li class=ref__authors__name>Cook A. </ul><div class=ref__title>Prescription Drug Pricing in the Private Sector: A CBO Study.</div> <span class=refPublisherName>US Congressional Budget Office</span>,
 <span class=refPublisherLoc>Washington, DC</span><span class=refDate>2007</span><div class=ref__controls><a href=#back-bib11 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2007&amp;author=Somers+J.&amp;author=Cook+A.&amp;title=Prescription+Drug+Pricing+in+the+Private+Sector%3A+A+CBO+Study">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Frank R.G. </ul><div class=ref__title>Prescription drug prices: Why do some pay more than others do?.</div><span class=ref__series><i>Health Aff (Millwood).</i> <span class=ref__seriesDate>2001; </span><span class=ref__seriesVolume>20</span></span>: <span class=ref__seriesPages>115-128</span><div class=ref__controls><a href=#back-bib12 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_12_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-0008271520&amp;cf=">Scopus (89)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_12_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=11260933&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_12_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1377%2Fhlthaff.20.2.115&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=20&amp;publication_year=2001&amp;pages=115-128&amp;journal=Health+Aff+%28Millwood%29&amp;author=Frank+R.G.&amp;title=Prescription+drug+prices%3A+Why+do+some+pay+more+than+others+do%3F">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Kirkwood J.B. </ul><div class=ref__title>Buyer Power and Healthcare Prices.</div><span class=ref__series><i>Washington Law Review.</i> <span class=ref__seriesDate>2016; </span><span class=ref__seriesVolume>91</span></span>: <span class=ref__seriesPages>253-293</span><div class=ref__controls><a href=#back-bib13 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=91&amp;publication_year=2016&amp;pages=253-293&amp;journal=Washington+Law+Review&amp;author=Kirkwood+J.B.&amp;title=Buyer+Power+and+Healthcare+Prices">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Mullins C.D. <li class=ref__authors__name>Seal B. <li class=ref__authors__name>Seoane-Vazquez E. <li>et al.</ul><div class=ref__title>Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force Report–Part IV.</div><span class=ref__series><i>Value Health.</i> <span class=ref__seriesDate>2010; </span><span class=ref__seriesVolume>13</span></span>: <span class=ref__seriesPages>18-24</span><div class=ref__controls><a href=#back-bib14 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-72949123739&amp;cf=">Scopus (17)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=19807903&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00604.x&amp;cf=abstract&amp;site=jval-site">Abstract</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00604.x&amp;cf=pdf&amp;site=jval-site">Full Text PDF</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2010&amp;pages=18-24&amp;journal=Value+Health&amp;author=Mullins+C.D.&amp;author=Seal+B.&amp;author=Seoane-Vazquez+E.&amp;title=Good+research+practices+for+measuring+drug+costs+in+cost-effectiveness+analyses%3A+Medicare%2C+Medicaid+and+other+US+government+payers+perspectives%3A+the+ISPOR+Drug+Cost+Task+Force+Report%E2%80%93Part+IV">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Mansley E.C. <li class=ref__authors__name>Carroll N.V. <li class=ref__authors__name>Chen K.S. <li>et al.</ul><div class=ref__title>Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force Report–Part III.</div><span class=ref__series><i>Value Health.</i> <span class=ref__seriesDate>2010; </span><span class=ref__seriesVolume>13</span></span>: <span class=ref__seriesPages>14-17</span><div class=ref__controls><a href=#back-bib15 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-72949094892&amp;cf=">Scopus (18)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=19883404&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00661.x&amp;cf=abstract&amp;site=jval-site">Abstract</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00661.x&amp;cf=pdf&amp;site=jval-site">Full Text PDF</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2010&amp;pages=14-17&amp;journal=Value+Health&amp;author=Mansley+E.C.&amp;author=Carroll+N.V.&amp;author=Chen+K.S.&amp;title=Good+research+practices+for+measuring+drug+costs+in+cost-effectiveness+analyses%3A+a+managed+care+perspective%3A+the+ISPOR+Drug+Cost+Task+Force+Report%E2%80%93Part+III">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Garrison Jr, L.P. <li class=ref__authors__name>Mansley E.C. <li class=ref__authors__name>Abbott III, T.A. <li>et al.</ul><div class=ref__title>Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force Report–Part II.</div><span class=ref__series><i>Value Health.</i> <span class=ref__seriesDate>2010; </span><span class=ref__seriesVolume>13</span></span>: <span class=ref__seriesPages>8-13</span><div class=ref__controls><a href=#back-bib16 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-72949096583&amp;cf=">Scopus (98)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=19883405&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00660.x&amp;cf=abstract&amp;site=jval-site">Abstract</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=4&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1111%2Fj.1524-4733.2009.00660.x&amp;cf=pdf&amp;site=jval-site">Full Text PDF</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2010&amp;pages=8-13&amp;journal=Value+Health&amp;author=Garrison+L.P.&amp;author=Mansley+E.C.&amp;author=Abbott+T.A.&amp;title=Good+research+practices+for+measuring+drug+costs+in+cost-effectiveness+analyses%3A+a+societal+perspective%3A+the+ISPOR+Drug+Cost+Task+Force+Report%E2%80%93Part+II">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Somers J. <li class=ref__authors__name>Cook A. </ul><div class=ref__title>Prices for brand-name drugs under selected federal programs. Regul Aff.</div><span class=ref__series><i>Focus.</i> <span class=ref__seriesDate>2006; </span><span class=ref__seriesVolume>11</span></span>: <span class=ref__seriesPages>13</span><div class=ref__controls><a href=#back-bib17 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=11&amp;publication_year=2006&amp;pages=13&amp;journal=Focus&amp;author=Somers+J.&amp;author=Cook+A.&amp;title=Prices+for+brand-name+drugs+under+selected+federal+programs.+Regul+Aff">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Hakim A. <li class=ref__authors__name>Ross J.S. </ul><div class=ref__title>High prices for drugs with generic alternatives: the curious case of Duexis.</div><span class=ref__series><i>JAMA Intern Med.</i> <span class=ref__seriesDate>2017; </span><span class=ref__seriesVolume>177</span></span>: <span class=ref__seriesPages>305-306</span><div class=ref__controls><a href=#back-bib18 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_18_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-85015278852&amp;cf=">Scopus (10)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_18_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=28114637&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_18_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1001%2Fjamainternmed.2016.8423&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=177&amp;publication_year=2017&amp;pages=305-306&amp;journal=JAMA+Intern+Med&amp;author=Hakim+A.&amp;author=Ross+J.S.&amp;title=High+prices+for+drugs+with+generic+alternatives%3A+the+curious+case+of+Duexis">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>Centers for Medicare &amp; Medicaid Services</ul><span class=ref__series><i>Methodology for calculating the National Average Drug Acquisition Cost (NADAC) for Medicaid covered outpatient drugs.</i> <span class=ref__seriesDate>2013; </span><span class=ref__seriesVolume></span> (<span class=refComment>Available from: https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/ful-nadac-downloads/nadacmethodology.pdf. [Accessed June 22, 2017]</span>)</span><div class=ref__controls><a href=#back-bib19 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2013&amp;journal=Methodology+for+calculating+the+National+Average+Drug+Acquisition+Cost+%28NADAC%29+for+Medicaid+covered+outpatient+drugs&amp;author=Centers+for+Medicare+%26+Medicaid+Services&amp;title=%5B19%5D">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Curtiss F.R. </ul><div class=ref__title>What is the price benchmark to replace average wholesale price (AWP)?.</div><span class=ref__series><i>J Manag Care Pharm.</i> <span class=ref__seriesDate>2010; </span><span class=ref__seriesVolume>16</span></span>: <span class=ref__seriesPages>492-501</span><div class=ref__controls><a href=#back-bib20 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_20_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=20726678&amp;cf=">PubMed</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=16&amp;publication_year=2010&amp;pages=492-501&amp;journal=J+Manag+Care+Pharm&amp;author=Curtiss+F.R.&amp;title=What+is+the+price+benchmark+to+replace+average+wholesale+price+%28AWP%29%3F">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>Academy of Managed Care Pharmacy</ul><div class=ref__title>AMCP Pharmaceutical Payment Guide 2013.</div> <span class=refPublisherName>Academy of Managed Care Pharmacy</span>,
 <span class=refPublisherLoc>Alexandria, VA</span><span class=refDate>2013</span><div class=ref__controls><a href=#back-bib21 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2013&amp;author=Academy+of+Managed+Care+Pharmacy&amp;title=AMCP+Pharmaceutical+Payment+Guide+2013">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>US Department of Health and Human Services</ul><div class=ref__title>Medicaid Rebates for Brand-Name Drugs Exceeded Part D Rebates by a Substantial Margin.</div><span>Report OEI-03-13-00650. </span> <span class=refPublisherName>US Department of Health and Human Services</span>,
 <span class=refPublisherLoc>Washington, DC</span><span class=refDate>2015</span><div class=ref__controls><a href=#back-bib22 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2015&amp;author=US+Department+of+Health+and+Human+Services&amp;isbn=Report+OEI-03-13-00650&amp;title=Medicaid+Rebates+for+Brand-Name+Drugs+Exceeded+Part+D+Rebates+by+a+Substantial+Margin">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Howard D.H. <li class=ref__authors__name>Bach P.B. <li class=ref__authors__name>Berndt E.R. <li>et al.</ul><div class=ref__title>Pricing in the market for anticancer drugs.</div><span class=ref__series><i>J Econ Perspect.</i> <span class=ref__seriesDate>2015; </span><span class=ref__seriesVolume>29</span></span>: <span class=ref__seriesPages>139-162</span><div class=ref__controls><a href=#back-bib23 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_23_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-84922419758&amp;cf=">Scopus (270)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_23_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=28441702&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_23_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1257%2Fjep.29.1.139&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=29&amp;publication_year=2015&amp;pages=139-162&amp;journal=J+Econ+Perspect&amp;author=Howard+D.H.&amp;author=Bach+P.B.&amp;author=Berndt+E.R.&amp;title=Pricing+in+the+market+for+anticancer+drugs">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>Medicaid and CHIP Payment and Access Commission</ul><div class=ref__title>Medicaid Payment for Outpatient Prescription Drugs. Issue Brief.</div> <span class=refPublisherName>Medicaid and CHIP Payment and Access Commission</span>,
 <span class=refPublisherLoc>Washington, DC</span><span class=refDate>2017</span><div class=ref__controls><a href=#back-bib24 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2017&amp;author=Medicaid+and+CHIP+Payment+and+Access+Commission&amp;title=Medicaid+Payment+for+Outpatient+Prescription+Drugs.+Issue+Brief">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>Center for Medicare &amp; Medicaid Services</ul><span class=ref__series><i>Medicaid covered outpatient prescription drug reimbursement information by state.</i> <span class=ref__seriesDate>2017; </span><span class=ref__seriesVolume></span> (<span class=refComment>Available from: https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/xxxreimbursement-chart-current-qtr.pdf. [Accessed June 22, 2017]</span>)</span><div class=ref__controls><a href=#back-bib25 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2017&amp;journal=Medicaid+covered+outpatient+prescription+drug+reimbursement+information+by+state&amp;author=Center+for+Medicare+%26+Medicaid+Services&amp;title=%5B25%5D">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>US Department of Health and Human Services</ul><div class=ref__title>Office of Inspector General. States’ Collection of Offset and Supplemental Medicaid Rebates.</div><span>Report No. OEI-03-12-00520. </span> <span class=refPublisherName>US Department of Health and Human Services</span>,
 <span class=refPublisherLoc>Washington, DC</span><span class=refDate>2014</span><div class=ref__controls><a href=#back-bib26 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2014&amp;author=US+Department+of+Health+and+Human+Services&amp;isbn=Report+No.+OEI-03-12-00520&amp;title=Office+of+Inspector+General.+States%E2%80%99+Collection+of+Offset+and+Supplemental+Medicaid+Rebates">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>Centers for Medicare &amp; Medicaid Services</ul><span class=ref__series><i>Draft methodology for calculating the National Average Drug Acquisition Cost (NADAC).</i> <span class=ref__seriesDate>2012; </span><span class=ref__seriesVolume></span> (<span class=refComment>Available from: https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/ful-nadac-downloads/nadacdraftmethodology.pdf. [Accessed June 22, 2017]</span>)</span><div class=ref__controls><a href=#back-bib27 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2012&amp;journal=Draft+methodology+for+calculating+the+National+Average+Drug+Acquisition+Cost+%28NADAC%29&amp;author=Centers+for+Medicare+%26+Medicaid+Services&amp;title=%5B27%5D">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>Centers for Medicaid &amp; Medicare Services</ul><span class=ref__series><i>National Average Drug Acquisition Cost (NADAC) questions and responses.</i> <span class=ref__seriesDate>2011; </span><span class=ref__seriesVolume></span> (<span class=refComment>Available from: https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/ful-nadac-downloads/nadacqa.pdf. [Accessed June 22, 2017]</span>)</span><div class=ref__controls><a href=#back-bib28 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2011&amp;journal=National+Average+Drug+Acquisition+Cost+%28NADAC%29+questions+and+responses&amp;author=Centers+for+Medicaid+%26+Medicare+Services&amp;title=%5B28%5D">Google Scholar</a></ul></div><li class=ref><p>US Department of Veterans Affairs. National Acquisition Center. Office of Acquisition and Logistics. Available from: <a href=http://www.va.gov/nac/ target=_blank>http://www.va.gov/nac/</a>. [Accessed June 22, 2017].<div class=ref__controls><a href=#back-bib29 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar?hl=en&amp;q=US+Department+of+Veterans+Affairs.+National+Acquisition+Center.+Office+of+Acquisition+and+Logistics.+Available+from%3A+http%3A%2F%2Fwww.va.gov%2Fnac%2F.+%5BAccessed+June+22%2C+2017%5D.">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>US Government Accountability Office</ul><span class=ref__series><i>Prescription drugs: comparison of DOD and VA direct purchase prices.</i> <span class=ref__seriesDate>2013; </span><span class=ref__seriesVolume></span> (<span class=refComment>Available from:</span>) (<span class=refComment>[Accessed June 22, 2017]</span>)</span><div class=citation-host><a href=http://www.gao.gov/assets/660/654019.pdf target=_blank>http://www.gao.gov/assets/660/654019.pdf</a></div><div class=ref__controls><a href=#back-bib30 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2013&amp;journal=Prescription+drugs%3A+comparison+of+DOD+and+VA+direct+purchase+prices&amp;author=US+Government+Accountability+Office&amp;title=%5B30%5D">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>Congressional Budget Office</ul><div class=ref__title>Prices for Brand-Name Drugs under Selected Federal Programs.</div> <span class=refPublisherName>Congressional Budget Office</span>,
 <span class=refPublisherLoc>Washington, DC</span><span class=refDate>2005</span><div class=ref__controls><a href=#back-bib31 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2005&amp;author=Congressional+Budget+Office&amp;title=Prices+for+Brand-Name+Drugs+under+Selected+Federal+Programs">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>US Department of Health and Human Services</ul><div class=ref__title>Prescription Drugs: Innovation, Spending, and Patient Access.</div> <span class=refPublisherName>US Department of Health and Human Services</span>,
 <span class=refPublisherLoc>Washington, DC</span><span class=refDate>2016</span><div class=ref__controls><a href=#back-bib32 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2016&amp;author=US+Department+of+Health+and+Human+Services&amp;title=Prescription+Drugs%3A+Innovation%2C+Spending%2C+and+Patient+Access">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Frank R.G. <li class=ref__authors__name>Newhouse J.P. </ul><div class=ref__title>Should drug prices be negotiated under Part D of Medicare? And if so, how?.</div><span class=ref__series><i>Health Aff (Millwood).</i> <span class=ref__seriesDate>2008; </span><span class=ref__seriesVolume>27</span></span>: <span class=ref__seriesPages>33-43</span><div class=ref__controls><a href=#back-bib33 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_33_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-38849203212&amp;cf=">Scopus (53)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_33_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=18180478&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_33_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1377%2Fhlthaff.27.1.33&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=27&amp;publication_year=2008&amp;pages=33-43&amp;journal=Health+Aff+%28Millwood%29&amp;author=Frank+R.G.&amp;author=Newhouse+J.P.&amp;title=Should+drug+prices+be+negotiated+under+Part+D+of+Medicare%3F+And+if+so%2C+how%3F">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Claxton K. </ul><div class=ref__title>Exploring uncertainty in cost-effectiveness analysis.</div><span class=ref__series><i>Pharmacoeconomics.</i> <span class=ref__seriesDate>2008; </span><span class=ref__seriesVolume>26</span></span>: <span class=ref__seriesPages>781-798</span><div class=ref__controls><a href=#back-bib34 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-51149088116&amp;cf=">Scopus (139)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=18767898&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.2165%2F00019053-200826090-00008&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=26&amp;publication_year=2008&amp;pages=781-798&amp;journal=Pharmacoeconomics&amp;author=Claxton+K.&amp;title=Exploring+uncertainty+in+cost-effectiveness+analysis">Google Scholar</a></ul></div><li class=ref><div class=section-paragraph>US Department of Veterans Affairs. Federal Supply Schedule Modification Request Forms. <a href=https://www.va.gov/oal/docs/business/nac/fssWebinarContractorGuide-RequestForModification_20130522.pdf target=_blank>https://www.va.gov/oal/docs/business/nac/fssWebinarContractorGuide-RequestForModification_20130522.pdf</a>. [ Accessed June 22, 2017].</div><div class=ref__controls><a href=#back-bib35 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>IMS Institute for Healthcare Informatics</ul><span class=ref__series><i>Medicines use and spending in the US.</i> <span class=ref__seriesDate>2016; </span><span class=ref__seriesVolume></span> (<span class=refComment>http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/medicines-use-and-spending-in-the-us-review-of-2016-outlook-to-2021#form. [Accessed June 22, 2017]</span>)</span><div class=ref__controls><a href=#back-bib36 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2016&amp;journal=Medicines+use+and+spending+in+the+US&amp;author=IMS+Institute+for+Healthcare+Informatics&amp;title=%5B36%5D">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>Lyles A. </ul><div class=ref__title>Pharmacy benefit management companies: Do they create value in the US healthcare system?.</div><span class=ref__series><i>Pharmacoeconomics.</i> <span class=ref__seriesDate>2017; </span><span class=ref__seriesVolume>35</span></span>: <span class=ref__seriesPages>493-500</span><div class=ref__controls><a href=#back-bib37 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_37_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-85013032132&amp;cf=">Scopus (9)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_37_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=28210864&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_37_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1007%2Fs40273-017-0489-1&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=35&amp;publication_year=2017&amp;pages=493-500&amp;journal=Pharmacoeconomics&amp;author=Lyles+A.&amp;title=Pharmacy+benefit+management+companies%3A+Do+they+create+value+in+the+US+healthcare+system%3F">Google Scholar</a></ul></div><li class=ref><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class=ref__authors__name>McRae J. <li class=ref__authors__name>Vogenberg F.R. <li class=ref__authors__name>Beaty S.W. <li>et al.</ul><div class=ref__title>A review of US drug costs relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016.</div><span class=ref__series><i>Pharmacoeconomics.</i> <span class=ref__seriesDate>2017; </span><span class=ref__seriesVolume>35</span></span>: <span class=ref__seriesPages>215-223</span><div class=ref__controls><a href=#back-bib38 title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
 in Article
 <i class=icon-section_arrow_u></i></a><ul class="rlist inline-bullet-list"><li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_38_2&amp;dbid=137438953472&amp;doi=10.1016/j.jval.2017.06.013&amp;key=2-s2.0-84992694377&amp;cf=">Scopus (12)</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_38_2&amp;dbid=8&amp;doi=10.1016/j.jval.2017.06.013&amp;key=27798809&amp;cf=">PubMed</a></li>
<li><a href="https://www.valueinhealthjournal.com/servlet/linkout?suffix=e_1_5_1_2_38_2&amp;dbid=16&amp;doi=10.1016/j.jval.2017.06.013&amp;key=10.1007%2Fs40273-016-0458-0&amp;cf=">Crossref</a></li>
<li><a class=google-scholar href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=35&amp;publication_year=2017&amp;pages=215-223&amp;journal=Pharmacoeconomics&amp;author=McRae+J.&amp;author=Vogenberg+F.R.&amp;author=Beaty+S.W.&amp;title=A+review+of+US+drug+costs+relevant+to+Medicare%2C+Medicaid%2C+and+Commercial+Insurers+Post-Affordable+Care+Act+Enactment%2C+2010%E2%80%932016">Google Scholar</a></ul></div></ol></section><section class=article-info><h2 class=top id=articleInformation>Article Info</h2><section><h3 class=publicationHistory__label>Publication History</h3><div class=article-info__dates><div class=article-info__date>Published online: September 07, 2017</div></div></section><section><h3>Footnotes</h3><p><a href=#back-article-footnote-%E2%98%86 id=article-footnote-☆>☆</a>Conflicts of interest: The authors have indicated that they have no conflicts of interest with regard to the content of this article.</p></section><section><h3>Identification</h3><p>DOI: <a href=https://doi.org/10.1016/j.jval.2017.06.013>https://doi.org/10.1016/j.jval.2017.06.013</a></p></section><section><h3>Copyright</h3><div class=copyright>© 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.</div></section><section class=userLicenseRpl> <h3>User License</h3> <a href=http://www.elsevier.com/open-access/userlicense/1.0/ class=userLicLnk target=blank>Elsevier user license</a> | <div class="dropBlock reference-citations"> <a data-db-target-for=modal-user-license href=# class=reference-citations__ctrl>How you can reuse</a> <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAAABGdBTUEAAK/INwWK6QAAABl0RVh0U29mdHdhcmUAQWRvYmUgSW1hZ2VSZWFkeXHJZTwAAAKcSURBVDjLpZPLa9RXHMU/d0ysZEwmMQqZiTaP0agoaKGJUiwIxU0hUjtUQaIuXHSVbRVc+R8ICj5WvrCldJquhVqalIbOohuZxjDVxDSP0RgzyST9zdzvvffrQkh8tBs9yy9fPhw45xhV5X1U8+Yhc3U0LcEdVxdOVq20OA0ooQjhpnfhzuDZTx6++m9edfDFlZGMtXKxI6HJnrZGGtauAWAhcgwVnnB/enkGo/25859l3wIcvpzP2EhuHNpWF9/dWs/UnKW4EOGDkqhbQyqxjsKzMgM/P1ymhlO5C4ezK4DeS/c7RdzQoa3x1PaWenJjJZwT9rQ1gSp/js1jYoZdyfX8M1/mp7uFaTR8mrt29FEMQILr62jQ1I5kA8OF59jIItVA78dJertTiBNs1ZKfLNG+MUHX1oaURtIHEAOw3p/Y197MWHEJEUGCxwfHj8MTZIcnsGKxzrIURYzPLnJgbxvG2hMrKdjItjbV11CYKeG8R7ygIdB3sBMFhkem0RAAQ3Fuka7UZtRHrasOqhYNilOwrkrwnhCU/ON5/q04vHV48ThxOCuoAbxnBQB+am65QnO8FqMxNCjBe14mpHhxBBGCWBLxD3iyWMaYMLUKsO7WYH6Stk1xCAGccmR/Ozs/bKJuXS39R/YgIjgROloSDA39Deit1SZWotsjD8pfp5ONqZ6uTfyWn+T7X0f59t5fqDhUA4ry0fYtjJcWeZQvTBu4/VqRuk9/l9Fy5cbnX+6Od26s58HjWWaflwkusKGxjm1bmhkvLXHvh1+WMbWncgPfZN+qcvex6xnUXkzvSiYP7EvTvH4toDxdqDD4+ygT+cKMMbH+3MCZ7H9uAaDnqytpVX8cDScJlRY0YIwpAjcNcuePgXP/P6Z30QuoP4J7WbYhuQAAAABJRU5ErkJggg==" alt="Information Icon" class=infoIcon> <div data-db-target-of=modal-user-license class="dropBlock__holder reference-citations__holder sf-hidden"> </div> </div> </section><section><h3>ScienceDirect</h3><a href=https://www.sciencedirect.com/science/article/pii/S1098301517303169>Access this article on ScienceDirect</a></section></section><div id=figure-viewer class="showCaption showThumbstrip figure-viewer landscape sf-hidden"></div><section><h2 id=figures class=top>Figures</h2><ul class="figures rlist"><li class=figures__thumbnail><div class="thumbnail__image thumbnail__image--img-ratio"><div><img class="b-lazy b-loaded ux-lazyloaded tall img-aspect-ratio-checked" loading=lazy alt="Fig. 1" data-locator=f0005 data-high-res=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9392f847-b862-4663-b245-61884ed9c1a7/gr1_lrg.jpg data-large-image=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6218808c-f2e4-4b02-98dc-b6c5c21b6ddd/gr1.jpg tabindex=0 src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="562" height="395"><rect fill-opacity="0"/></svg>' style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-15)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"></div></div><div class=figure__title><span class="label figure__label">Fig. 1</span><span class=figure__title__text>Histograms of NADAC/Minimum WAC Ratio.</span></div><li class=figures__thumbnail><div class="thumbnail__image thumbnail__image--img-ratio"><div><img class="b-lazy b-loaded ux-lazyloaded tall img-aspect-ratio-checked" loading=lazy alt="Fig. 2" data-locator=f0010 data-high-res=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c5e76630-f8ad-4db2-b707-0de6ae691e07/gr2_lrg.jpg data-large-image=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/082ddeaf-a0a6-4217-b656-ca8ea9adc9df/gr2.jpg tabindex=0 src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="562" height="396"><rect fill-opacity="0"/></svg>' style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-18)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"></div></div><div class=figure__title><span class="label figure__label">Fig. 2</span><span class=figure__title__text>Histogram of VAFSS/Minimum WAC Ratio.</span></div><li class=figures__thumbnail><div class="thumbnail__image thumbnail__image--img-ratio"><div><img class="b-lazy b-loaded ux-lazyloaded tall img-aspect-ratio-checked" loading=lazy alt="Fig. 3" data-locator=f0015 data-high-res=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2df9c122-3f70-4859-a0af-4411b9f32ea4/gr3_lrg.jpg data-large-image=//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a69732d5-d234-4edf-b83d-73dc1f3f26a1/gr3.jpg tabindex=0 src='data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="565" height="395"><rect fill-opacity="0"/></svg>' style="background-blend-mode:normal!important;background-clip:content-box!important;background-position:50% 50%!important;background-color:rgba(0,0,0,0)!important;background-image:var(--sf-img-19)!important;background-size:100% 100%!important;background-origin:content-box!important;background-repeat:no-repeat!important"></div></div><div class=figure__title><span class="label figure__label">Fig. 3</span><span class=figure__title__text>Histogram of Basecase/Minimum WAC Ratio. NADAC, National Average Drug Acquisition Cost; VAFSS, Veterans Affairs Federal Supply Schedule; WAC, wholesale acquisition cost</span></div></ul></section><section class=table-list><h2 id=tables class=top>Tables</h2><ul class="tabels-list__wrapper rlist"><li class=table-list__item><a target=_blank href=https://www.valueinhealthjournal.com/article/S1098-3015(17)30316-9/undefined></a><li class=table-list__item><a target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0005&amp;pii=S1098-3015%2817%2930316-9"><span class=inline-table__label>Table 1</span><span class=inline-table__title>Drug cost measures’ descriptions and suggestions to inform CEA</span></a><li class=table-list__item><a target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0010&amp;pii=S1098-3015%2817%2930316-9"><span class=inline-table__label>Table 2</span><span class=inline-table__title>Average unit cost and average ratio between price measures by brand designation</span></a><li class=table-list__item><a target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0015&amp;pii=S1098-3015%2817%2930316-9"><span class=inline-table__label>Table 3</span><span class=inline-table__title>Unit cost of top 20 drug groups by the number of prescriptions in the United States in 2015</span></a><li class=table-list__item><a target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0020&amp;pii=S1098-3015%2817%2930316-9"><span class=inline-table__label>Table 4</span><span class=inline-table__title>Unit cost of top 20 drug groups by spending in the United States in 2015</span></a><div class="dropBlock reference-citations"><a target=_blank href="https://www.valueinhealthjournal.com/action/showFullTableHTML?isHtml=true&amp;tableId=t0020&amp;pii=S1098-3015%2817%2930316-9"></a><a href=# id=back-tbl4fnStar data-db-target-for=tbl4fnStar-d1592139e484 class="reference-citations__ctrl scroll-into-link" aria-expanded=false aria-controls=tbl4fnStar><sup>*</sup></a><div data-db-target-of=tbl4fnStar-d1592139e484 class="dropBlock__holder sf-hidden"></div></div></ul></section>
 
 
 
 
 
 
 
 
 
 <section><h2 id=relatedArticles class=top>Related Articles</h2><div data-pb-widget-type=ux3-relatedArticles data-widget-id=55d12544-88af-4b41-92cd-fa404a51ef23 data-widget-name=AtyponTempUX3RelatedArticlesWidget data-article-pii=S1098301517303169 class="ux3DeferredOnScrollWidget ux3DeferredLoaded"><div class="section-paragraph linked-article"><ul class=rlist><li class=linked-article__item><a class="linked-article__title link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60386-5/fulltext title="Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I">Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I</a><div><ul class="meta__authors rlist--inline comma" title="list of authors">Hay et al.</ul></div><div class=linked-article__details><span><i>Value in Health</i></span><span></span></div><ul class="rlist rlist--inline linked-article__links clearfix"><li class="bulleted preview-label"><a href=# data-db-target-for=related-article-in-brief-S1098-3015(10)60386-5 class=link--underlined title="Preview Abstract">Preview</a><div data-db-target-of=related-article-in-brief-S1098-3015(10)60386-5 class="dropBlock__holder__article-preview dropBlock__holder sf-hidden"></div><li class=bulleted><a title=Full-Text class="faded link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60386-5/fulltext>
 Full-Text
 </a><li class=bulleted><a title=PDF class=link--underlined target=_blank href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60386-5/pdf>
 PDF
 </a></ul><span class=OALabel>Open Archive</span><li class=linked-article__item><a class="linked-article__title link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60389-0/fulltext title="Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV">Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV</a><div><ul class="meta__authors rlist--inline comma" title="list of authors">Mullins et al.</ul></div><div class=linked-article__details><span><i>Value in Health</i></span><span></span></div><ul class="rlist rlist--inline linked-article__links clearfix"><li class="bulleted preview-label"><a href=# data-db-target-for=related-article-in-brief-S1098-3015(10)60389-0 class=link--underlined title="Preview Abstract">Preview</a><div data-db-target-of=related-article-in-brief-S1098-3015(10)60389-0 class="dropBlock__holder__article-preview dropBlock__holder sf-hidden"></div><li class=bulleted><a title=Full-Text class="faded link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60389-0/fulltext>
 Full-Text
 </a><li class=bulleted><a title=PDF class=link--underlined target=_blank href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60389-0/pdf>
 PDF
 </a></ul><span class=OALabel>Open Archive</span><li class=linked-article__item><a class="linked-article__title link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60388-9/fulltext title="Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III">Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III</a><div><ul class="meta__authors rlist--inline comma" title="list of authors">Mansley et al.</ul></div><div class=linked-article__details><span><i>Value in Health</i></span><span></span></div><ul class="rlist rlist--inline linked-article__links clearfix"><li class="bulleted preview-label"><a href=# data-db-target-for=related-article-in-brief-S1098-3015(10)60388-9 class=link--underlined title="Preview Abstract">Preview</a><div data-db-target-of=related-article-in-brief-S1098-3015(10)60388-9 class="dropBlock__holder__article-preview dropBlock__holder sf-hidden"></div><li class=bulleted><a title=Full-Text class="faded link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60388-9/fulltext>
 Full-Text
 </a><li class=bulleted><a title=PDF class=link--underlined target=_blank href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60388-9/pdf>
 PDF
 </a></ul><span class=OALabel>Open Archive</span><li class=linked-article__item><a class="linked-article__title link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(21)01645-4/fulltext title="Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications">Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications</a><div><ul class="meta__authors rlist--inline comma" title="list of authors">Neumann et al.</ul></div><div class=linked-article__details><span><i>Value in Health</i></span><span>November 12, 2021</span></div><ul class="rlist rlist--inline linked-article__links clearfix"><li class="bulleted preview-label"><a href=# data-db-target-for=related-article-in-brief-S1098-3015(21)01645-4 class=link--underlined title="Preview Abstract">Preview</a><div data-db-target-of=related-article-in-brief-S1098-3015(21)01645-4 class="dropBlock__holder__article-preview dropBlock__holder sf-hidden"></div><li class=bulleted><a title=Full-Text class="faded link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(21)01645-4/fulltext>
 Full-Text
 </a><li class=bulleted><a title=PDF class=link--underlined target=_blank href=https://www.valueinhealthjournal.com/article/S1098-3015(21)01645-4/pdf>
 PDF
 </a></ul><li class=linked-article__item><a class="linked-article__title link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60391-9/fulltext title="Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI">Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI</a><div><ul class="meta__authors rlist--inline comma" title="list of authors">Shi et al.</ul></div><div class=linked-article__details><span><i>Value in Health</i></span><span></span></div><ul class="rlist rlist--inline linked-article__links clearfix"><li class="bulleted preview-label"><a href=# data-db-target-for=related-article-in-brief-S1098-3015(10)60391-9 class=link--underlined title="Preview Abstract">Preview</a><div data-db-target-of=related-article-in-brief-S1098-3015(10)60391-9 class="dropBlock__holder__article-preview dropBlock__holder sf-hidden"></div><li class=bulleted><a title=Full-Text class="faded link--underlined" href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60391-9/fulltext>
 Full-Text
 </a><li class=bulleted><a title=PDF class=link--underlined target=_blank href=https://www.valueinhealthjournal.com/article/S1098-3015(10)60391-9/pdf>
 PDF
 </a></ul><span class=OALabel>Open Archive</span></ul></div></div></section>
 
 
<div id=figure-viewer role=dialog aria-modal=true aria-label="Figure Viewer" class="showCaption showThumbstrip figure-viewer sf-hidden"></div><div data-toggle=transplant data-direction=from data-transplant=self data-target=".adplaceholder--slot2, .adplaceholder--slot3 " data-remove=false class="adplaceholder__transplant hidden-md hidden-lg sf-hidden"></div></div><div class="col-md-3 col-lg-2"></div></div></div></div></article>
 
 
 </main>
 
</div></div>
 
 </div>
 
 
 </div>
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 <div class="widget sessionValidationWidget none widget-none" id=454875d4-cdd3-43d7-8792-9ad9208efb7a>
 
 
 <div class=wrapped>
 
 <div class="widget-body body body-none"></div>
 </div>
 </div>
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 <div class="widget csasSsoUrls none widget-none" id=50d01d29-5810-433b-8bff-c2b88479f2e2>
 
 
 <div class=wrapped>
 
 <div class="widget-body body body-none"><div id=sso-urls-div class="hidden ssoUrls sf-hidden">
 
 
 
 
 
 
 
 </div>
</div>
 </div>
 </div>
 
 
 
 
 
 
 <div data-widget-id=a44bbb22-c612-4402-addc-e23d4257b5c3 data-widget-name=UX3HTMLWidget>
</div>
 
 
 <div data-widget-def=ux3-layout-widget data-widget-id=637fb9ce-735b-43bf-a200-c13296f28a9b class=ux3>
 
 
 
 
 
 
 <div data-widget-id=637fb9ce-735b-43bf-a200-c13296f28a9b data-widget-name=ux3-layout-widget class=fonts-loaded><div class="footer clearfix">
 
 
 
 
 
 
 
 <div data-widget-id=c7617e63-9788-4e9b-9592-37f0c6bf7ae0 data-widget-name=UX3HTMLWidget><div class="footer__bottom text-onDark">
 <ul id=footerSiteLinks>
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/home>Home</a>
 </li>
 <li class=footerHeading>Articles and Issues</li>
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/inpress>Articles in Press</a>
 </li>
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/current>Current Issue</a>
 </li>
 <li class=footerLink>
 <a href=http://www.ispor.org/workpaper/practices_index.asp target=_blank>Good Research Practices</a>
 </li>
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/issues>List of Issues</a>
 </li>
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/supplements>Supplements</a>
 </li>
 <li class=footerHeading><a href=https://www.valueinhealthjournal.com/collections>Collections</a></li>
 
 <li class=footerHeading>For Authors</li>
 <li class=footerLink>
 <a href=http://www.elsevier.com/journals/value-in-health/1098-3015/open-access-options target=_blank>About Open Access</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/publications/journals/value-in-health/for-authors/guide-for-authors target=_blank>Guide for Authors</a>
 </li>
 <li class=footerLink>
 <a href=http://www.researcheracademy.com/ target=_blank>Researcher Academy</a>
 </li>
 <li class=footerLink>
 <a href=https://mc.manuscriptcentral.com/valueinhealth target=_blank>Submit a Manuscript</a>
 </li>
 <li class=footerHeading>Journal Info</li>
 <li class=footerLink>
 <a href=http://www.elsevier.com/journals/value-in-health/1098-3015/open-access-options target=_blank>About Open Access</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/publications/journals/value-in-health/for-authors/about-the-journal target=_blank>About Value in Health</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/publications/journals/value-in-health/vih-about-the-editors target=_blank>Editors-in-Chief</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/publications/journals/value-in-health/vih-about-the-editors target=_blank>Associate Editors</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/publications/journals/value-in-health/vih-about-the-editors target=_blank>Editorial Advisory Board</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/publications/journals/value-in-health/vih-about-the-editors target=_blank>Editorial Office</a>
 </li>
 <li class=footerLink>
 <a href=http://www.elsmediakits.com/journal_home/details/JVAL target=_blank>Info for Advertisers</a>
 </li>
 
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/user/alerts>New Content Alerts</a>
 </li>
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/pricing>Subscribe</a>
 </li>
 <li class=footerHeading>Press</li>
 <li class=footerLink>
 <a href=https://els-jbs-prod-cdn.literatumonline.com/pb/assets/raw/Health%20Advance/journals/jval/PRESS-RELEASE_ClinRO_Assessment_Task_Force_Report_2017_02_13_Final-1490107220960.pdf target=_blank>2/2017: ISPOR Releases New Task Force Recommendations for the Development of Clinician-Reported Outcome Assessments</a>
 </li>
 <li class=footerLink>
 <a href=https://els-jbs-prod-cdn.literatumonline.com/pb/assets/raw/Health%20Advance/journals/jval/PRESS-RELEASE_Mapping_to_Estimate_Health-State_Utility_Task_Force_Report_2017_02_14_Final-1490107219063.pdf target=_blank>2/2017: "Mapping Studies" In Cost-Utility Analyses: New Recommendations From ISPOR Task Force</a>
 </li>
 <li class=footerLink>
 <a href=https://els-jbs-prod-cdn.literatumonline.com/pb/assets/raw/Health%20Advance/journals/jval/Economics_of_Universal_Health_Care_Coverage-1489078855617.pdf target=_blank>12/2016: Making Choices on the Journey to Universal Health Care Coverage: From Advocacy to Analysis</a>
 </li>
 <li class=footerHeading>
 <a href=https://www.valueinhealthjournal.com/Themes>Themed Sections</a>
 </li>
 <li class=footerHeading>ISPOR</li>
 <li class=footerLink>
 <a href=https://www.valueinhealthjournal.com/content/ISPORMemberAccess>ISPOR Member Access Information</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/about/our-mission target=_blank>Mission, Vision, Strategy</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/about/our-society target=_blank>About ISPOR</a>
 </li>
 <li class=footerLink>
 <a href=https://www.ispor.org/about/our-members target=_blank>Membership Profile</a>
 </li>
 <li class=footerHeading>
 <a href=https://www.valueinhealthjournal.com/videos>Videos</a>
 </li>
 <li class=footerHeading>
 <a href=http://www.valuehealthregionalissues.com/>VHRI</a>
 </li>
 <li class=footerHeading>More Periodicals</li>
 <li class=footerLink>
 <a href=http://www.journals.elsevierhealth.com/periodicals/home>Find a Periodical</a>
 </li>
 <li class=footerLink>
 <a href=http://www.elsevierhealth.com/ target=_blank>Go to Product Catalog</a>
 </li>
 
 </ul>
</div>
<style class=sf-hidden>.footer__bottom a{text-decoration:none;color:#005789}.footer__bottom a:hover{text-decoration:underline}ul#footerSiteLinks{column-count:5;list-style:none;margin-top:2em;margin-right:20px;margin-bottom:40px}ul#footerSiteLinks li{margin-bottom:20px;color:#505050;text-decoration:none;font-size:14px}ul#footerSiteLinks li.footerHeading{text-transform:uppercase;color:#63666a;font-weight:bold;font-size:13px}@media screen and (max-width:1100px){ul#footerSiteLinks{column-count:2}}@media screen and (max-width:550px){ul#footerSiteLinks{column-count:1}}</style></div>
 
 
 
 
 
 
 
 <div class="align-center copy-right">
 
 <div data-widget-id=0c47df72-dc53-47d6-a894-88946220b838 data-widget-name=UX3HTMLWidget><div class=es-footer-cookie>
 We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the 
 <button class="es-link bold external ot-sdk-show-settings">Cookie Settings</button> for this site.<br>
</div>
 Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.
<br><br>
<ul class=rlist--inline>
 <li><a href=https://www.elsevier.com/legal/privacy-policy target=_blank>Privacy Policy</a>&nbsp;&nbsp;</li>
 <li><a href=https://www.elsevier.com/legal/elsevier-website-terms-and-conditions target=_blank>Terms and Conditions</a>&nbsp;&nbsp;</li>
 <li><a href=https://www.healthadvance.com/accessibility target=_blank>Accessibility</a>&nbsp;&nbsp;</li>
 <li><a href=https://service.elsevier.com/app/overview/healthadvance/ target=_blank>Help &amp; Contact</a></li>
</ul>
<br>
<a href=https://www.relx.com/><img src=data:null;base64, alt=RELX rel=nofollow target=_new></a>
<br>
<br></div>
 
 </div>
 
 
 
 
 
 
 
 <div data-widget-id=50c9dc39-d4fb-48f7-9891-1192d9d27bd3 data-widget-name=UX3HTMLWidget><style class=sf-hidden>.ux3 .footer .copy-right{padding:0}</style></div>
 
 
 
 
 
 
 
 <div data-widget-id=3c9b021b-bfb2-4fcd-9711-c919a04ed2a6 data-widget-name=UX3HTMLWidget></div>
 
 
</div></div>
 
 
 </div>
 
 </div>
 </div><div id=_atssh style=visibility:hidden;height:1px;width:1px;position:absolute;top:-9999px;z-index:100000></div>
 
 
 
 
 
 
 
 
 
<div id=crossmark-tooltip-130 class=crossmark-tooltip style=display:none></div><div id=crossmark-widget style=display:none></div><div id=onetrust-consent-sdk><div class="onetrust-pc-dark-filter ot-hide ot-fade-in sf-hidden"></div></div><div class="gpt-ad gpt-ad-defined sf-hidden" data-adsize=prestitial id=gpt-ad-31></div>